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Summary 
The use of multidisciplinary team (MDT) meetings have proven benefits in cancer 
care. In this thesis, prospectively collected data for men with new diagnosis prostate 
cancer discussed at a single specialist MDT over a 20-year period is analysed to 
address several clinically relevant questions in the pathway of prostate cancer 
management. 
 
This study has not shown any significant association between symptomatic men and 
more aggressive disease but did show that they were less likely to have radical 
treatment. It also reports that men with a positive family history are more likely to 
present with low risk disease and are more likely to have radical treatment. 
 
Isotope bone scanning for the staging of metastatic disease remains the most 
commonly used imaging modality. However, guidelines for use in men with 
intermediate risk disease are inconsistent. This study represents the largest UK study 
to date of bone scan positivity rates and supports its use in men with high risk disease 
and men with intermediate risk disease with ISUP grade group 3. 
 
The role of MRI imaging in prostate cancer spans diagnostics, staging, and disease 
surveillance. This study has shown that changes in MRI protocol and technology has 
not decreased the rate of upstaging following radical prostatectomy and established 
markers of biochemical recurrence remain superior to MRI staging at predicting 
disease relapse.  
 
The use of MRI in active surveillance regimes remains an area of debate. In this study, 
a normal bi-parametric restaging MRI in the absence of other clinical markers of 
progression conveys a very low risk of disease progression and the possibility of 
avoiding repeat prostate biopsies. 
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In this study, the effect of introducing protocol restaging in a cohort of clinically 
stable active monitoring patients is also reported and highlights expected rates of 
upgrading but significantly higher rates of radical treatment following restaging.  
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CHAPTER 1 - INTRODUCTION 
 
1.1 Prostate gland function and anatomy 
 
1.1.1 Gross anatomy of the prostate 
The prostate is an accessory reproductive organ located within the male pelvis.  
 
Embryologically the prostate develops from the primitive endoderm from which the 
digestive system also forms. Within the hindgut there is a caudal swelling termed the 
cloaca that is divided by the uro-rectal septum. From this the respective urinary and 
digestive outlets develop. The urogenital sinus is formed from the ventral aspect of 
the uro-rectal septum and from this the cranial end forms the urinary bladder and 
caudal end the urethra. The prostate is also derived from the uro-genital sinus and 
develops through dihydrotestosterone stimulation (Berman et al., 2012) 
 
When fully developed, the prostate is intimately related to the base of the bladder 
superiorly and the urethra runs through the middle of the gland. Anterior to the 
prostate is the pubic symphysis, posteriorly is the rectum separated by the fascia of 
Denonvilliers and inferiorly is the urogenital diaphragm.  The seminal vesicles lie 
superiorly and merge with the vas deferens to form the ejaculatory ducts which 
enter the prostatic urethra at the site of the veru-montanum. The pubo-prostatic 
ligaments provide support anteriorly, while the external urinary sphincter and the 
perineal membrane provide support posteriorly. 
 
The true capsule of the prostate is composed of collagen, elastin and smooth muscle 
(fibromuscular stroma) and forms a distinct layer separating it from the surrounding 
tissues. It is most well defined posteriorly and posterior-laterally. It is less well 
defined at the apex, bladder neck and anterior prostate. 
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1.1.2 Microscopic anatomy of the prostate  
Within the adult prostate there are four distinct zones (Berman et al., 2012, McNeal, 
1981). 
- The central zone contains around 25% of the glandular elements and 
surrounds the ejaculatory ducts 
- The anterior fibromuscular stroma makes up 30% of the prostate mass, 
contains smooth muscle and does not have a glandular component.  
- The transitional zone is the smallest zone and makes 15-30% of the 
prostate volume. It surrounds the urethra and sphincter and contains 
around 5% of the glandular elements. It is the site of benign prostatic 
hyperplasia 
- The peripheral zone is the largest zone and contains 75% of the glandular 
component. It is the most common site for prostate cancer.  
 
1.1.3 Histological and functional anatomy of the prostate 
The epithelium of the prostate is made up of two major cellular compartments 
comprising of epithelial cells and stromal cells. There are four different types of 
epithelial cells; basal cells, intermediate cells, neuroendocrine cells and luminal 
secretory epithelial cells. It is the luminal secretory cells that make up much of the 
prostatic epithelium and they are responsible for creating an epithelial barrier that 
lines acini. They are also responsible for producing prostate secretions which include 
PSA (prostate specific antigen) and acid phosphatase (PAP)(McNeal, 1988). The 
stromal cells provide structural stability and are made up smooth muscle cells, 
fibroblasts and connective tissue. 
 
PSA and PAP have strong proteolytic properties and help to liquefy the semen (Lilja 
et al., 1987). Specifically, PSA is a 33kD glycoprotein belonging to the kallikrien family 
of serine proteases under direct androgen control.  It is thought to break down 
semenogelin, a structural protein within seminal fluid that causes it to clot (Lilja et 
al., 1987). The exact importance to the reproductive cycle of this clotting and 
subsequent liquefication process within the semen is unknown.  
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Prostate growth, maintenance and excretory function is under endocrine control 
with testosterone exhibiting the most influence. The hypothalamic-pituitary-testis 
axis controls testosterone production. In a healthy male, 95% of testosterone is 
produced by the Leydig cells within the testes, stimulated by gonadotrophin 
releasing hormones released from the hypothalamus and subsequent release of LH 
and FSH from the pituitary gland, which then act upon the testes. The remaining 5% 
of testosterone comes from androstenedione secreted by the adrenal glands and 
stimulated by ACTH secreted from the pituitary. Most testosterone is bound to 
serum proteins such as sex-hormone binding globulin or albumin. Only 1-2% of 
testosterone is free and unbound. Testosterone is then converted in to its more 
active form, dihydrotestosterone (DHT), by the cytochrome P450 enzyme 5-alpha 
reductase (type 1 and 2) in the prostate. It can also be peripherally converted to 
oestrogen by aromatase. Both processes are irreversible. 
 
DHT and testosterone both bind to the androgen receptor (AR) but DHT has a much 
higher affinity for it. When bound to the AR it translocates in to the nucleus and 
result in the upregulation of certain gene expression, such as PSA. AR upregulation 
is fundamental in prostate cancer development and progression (Berman et al., 
2012) 
 
The half-life of testosterone is between 10-20 mins and therefore after surgical 
castration patients can be functionally castrate within a couple of hours (Berman et 
al., 2012). This formed the basis of early prostate cancer management and the 
pharmacological effects of blocking testosterone are central to the treatment of 
advanced prostate cancer. 
 
1.2 Prostate cancer 
 
1.2.1 Adenocarcinoma of the prostate and natural history 
Adenocarcinoma is by far the most common type of invasive prostate cancer. The 
natural history of prostate cancer is not fully understood but can be divided in to the 
following stages (PCRMG, 2016). 
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- Initiation 
- Diagnosis by screening 
- Diagnosis by clinical symptoms 
- Clinically detectable metastatic disease 
- Death 
 
The challenge with management lies with detecting aggressive tumours early and 
treating such cases but avoiding over treatment of indolent disease which may not 
effect quality or duration of life. The natural course of prostate cancer can often be 
extremely long from initiation to a point where it has metastasised and is life 
threatening.  
 
In the initiation from a normal prostate developing to cancer it is thought that 
prostate intra-epithelial neoplasia (PIN) may play a significant role. PIN is 
characterised by architecturally benign prostate glands that are lined by cytologically 
atypical cells. PIN can be sub-classified as low or high grade. However, low grade PIN 
is not reported histologically as it conveys no increased risk of progression to 
prostate cancer and the reporting of low-grade PIN lacks reproducibility (Epstein, 
2012). 
 
The risk of progression to invasive disease from high grade PIN is not clearly known 
but around a quarter of cases may progress (Epstein, 2012). Multi-focal PIN confers 
a higher risk than uni-focal PIN (Merrimen et al., 2009) and in such cases follow up 
should be more rigorous. Re-biopsy should be considered when greater than 3 cores 
at biopsy are involved with PIN or atypical cells are found adjacent to PIN (Mottet et 
al., 2017a). 
 
In those men that do go on to develop invasive adenocarcinoma the course of the 
disease can be extremely varied. Often screen detected cases of prostate cancer are 
low grade and reducing the rate of screening reduces such cases (Shah et al., 2018). 
Low grade or low risk cancers may have no impact on life expectancy and treatment 
may be unwarranted. In a recent trial, comparing men with low to intermediate risk 
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screen detected prostate cancer that had no treatment to those that had radical 
treatment, there was no difference in death rate from prostate cancer after 10 years’ 
follow-up (Hamdy et al., 2016). Other surveillance programmes for men with 
indolent cancers have also reported 100% 10 year prostate specific survival rates 
(Dall'Era et al., 2012).  
 
In men with low grade prostate cancer a small proportion will go on to develop 
higher grade disease that will progress, with the potential to metastasise and cause 
subsequent mortality. It is not known if the reason behind this progression is de—
differentiation of the existing tumour or the development of a new more aggressive 
separate tumour. 
 
In men with localised disease the more aggressive tumour, or poorly differentiated 
the tumour, the worse the prognosis. The 20 year death rate from prostate cancer  
in men with localised Gleason 6, 7 and 8-10 disease was noted to 27%, 45% and 66% 
(Albertsen et al., 2005).  
 
Men presenting with symptoms often have higher grade disease and indeed men 
who are diagnosed with metastatic disease at presentation do very poorly. The 
control arm of the STAMPEDE trial showed men with metastatic disease at 
presentation have a 3.5 year median survival (James et al., 2015). 
  
1.2.2 Other subtypes of prostate cancer 
1.2.2.1 Small cell prostate cancer 
Small cell prostate cancer is identical to small cell lung cancer. Approximately half of 
small cell prostate cancer are mixed with adenocarcinomas. However, this does not 
affect prognosis which is poor. Gleason grading is not applied to small cell tumours 
(Epstein, 2012). 
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1.2.2.2 Ductal adenocarcinoma 
Account for less than 1% of prostate cancer. Arise from prostatic ducts and behave 
in an aggressive manner and can subsequently present at an advanced stage with 
normal PSA levels (Epstein, 2012). 
 
1.2.2.3 Squamous cell carcinoma of the prostate 
Very rare and associated with osteolytic bony metastases and poor prognosis 
(Epstein, 2012) 
 
1.2.2.4 Sarcoma 
Very rare accounting for less 0.1% of prostate tumours. Rhabdomyosarcomas are 
most common and seen in childhood, whereas, leiomyosarcomas are more common 
in adulthood (Epstein, 2012). 
 
1.3 Prostate cancer incidence and mortality 
 
1.3.1 Incidence 
The lifetime risk of developing of prostate cancer is around 1 in 8 in the UK. Men 
from an African-Caribbean background are most commonly affected followed by 
Caucasians and it is least common amongst Asian men.  
 
Globally, prostate cancer is the second most common cancer affecting males. In 
developed countries, it is the most common cancer and in the developing world it is 
the 4th most common. In 2012, new cases of prostate cancer in the developed world 
accounted for nearly two-thirds of the global cases in just 17% of the world’s 
population (Siegel et al., 2013).  Incidence rates vary dramatically across the globe 
with much higher rates in the more developed countries, probably reflecting a 
greater use of screening tools and disease awareness (Figure 1.1) (Torre et al., 2015). 
However, it is interesting to note that the much higher incidence rate in certain 
global areas has not had a marked effect on the mortality rate, probably highlighting 
an increased detection of insignificant cancers. 
 
 12 
 
 
Figure 1.1. Incidence and mortality rates of prostate cancer by world area (Torre et 
al., 2015). 
 
In North America, incidence rates increased dramatically in the 1990s following the 
introduction of PSA testing but are now declining (Figure 1.2) (Siegel et al., 2017). 
This contrasts with other areas of the developed world such as Western Europe that 
are still seeing a rising incidence due to the slower uptake of PSA testing (Siegel et 
al., 2013) In 2012 the US Preventive Services Task Force issued evidence against the 
use of screening for prostate cancer (Klotz, 2015). However, despite the decreasing 
incidence rates in America new cases of prostate cancer are still expected to account 
for 19% of all new cancers in 2017 (Siegel et al., 2017). 
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 Figure 1.2. Incidence rates for cancers in USA, 1975 to 2013. (Siegel et al., 2017) 
 
Within the UK the incidence of prostate cancer is rising (Figure 1.3). This is 
multifactorial and can be attributed to increased patient awareness and the 
widespread use of PSA testing. An ageing population, improved ascertainment rates 
of cancer registries and the increased use of trans-rectal biopsy have also had an 
impact on rising incidence rates (PCRMG, 2016). Since the 1970’s the incidence has 
more than doubled with an increase of 155% with further rises predicted over the 
next 20 years.  In the UK in 2014 there were approximately 46,700 new diagnoses of 
prostate cancer with an incidence rate of 147 cases per 100,000 men (CRUK, 2015) 
These cases account for 13% of all newly diagnosed cancers making it the second 
most common type of cancer within the UK and the most common in males (CRUK, 
2015).  
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Figure 1.3. Age standardised incidence rates in UK, rate per 100,000, by year of 
diagnosis (CRUK, 2015). 
 
The incidence of prostate cancer is strongly linked to age (Figure 1.4). Post-mortem 
studies have identified microscopic lesions in 30% of men in their fourth decade, 50% 
of men in their sixth decade and 75% of men older than 85 years of age (Grönberg, 
2003, Sakr et al., 1993). The majority of new diagnoses are in men over 70 years of 
age with 54% of cases in this age group between 2012-14 (CRUK, 2015) and 50% for 
men diagnosed in England between April 2014-15 (NPCA., 2017). 
 
Since the 1990s incidence rates have increased in all age group categories apart from 
those men above 80 years of age where there has been a fall.  The most dramatic 
rise is seen in younger men with an increase in rates of 507% in men between 25-49 
years of age. In men over 80 years there has been a 23% fall in incidence rates. 
(Figure 1.5) (CRUK, 2015). 
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Figure 1.4 Average number of cases per year and incidence rates per 100,000 
population (CRUK, 2015) 
 
 
Figure 1.5 European age related incidence rates of prostate cancer, 1993-2015. 
(CRUK, 2015) 
 
The increased incidence of prostate cancer is associated with a higher percentage of 
lower stage disease detected. However, there remain many other factors that 
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influence the disease stage at presentation. Within the UK, geographical variations 
occur (Figure 1.6), as well as other factors such as age, deprivation and race. Men 
who are older, more deprived and white British are more likely to present with later 
stage disease (CRUK, 2015). 
 
Figure 1.6. Proportion of cases diagnosed at each stage between 2010-2014 in the 
UK (CRUK, 2015). Stage 1, T1-T2a. Stage 2, T2a-c N0. Stage 3, T3N0. Stage 4, T4N0, 
or any N1 or M1. 
 
1.3.2 Mortality  
Prostate cancer is the fifth leading cause of cancer deaths worldwide. Within the UK 
in 2016 there were approximately 11,600 deaths from prostate cancer making it the 
4th most common cause of deaths from cancer overall and 2nd most common 
amongst males (13% of all males cancer deaths) (CRUK, 2015). In 2008, globally in 
the developed world it was the 3rd most common cause of death amongst males and 
5th most common in the developing countries (Jemal et al., 2011). Nearly 60% of all 
death from prostate cancer are in those men aged 80 years or over.  
 
As expected prostate cancer mortality is directly related to age with much higher 
rates in the elderly (Figure 1.7). Since the 1970’s mortality rates in the UK have 
increased by nearly 20% overall but have decreased in the last 10 years by around 
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13% (CRUK, 2015) and predicted to fall by a further 16% from now until 2035 
(Smittenaar et al., 2016). Age group related mortality rates have remained stable in 
the younger age groups, with only the 70-79 years age group seeing a decrease of 
10% and the over 80s seeing a rise of 44% (CRUK, 2015). 
 
The improvements in mortality rates are thought to be a result of many factors. A 
higher incidence of indolent cancers through PSA screening, improved diagnostics, 
as well as advances in treatment pathways and techniques. 
  
 
Figure 1.7. Average number of deaths per year and age specific mortality rates per 
100,000 population, UK, 2014-26. (CRUK, 2015) 
 
1.4 Risk factors 
 
As already discussed, increasing age represents the biggest risk in developing 
prostate cancer. However, several other factors play a role including race and 
geographical location, family history and genetics, obesity, testosterone levels and 
diet and lifestyle choices. 
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1.4.1 Race and geographical factors 
As emphasised in Figure 1.1 there is a wide variation in global incidence rates across 
the world with higher rates in Australia and New Zealand and the lowest rates in 
Eastern and South Central Asia. The highest mortality rates are seen in Southern 
Africa (26.8 per 100,000 men) compared with very low rates in South Central Asia 
(3.3 per 100,000) (Bray et al., 2018). 
 
It is not known why there is such a variety in mortality rates between ethnic groups 
as rates of indolent cancer on autopsy studies have been found to be similar (Breslow 
et al., 1977). This therefore brings in to question the influence of genetic and 
environmental factors in developing significant cancer.  
 
1.4.2 Family history and genetics 
The first reported evidence of familial clustering in prostate cancer occurred over 50 
years ago.  Overall, sporadic cancers account for around 85% of new cases and 15% 
are familial. However, the percentage of familial cases presenting in men younger 
than 55 years old rises to around 43% and falls to 9% in men over 85 (Abouassaly et 
al., 2012). Men with a positive family history presenting with prostate cancer often 
do so earlier but this does not appear to affect disease course (Breslow et al., 1977). 
Relative risk associated with hereditary prostate cancer is higher when first degree 
relative are involved and this rises with the number of relatives affected and a lower 
age at presentation (Kicinski et al., 2011, Bruner et al., 2003). 
 
FAMILY HISTORY LIFETIME RISK 
NO HISTORY 8% 
FATHER, DIAGNOSED >60 12% 
1 BROTHER AFFECTED >60 15% 
FATHER AFFECTED <60 20% 
1 BROTHER <60 25% 
2 MALE RELATIVES 30% 
3 OR MALE AFFECTED RELATIVES 35 to 45% 
Table 1.1. Table showing lifetime risk of prostate cancer in men with a positive family 
history (Bruner et al., 2003). 
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Germline mutations in genes such as BRCA1 and 2 and HOXB-13 have been shown 
to increase the risk of developing prostate cancer. BRCA 2 conveys the highest risk 
with a near 9-fold increase for BRCA 2 (Kote-Jarai et al., 2011) and 4-fold for BRCA 1 
(Leongamornlert et al., 2012). BRCA 2 is also though to associated with a more 
aggressive disease phenotype with a higher rate of locally advanced disease and 
subsequent risk of metastases (Castro et al., 2013). Family history should therefore 
be borne in mind when considering PSA testing. 
 
1.4.3. Diet and obesity 
Men who are overweight have a lower incidence of low grade cancer but a higher 
incidence of aggressive cancer (Castro et al., 2013). The higher rate of aggressive 
cancer in overweight men may be due difficulties in presentation and diagnosis, and 
also based on hormonal factors that are promoted in obesity. Weak evidence exists 
suggesting an increase risk in developing prostate cancer with diets high in dairy and 
alcohol.  
 
1.5 Clinical and pathological staging of prostate cancer 
 
1.5.1 Staging of prostate cancer 
Staging is important for several reasons; it helps to characterise the disease, predict 
outcome and aid treatment decisions as well as helping health care providers and 
researchers in exchanging information about patients (Buyyounouski et al., 2017). 
 
The first tumour-node-metastasis (TNM) staging system was published in 1958 by 
the International Union Against Cancer (UICC) having been developed by Frenchman 
Pierre Denoix as a method of staging cancer uniformly across all sites. Initially it was 
used to stage breast and laryngeal cancer (Greene and Sobin, 2008) but over the 
following years more cancer sites were added. In 1982, the UICC collaborated with 
the American Joint Committee on Cancer (AJCC) to develop the Fourth Edition of 
TNM and thereby achieve a worldwide agreement on the staging of adult solid 
tumours (Greene and Sobin, 2008). In 2017, the eighth edition was published and all 
previous editions since 1982 have been identical to the AJCC classifications.  
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Currently the eighth edition of the TNM staging remains in use and remains the gold 
standard for the staging of prostate cancer. This is used in combination with pre-
treatment PSA and the Gleason grading of tissue obtained at biopsy to risk stratify 
patients newly diagnosed and aid treatment decisions. 
 
Tumour stage (T stage) 
T stage is used to classify the extent of disease within the prostate. T stage is defined 
as either clinical tumour stage (cT) or pathological stage (pT).  
 
Clinical stage should only be derived from findings on digital rectal examination 
(DRE). Findings from radiological investigations may help to plan potential staging 
investigations, i.e. targeted TRUS biopsy, and to aid subsequent treatment decisions, 
i.e., presence of T3 disease, but due to the lack of uniformity of staging investigations 
should not be used to define cT stage. 
 
Pathological stage can only be defined in those patients who undergo radical 
prostatectomy and have the prostate examined histologically. The boundary of the 
prostate, or capsule, is a formed by a dense layer of fibromuscular stroma and is 
most well defined posteriorly and posterior-laterally. It is less well defined at the 
apex, bladder neck and anterior prostate and subsequently defining extra-prostatic 
extension at these sites can sometimes be challenging.  
 
Nodal stage (N stage) 
N stage is used to determine the extent of nodal disease. Regional nodes are defined 
as those nodes within the true pelvis and include iliac, obturator, sacral and 
hypogastric. Involvement of non-regional nodes is defined as metastatic disease and 
is not defined as part of N stage. 
 
Clinical nodal stage is often identified on staging CT or MRI scans although can be 
underestimated if nodes to not reach standard size criteria for positivity. 
Lymphadenectomy is the gold standard for determining pathological nodal status. 
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Metastasis stage (M stage) 
M stage is used to define presence of metastases. This is most often assessed using 
isotope bone scan as prostate cancer most commonly metastasises to the axial 
skeleton. CT, MRI and PET scans are also used. 
 
TNM Classification 8th Edition 
T categories 
Tx Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
T1 Clinically unapparent tumour neither palpable nor visible by 
imaging 
T1a Tumour was incidentally found in less than 5% of prostate tissue 
resected 
T1b Tumour was incidentally found in more than 5% of prostate 
tissue resected 
T1c Tumour identified on needle biopsy (e.g. because of elevated 
PSA) 
T2 Tumour confined within the prostate 
T2a Tumour involves one half or less of one lobe 
T2b Tumour involves more than one half of one lobe but not both 
lobes  
T2c Tumour involves both lobes 
T3 Tumour invades through the prostate capsule 
T3a Extra-capsular extension (unilateral or bilateral) 
T3b Tumour invades seminal vesicles 
T4 Bladder invasion, fixed to pelvic side wall, or invasion of adjacent 
structures 
 
 
N categories 
Nx Regional lymph nodes were not assessed 
 22 
N0 There is no spread to regional lymph nodes 
N1 There is spread to regional lymph nodes 
 
M categories 
Mx Distant metastasis cannot be assessed  
M0 No distant metastasis 
M1 Distant metastases 
M1a Metastasis to non-regional lymph nodes 
M1b Metastasis to bone 
M1c Metastasis to other distant sites 
Table 1.2. TNM 8th Edition staging classification of prostate cancer. 
 
In 1992, the AJCC and UICC adopted a new TNM system whereby the pT2 stage was 
sub-classified in to three tiers as seen in the current 7th edition. In 1997, this was 
revised and the T2a and T2b categories combined to form one category for unilateral 
disease, T2a, and a second category was created for bilateral tumours, T2b. In 2002, 
this change was revised again and reverted to the three-tier system used in 1992 
(Hong et al., 2008). This classification was kept when the 7th and the most recent 8th 
TNM editions were published. 
 
The AJCC has recommended the sub-classification of pT2 tumours is to be scrapped 
in favour of one T2 group incorporating all organ confined tumours. This is following 
a lack of evidence to suggest prognostic differences between the three sub 
classifications. This change will eliminate the dilemma that pathologists face in 
having to create an imaginary midline. It will also eliminate the potential of 
classifying a small tumour that crosses the midline higher than a large solitary 
tumour on one side of the prostate (Buyyounouski et al., 2017). 
 
 
 
 
 23 
1.6 Grading of prostate cancer 
 
1.6.1 Gleason grading  
The histopathological grading system used for prostate cancer was developed in the 
1960’s and 1970’s by Donald F Gleason. It has undergone a number of adaptations 
since inception with the latest changes made in 2014 by the International Society of 
Urological Pathology (ISUP)(Epstein et al., 2016a). 
 
Gleason established a system whereby the architectural growth patterns of prostate 
cells were graded and assigned a score of between 1 and 5. Originally the overall 
score was the addition of the primary (most common grade present) pattern and 
secondary (least common grade present) pattern scores. If only one grade is present 
it is doubled to give an overall score. In 2005, this rule changed whereby if there 
were 3 grades present the score comprised the most common grade plus the most 
aggressive grade, regardless of the extent. Overall scores are between 2 – 10. Less 
well-differentiated cells are given higher scores, therefore, an overall score of 10 
conveys the worse prognosis. Following changes to the Gleason scoring system both 
in 2005 and 2014 by ISUP it is now very different to how it was originally (Epstein et 
al., 2016a). Scores of between 2 and 5 are no longer used and therefore current 
scoring for cancer ranges between 6 and 10. Also, Gleason 7 now includes patterns 
that were once graded 6 and hence current Gleason 6 tumours convey a better 
prognosis than those diagnosed using original Gleason criteria. 
 
Matoso and Epstein (2016) sought to clarify the all the changes made by ISUP in 
2014. Original Gleason scoring criteria had the presence of cribriform glands, 
regardless of size, as part of pattern 3. In 2005 ISUP modified this and recommended 
those with large cribriform glands be included in pattern 4. This was further adapted 
in 2014 by ISUP to incorporate all cribriform glands as part of pattern 4. The decision 
between this was two-fold; firstly, an increasing body of evidence to suggest that the 
presence of cribriform patterns is a poor prognostic feature and secondly problems 
with reproducibility amongst pathologists (Matoso and Epstein, 2016). There were 
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also clarifications about glomeruloid glands, mucinous carcinoma and intra-ductal 
carcinoma.  
 
 
Figure 1.8. Histological representation of different Gleason grade patterns with 
H&E staining. (Courtesy of Dr D Griffiths, Histopathologist, UHW Cardiff.)  
 
In 2005, ISUP agreed not to report tertiary Gleason scores for prostate biopsy. 
Tertiary scores would be reserved for radical prostatectomy specimens only to help 
differentiate more aggressive disease. It was agreed that the third most common 
pattern of highest grade cancer be considered tertiary only if it was less than 5%. If 
it was more than 5% it would be considered the secondary pattern. This scoring 
system helped to differentiate and stratify patients more accurately (Matoso and 
Epstein, 2016). 
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The main change at the ISUP in 2014 was to introduce a new grade grouping system 
(shown in Table 1.3) which better reflected the distinction between the different 
Gleason groups particularly the 2 types of Gleason 7 and also to separate Gleason 8 
from 9 and 10.  
 
ISUP GRADE GROUP GLEASON SCORE BCR FREE AFTER RP (%) 
1 3+3 96 
2 3+4 88 
3 4+3 63 
4 8 48 
5 9-10 26 
Table 1.3. Table highlighting ISUP 2014 grade group for prostate cancer and 
associated biochemical recurrence-free progression after radical prostatectomy 
(Epstein et al., 2016a, Pierorazio et al., 2013) 
 
Pierorazio et al reported distinct and important differences in biochemical 
recurrence-free survival between these grade groups and this was later validated in 
a much larger study (Epstein et al., 2016b). This new grade group system will make 
it is easier to interpret Gleason grading and emphasises the clinical importance of 
distinguishing between the different Gleason scores in deciding on how to treat and 
counsel patients. 
 
1.7 Detection of prostate cancer 
 
Most men with suspected prostate cancer will present with a raised PSA, with or 
without LUTS, that are often not a result a of the underlying cancer and/or an 
abnormal feeling prostate on digital rectal examination. Patients are then 
investigated and staged with a combination of TRUS guided biopsy of the prostate, 
MRI scan, isotope bone scan and CT imaging. 
The challenge for prostate cancer diagnostic remains identifying clinically significant 
disease and avoiding over diagnosis and subsequent overtreatment of indolent 
disease. 
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A point of controversy amongst diagnostics is producing a common definition of 
clinically significant disease with many existing criteria.  
 
1.7.1 Digital rectal examination (DRE) 
Most prostate cancers are located within the peripheral zone of the prostate and 
hence should theoretically be palpable on digital rectal examination with tumours 
becoming apparent when greater than 0.2ml in volume (Heidenreich et al., 2014). 
The obvious pitfall for DRE is with smaller high grade tumours and anteriorly sited 
tumours and considerable inter-observer variation which may be affected by clinical 
experience. For this reason, it is essential to incorporate clinical findings with other 
staging modalities such as MRI and TRUS findings. 
 
1.7.2 Prostate specific antigen (PSA) 
Prostate specific antigen is an enzyme produced only by the prostate to liquefy 
seminal fluid. It is therefore prostate specific but not cancer specific and be elevated 
in cases of benign prostatic hyperplasia, prostatitis and when there is concurrent 
urinary tract infection. PSA levels also vary with age and race and must be adjusted 
accordingly (DeAntoni et al., 1996) (Table 1.4). Interpretation of PSA results does 
therefore require correlation with the clinical picture. Currently in the UK the PCRMG 
suggest urgent referral if PSA 3 for men between 50-69 (PCRMG, 2016). 
 
AGE (YEARS) WHITE BLACK ASIAN 
40-49 0-2.3 0-2.7 0-2.0 
50-59 0-3.8 0-4.4 0-4.5 
60-69 0-5.6 0-6.7 0-5.5 
70-79 0-6-9 0-7.7 0-6.5 
Table 1.4. Age specific PSA levels (ng/ml), by race (DeAntoni et al., 1996). 
 
Commercial serum PSA assays were introduced in the late 1980s. Prior to 
widespread PSA testing many patients with prostate cancer presented at a very 
advanced stage and hence with incurable disease. PSA testing has revolutionised 
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prostate cancer diagnostics and management and has led to an increase in the 
number of men presenting with localised disease. 
 
The predictive value of PSA improves with increasing scores. With a normal DRE and 
an PSA between 4 and 10ng/ml there is a 25% chance of detecting prostate cancer 
on TRUS biopsy, this rises to 50% if the PSA > 10ng/ml with half of these men having 
at least T3 disease.  
 
PSA is most accurate in the post treatment period particularly after radical 
prostatectomy when one would expect PSA levels to be undetectable if all prostate 
and cancer tissue has been removed. PSA levels are then monitored to identify 
disease recurrence with a PSA >0.2 widely accepted as the definition of disease 
recurrence.  
 
In the UK, the prostate cancer risk management group was created to advise primary 
care physicians on asymptomatic men requesting a PSA test. It is recommended that 
all men are counselled regarding advantages and disadvantages of PSA testing, what 
is involved in the investigation of a raised PSA and potential treatment options for 
prostate cancer. It has been shown that this is not always achieved and that 
additional patient decision aids may help in the decision-making process (PCRMG, 
2016). 
 
1.7.3 TRUS biopsy 
Historically patients with elevated PSA levels or abnormal DRE would have been 
referred for TRUS biopsy.  
 
TRUS biopsy does have potential severe side effects including sepsis and bleeding 
and these must not be overlooked when counselling men. The biopsy is most 
commonly performed with local anaesthetic and in a clinic based setting. A more 
thorough form of prostate biopsy is Template Prostate Mapping (TPM), this involves 
taking biopsies through the perineum to obtain tissue from the prostate at 5mm 
intervals. This enables the clinician to create a comprehensive map of the prostate 
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and offers a more accurate method of diagnosis, with 95% sensitivity for clinically 
significant cancer (Ahmed et al., 2017). However, TPM involves general anaesthesia 
and the associated morbidity and logistical problems that come with this and as a 
result it is less commonly performed.  
 
Prior to the introduction of modern imaging techniques such as multi-parametric 
MRI TRUS biopsy was performed in a systematic fashion whereby 8-12 random core 
biopsies were taken.  This method has the potential to miss significant cancer and 
potentially under stage disease. In fact, around a quarter of men with a negative 
TRUS biopsy or a biopsy that was defined as non-significant cancer were then found 
to have clinically significant cancer on a subsequent template mapping biopsy 
(Ahmed et al., 2017). 
 
Given the pitfalls of systematic or blind TRUS biopsy and the difficulties associated 
with offering a TPM service there was a real need for a better way to diagnose 
prostate cancer. Advances in MRI diagnostics have now brought about change 
whereby it is common practice for patients to receive an MRI scan before TRUS 
biopsy with the aim of targeting abnormal areas.  
  
1.7.4 Magnetic resonance imaging 
The usefulness of MRI in the detection of clinically significant prostate cancer has 
improved significantly in recent years. Historically, the use of MRI in the diagnostic 
pathway was variable and only in recent years has there been widespread uptake of 
pre-biopsy MRI in the UK (NPCA., 2018). There has been a shift from using MRI as a 
tool for staging towards one for cancer detection and targeting at biopsy (Futterer 
et al., 2015). It also now plays a role in surveillance, guidance for focal treatment, 
and for assessment of possible disease recurrence (Weinreb et al., 2016b). 
 
The advances in accuracy in MRI have been a result of the introduction of multi-
parametric MRI. In the early stages of prostate staging MRI only T1 and T2 images 
were used. A multi-parametric MRI includes T1 and T2 weighted images, diffusion 
weighting imaging (DWI) and its derivative apparent-diffusion co-efficient (ADC) 
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maps, dynamic contrast enhancement (DCE) and sometimes proton spectroscopy. 
The combined outputs from these sequences define mpMRI and have been 
instrumental in improving accuracy. 
 
There is still wide variability between different centres as to the type of MRI machine 
that is used and the sequences that are used to report. The use of contrast may not 
be available, the age of the MRI machine and the type of magnet, the use of endo-
rectal coils and obvious inter-observer variability may all affect ability to produce 
accurate reports. It is widely accepted that MRI is more accurate for larger and more 
aggressive tumours.  
 
In an attempt to standardise reporting of MRI, scoring systems have been 
introduced. The PI-RADS score (Prostate Imaging – Reporting and Data System), now 
in its second version, was designed by the American Society of Radiology, the 
European Society of Uroradiology and AdMetech foundation. Aside from introducing 
a scoring system PI-RADS have recommended minimal standards for mpMRI and 
guidance on how they should be reported. It has helped decrease variation in 
acquisition, interpretation and reporting (Weinreb et al., 2016b) making PIRADS 
useful for everyday practise as well as using it as standard for data collection in 
clinical trials and research. The PIRADS scoring system uses a five-point scale to 
indicate the likely presence of clinically significant cancer in each lesion (Table 1.5) 
Clinically significant cancer is defined as Gleason  7, and/or volume 0.5cc, and/or 
extra-prostatic extension (Weinreb et al., 2016b). 
 
PIRADS 
SCORE 
PROBABILITY OF CLINICALLY SIGNFICANT CANCER 
1 Very low (clinically significant cancer is highly unlikely to be present) 
2 Low (clinically significant cancer is unlikely to be present) 
3 Intermediate (the presence of clinically significant cancer is equivocal) 
4 High (clinically significant cancer is likely to be present) 
5 Very high (clinically significant cancer is highly likely to be present) 
Table 1.5. PIRADS score of mpMRI indicating likelihood of cancer being present. 
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The use of PIRADS scoring has helped to increase the detection of cancers likely to 
cause harm and also decrease the detection of the indolent cancers that one 
probably does not to treat (Padhani et al., 2018). Other scoring systems such as the 
LIKERT score use clinical and radiological features to determine the likelihood of 
cancer rather than PIRADS which is based purely on pre-determined MRI 
characteristics. As a result of this, PIRADS is used in diagnosis of prostate cancer and 
scoring cannot be applied to patients with already known prostate cancer, such as 
those on surveillance. 
 
LIKERT is also preferred in the updated NICE guidance again because of the ability to 
use other parameters such as DRE findings, PSA scores and PSA density and other 
clinical features which increase the likelihood of cancer such as family history. LIKERT 
uses a 5-point scoring system with the same definitions as in PIRADS (Dickinson et 
al., 2013). Unlike PIRADS it can be used to risk stratify biopsies in the active 
surveillance cohorts and therefore has a wider scope. 
 
Given improvements in mpMRI, there is now evidence to suggest that MRI be used 
routinely in the diagnostic pathway before biopsy. The PROMIS trial showed both 
higher sensitivity (93% vs 48%) and better negative predictive value (89% vs 74%) for 
MRI compared to TRUS biopsy in detecting clinically significant cancer (defined as 
Gleason 4+3 or core length 6mm). However, TRUS biopsy had better specificity 
(96% vs 41%) and positive predictive rates (90% vs 51%). In this trial if MRI was used 
as a triage test and all those patients with a Likert score  3 had targeted biopsies it 
was predicted that around a quarter of patients could avoid an immediate biopsy 
and around 5% less clinically insignificant cancers would be detected (Ahmed et al., 
2017). 
 
The PRECISION study took this further and compared outcomes of TRUS biopsy alone 
versus only targeted biopsies following an abnormal mpMRI (classified as PI-RADS 
3) for investigation of men with a raised PSA. Targeted biopsy alone was shown to 
be non-inferior to TRUS biopsy and in fact led to a higher percentage of clinically 
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significant cancers being detected and a lower percentage of insignificant disease 
(Kasivisvanathan et al., 2018). 
 
With this new evidence, NICE guidance has now recommended that mpMRI be 
performed before TRUS-biopsy in men suitable for radical treatment. If the MRI is 
abnormal targeted as well as systematic biopsies are still recommended given the 
lower specificity and NPV of MRI. If the mpMRI is normal (Likert 1 or 2) and other 
clinical parameters allow one may be able to discuss with patients the opportunity 
to omit a biopsy but be aware there is still a 28% chance of having significant cancer 
(NICE., 2019). 
 
In addition to local prostate imaging and staging MRI is also used to stage abdominal 
lymphadenopathy and there is increasing use of whole body MRI as a means of 
staging men with more aggressive cancer with a risk of metastatic disease. 
  
1.7.5 Isotope bone scan 
Prostate cancer most commonly metastasises to the lymph nodes and to bone, 
causing an osteoblastic reaction and subsequent sclerotic bony metastases. The 
detection of metastases is both important for evaluating prognosis and treatment 
options. 
 
Isotope bone scans are used in the staging of prostate cancer when there is a concern 
for the presence of metastatic disease. Despite other options being available for the 
assessment of bony metastases, PET-CT, SPECT and MRI, bone scan remains the 
investigation of choice. This is largely due its relatively high sensitivity, affordability 
and availability compared to the other options (Shen et al., 2014). 
 
1.7.6 PET-CT 
Positron Emission Tomography (PET) couple with CT, i.e. PET-CT, offers promising 
results for accurately staging men with advanced disease where accurate nodal and 
metastatic staging is important in defining disease status. PET is reliant upon the 
detection of positron emitting radionucleotides which are attached to metabolically 
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active carriers used in rapidly producing cancer cells, such as flourodeoxyglucose (an 
analogue of glucose). Within prostate cancer both choline-PET and PSMA (prostate 
specific membrane antigen)-PET have shown the most encouraging results and their 
use is increasing. However, what is not clear is how men should be treated who have 
lesions picked up on PET that would not otherwise have been detected on MRI or CT 
staging (Heidenreich et al., 2014) 
 
1.8 Screening for prostate cancer 
 
Screening aims to reduce the rate of death from a specific disease with minimal 
impact on quality of life. Screening for prostate cancer remains a controversial topic 
as currently many of the required criteria to establish a screening program are not 
met(Wilson and Junger, 1968). To date the two largest studies assessing outcomes 
for screening, the ERSCP and the PLCO trials, offer conflicting messages. 
 
The European Randomised Study of Screening for Prostate Cancer (ERSCP), a large 
multi-centre randomised trial compared the effects of screening on rates of prostate 
cancer mortality in 182,160 men. At 13 years follow up, there was a relative risk 
reduction of 21% in a subgroup of men aged 55-69 years of age, and an absolute risk 
reduction of 1.28 per 1000 men randomised was demonstrated. This equates to 781 
men being screened to avoid one death and 27 additional new cases being diagnosed 
to prevent one death (Schröder et al., 2014).  
 
This reduction in mortality was not seen in the other large screening study, carried 
out in the United States. The Prostate, Lung, Colorectal and Ovarian (PLCO) cancer 
screening trial randomised 76,693 men to receive annual screening (PSA test for 6 
years and DRE) versus the control group. At 15 years’ median follow-up, there was 
no significant difference between rate of death from prostate cancer (Pinsky et al., 
2017). There is, however, increasing debate regarding the validity of this study due 
to the high percentage of patients in the control group that received screening PSA 
tests. Hence, it is argued this study cannot reliably used when comparing screening 
to a non-screened group (Shoag et al., 2016).  
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A Cochrane review of 5 RCT’s on screening, published in 2013, did not demonstrate 
any improvement in prostate cancer specific mortality. They concluded that 
morbidity from diagnostics tests was not insignificant and over diagnosis and over 
treatment were common. An increased number of prostate cancer cases was seen, 
particularly low risk cases. It was highlighted that any improvement in disease 
specific mortality from screening is likely to take at least 10-15 years to be seen and 
therefore should not be undertaken in those with a lower expectancy than this (Ilic 
et al., 2013).  
 
Currently NICE guidelines in the UK make no recommendations on screening. 
However, the most recent UK National screening committee (NSC) published in 
2016, advised against the introduction of screening for prostate cancer. They 
concluded that PSA remains a poor test for detecting cancer with a better test with 
higher sensitivity needed, and one that can differentiate between aggressive and 
non-aggressive cancers, with minimal morbidity (UKNSC, 2016). This mirrors the 
recommendation made by the United States Preventative Task Force (USPTF) in 2012 
to stop routine PSA testing due to concerns over safety. Interestingly one study 
found that in the 3 years after this recommendation was introduced the biopsy rate 
decreased but the detection rate, percentage of higher grade tumours and the 
percentage of positives biopsies all increased (Shah et al., 2018). 
 
One large UK based study assessed whether a one-off PSA test for men between 50 
and 69 years of age would reduce the risk of dying from prostate cancer. In the 
control group (no PSA test) 36 men per 1000 were diagnosed with cancer compared 
to 43 per 1000 in men that had had a PSA test. The group who had a test were more 
likely to be diagnosed at a younger age, with a lower grade of disease and less likely 
to have distant disease and therefore less chance of needing treatment. No 
difference in death rate from prostate cancer was noticed after 10 years and the trial 
concluded that a one-off PSA test was of no benefit for screening of prostate cancer 
(Martin et al., 2018). 
 
 34 
The EAU statement regarding PSA testing in 2017 (Mottet et al., 2017a) are detailed 
below-  
- Don’t offer men PSA testing without explanation of potential risks and 
benefits 
- Offer an individualised risk-adapted strategy for early detection to a well-
informed individual with a good performance status and a life-expectancy of 
at least 10-15 years 
- Offer early PSA testing in well-informed men at elevated risk of CaP 
o Men > 50 years old 
o Men > 45 years old with a family history 
o African-Americans >45 years old 
o Men with PSA level >1ng/ml at 40 years old 
o Men with PSA level >2ng/ml at 60 years old 
- Offer risk adopted strategy with 2 yearly PSA testing for those initially at risk 
o Men with PSA level >1ng/ml at 40 years old 
o Men with PSA level >2ng/ml at 60 years old 
- Those not at risk offer 8 yearly follow-up. 
 
In conclusion, screening for prostate cancer and the decision for PSA testing should 
take in to account family history, the presence of symptoms and suitability for 
treatment. PSA testing should only be done after a well-informed and patient 
centred discussion. 
 
1.9 Risk stratification for prostate cancer 
 
Risk stratification for newly diagnosed cases of prostate cancer is vital in decision 
making processes for treatment. They are also used to define clinical trial groups and 
reports outcomes (Rodrigues et al., 2012). Ideally stratification processes should be 
simple to use and remember. The prognostic powers of pre-treatment PSA level, 
Gleason score from diagnostic biopsy and clinical T stage have been used to develop 
risk stratification tools. National governing bodies have used and adapted pre-
existing classification to aid clinicians deciding on treatment course. 
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1.9.1 D’Amico classification 
Published in 1998, D’Amico et al developed a three-tier risk stratification tool to help 
predict outcomes for patients with clinically localised CaP undergoing radical 
treatment. Patients were grouped in to low, intermediate and high risk groups based 
upon pre-treatment PSA level, Gleason score of needle biopsy and clinical T stage as 
per TNM staging (Table 1.6). Outcome was judged by PSA control post treatment and 
development of biochemical failure. Treatment groups included radical 
prostatectomy, external bean radiotherapy and brachytherapy. The study reported 
no difference in outcome at 5 years for low-risk patients between treatment groups. 
However, intermediate and high risk patients treated with RP and EBRT did better 
than those treated with brachytherapy (D'Amico et al., 1998).  
 
Following on from this study there has been a wide scale uptake in the use of the 
D’Amico risk stratification largely because of its simplicity. 
 
Risk group PSA level 
(ng/ml) 
 Gleason 
score 
 Clinical T 
stage 
Low <10 and 6 and T1a – T2a 
Intermediate 10-20 or 7 or T2b 
High >20 or 8 - 10 or T2c 
Table 1.6. D’Amico risk classification of localised prostate cancer (D'Amico et al., 
1998). 
 
1.9.2 Epstein criteria 
Developed in 1994 by Epstein and colleagues to identify insignificant cancers 
(Epstein, 1994). They examined pre-treatment clinical and pathological parameters 
for men with T1c disease undergoing radical prostatectomy and found the following 
criteria predictors for insignificant disease; 
 
- PSA density 0.1-0.15ng/ml 
- Gleason score <7 
- 1 positive core 
- Longest tumour length <3mm 
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- Clinically organ confined 
 
Various validation studies have been carried out since Epstein created these 
parameters and the generally accepted criteria is now defined as; 
 
- PSA density <0.15ng/ml 
- Gleason score <7 
- <3 positive cores 
- <50% volume of core positive for tumour 
- T1c 
 
However, the ability of the Epstein criteria to accurately predict insignificant disease 
has been questioned. Since it was defined over 20 years ago there have been several 
modifications to Gleason grading criteria, most notably by ISUP in 2005. Oon et al 
reviewed the accuracy of Epstein criteria in predicting insignificant cancer, Gleason 
6 disease and organ confined disease. It remained accurate in predicting organ 
confined disease with rates between 80 – 96.9% across studies. However, it was less 
accurate at predicting insignificant disease and Gleason 6 disease and this is thought 
in part to be down to changes in Gleason grading (Oon et al., 2011). 
 
1.9.3 NICE 
NICE guidance 2014 (NICE, 2014) recommend risk stratification as per D’Amico risk 
stratification and treatment recommendations are based upon this. 
 
1.9.4 EAU 
The EAU guidelines 2017 are very like those of D’Amico but also include ISUP 
grouping in a move to transition away from the use of traditional Gleason scoring. 
The higher risk group is also divided in to localised and locally advanced disease. It is 
likely that intermediate risk disease will be further divided in to low and high risk 
sub-groups based upon ISUP grading and increasing evidence to suggest better 
outcomes for patients with ISUP group 2 (Table 1.7) (Mottet et al., 2017a). 
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RISK GROUP PSA LEVEL 
(NG/ML) 
GLEASON 
SCORE 
ISUP 
GROUP 
CLINCAL 
STAGE 
LOW <10 and <7 and 1 T1-2a 
INTERMEDIATE 10-20 or, 7 or, 2 and 3 T2b 
HIGH - LOCALISED >20 >7 4 and 5 T2c 
HIGH – LOCALLY ADVANCED any any any T3-4 or cNx 
Table 1.7 EAU risk stratification of new diagnosis prostate cancer (Mottet et al., 
2017b). 
  
1.9.5 NCCN 
The National Comprehensive Cancer Network (NCCN) is an alliance of US cancer 
centres and produces up to date guidelines for treatment of cancers within the US. 
Currently their risk stratification for prostate cancer has 7 tiers with 5 tiers for 
localised cancer with the inclusion of both very low and very high risk disease. 
Regional (any T stage and N1 disease) and metastatic disease complete the 7 tiers. 
Treatment strategies are recommended for each stage depending on patient factors 
such as wellbeing and life expectancy (Table 1.8) (NCCN, 2016).  
 
RISK GROUP PSA 
LEVEL 
(NG/ML) 
GLEASON 
SCORE 
CLINICAL 
STAGE 
NUMBER 
OF CORES 
POSITIVE 
% OF 
CANCER 
IN ANY 
CORE 
PSA 
DENSITY 
(NG/ML/G) 
VERY LOW <10 6 T1c <3 50% <0.15 
LOW <10 6 T1-2a - - - 
INTERMEDIATE 10-20, or  7, or T2b-c - - - 
HIGH >20, or 8-10, or T3a - - - 
VERY HIGH - Primary Gl 
pattern 5, 
or, >4 
score 8-10 
T3b-4 - - - 
Table 1.8. NCCN risk stratification of new diagnosis prostate cancer (NCCN, 2016).  
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In summary, the different risk stratifications are all very similar and all aid to 
characterise disease for the benefit of decision making and reporting of outcomes. 
The D’Amico classification remains the most widely used due its simplicity and easy 
application in clinical practice. 
 
1.10 Treatment options for prostate cancer 
 
The treatment of prostate cancer is varied and depends on the tumour grade and 
stage. In simplistic terms one can classify disease at presentation in to three main 
groups, localised prostate cancer, locally advanced non-metastatic prostate cancer 
and metastatic disease. 
  
1.10.1 Localised prostate cancer 
Localised prostate cancer, i.e. T2 or lower, can be treated in several ways and largely 
depends on the risk classification (as previously discussed) at presentation. 
 
The mainstay of treatment for low risk cases is with deferred treatment strategies 
with the aim to reduce the morbidity associated with radical treatment.  If patient 
fitness allows, intermediate and high risk cases should be treated with radical 
(curative) treatments such as radical prostatectomy, external beam radiotherapy or 
brachytherapy. Other novels techniques such as high intensity focused ultrasound 
(HIFU) and cryotherapy remain outside the scope of mainstream therapy and are 
only recommended as part of clinical trials. 
 
Radical treatment options for prostate cancer can result significant in morbidity. As 
discussed, many newly diagnosed prostate tumours will have a protracted natural 
history and may pose no threat to overall life expectancy. Despite this, some patients 
will still choose to have radical treatment and expose themselves to the potential 
side effects of such treatment. With an increasing incidence of CaP there are real 
concerns regarding the over-diagnosis and over-treatment of clinically insignificant 
prostate cancer. The ProtecT study recently demonstrated no difference in overall 
survival in men with low risk, screening detected prostate cancer, undergoing either 
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active surveillance, radical prostatectomy or radical radiotherapy. The only benefit 
seen was in those men that had surgery and radiotherapy had a lower rate of disease 
progression and metastases but this number was low. They concluded that 27 men 
would need to have a prostatectomy or 33 receive radiotherapy to prevent 1 man 
from developing metastases, or 9 men treated with either to prevent one case of 
disease progression(Hamdy et al., 2016). This study therefore emphasises the 
indolent course of low risk prostate cancers and the need to try and avoid over 
treatment of such disease. One could argue that ProtecT results may represent 
worse outcomes than current practise as current active surveillance protocols 
include re-biopsy and MRI neither of which were included in ProtecT protocol. 
 
Two other notable studies, PIVOT and SPCG-4, looked at the effect of surgery versus 
observation in localised prostate cancer have produced interesting results. PIVOT 
(Prostate cancer Intervention Versus Observation Trial) looked at the difference in 
all-cause mortality and prostate cancer mortality in patients with localised disease 
having either surgery or observation. With nearly 20 years’ follow-up (13 years’ 
median) there was no difference in all cause or prostate cancer mortality between 
those that had surgery or observation. Within sub-groups there was slight 
improvement in all-cause mortality for men with intermediate risk disease but not 
for low or high risk. Surgery was associated with higher rates of complications such 
as incontinence and impotence and lower rates of progression. It is worth noting 
that this study includes men prior to changes in Gleason scoring and therefore men 
with Gleason 6 disease may now be classified as Gleason 7 with recent changes (Wilt 
et al., 2017).  
SPCG-4 was also carried out in the early days of PSA testing when Gleason scoring 
was different to today and most patients had palpable disease. They noted a 
decrease in death from prostate cancer in the surgery group versus observation at 
29 years’ follow-up. Those that had surgery had a mean increase in life of 2.9 years. 
This was more marked in patients under 65 years of age and they stated that just 
under 7 prostatectomies were needed to avoid one death in this subgroup (Bill-
Axelson et al., 2018). 
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1.10.1.1 Deferred treatment strategies 
Given the body of evidence suggesting low risk disease follows an indolent course 
deferred treatment strategies offer an excellent option for men wanting to avoid 
unnecessary treatment. Encouragingly figures show a shift away from over 
treatment of low risk disease with only 8% of men in England receiving treatment in 
2017 compared with 12% in 2014 (NPCA., 2018). 
 
Deferred treatment strategies for prostate cancer are well established, however, 
long term follow-up data on these remains limited and patient selection continues 
to cause debate. The deferred treatment strategy chosen depends on patient fitness 
and anticipated life expectancy. There are 3 defined strategies- active surveillance, 
active monitoring and watchful waiting. 
 
Active surveillance  
Active surveillance is defined as a deferred treatment strategy with the intention to 
treat patients with radical intent if evidence of disease progression develops or the 
patient expresses a wish for treatment. 
 
After initial diagnosis patients are closely monitored with regular PSA blood tests and 
clinical examination.  Restaging prostate biopsies +/- repeat MRI is typically 
performed arounds 12 months after diagnosis.  
 
To be eligible for active surveillance patients should be in good health and have a life 
expectancy of at least 10 years. 
 
Active monitoring  
A predecessor to active surveillance, this term was coined from the ProtecT study. 
Again, this strategy involves a plan to treat with radical intent if patient 
demonstrates disease progression or expresses a wish for treatment. 
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After diagnosis patients are monitored with PSA blood tests and regular clinical 
examination. The main difference with this compared to AS is that patients are only 
offered restaging if clinically triggered i.e. rising PSA or change in clinical staging. 
It has now largely been superseded by AS but does remain relevant in a small subset 
of patients who did not wish to follow the strict regime of AS. 
 
Watchful waiting 
Defined as deferred treatment with the intentional to palliate if a patient develops 
disease progression. This is suitable for elderly or frail patients with a limited life 
expectancy, typically less than 10 years, who are not suitable for radical treatment. 
Treatment is usually with hormones when indicated. 
 
Currently NICE guidelines (NICE., 2019) within the UK recommend active surveillance 
for men with D’Amico low risk disease i.e., Gleason score of 6 or less, PSA <10 and 
clinical T2a or lower, and suggest considering it in men with intermediate risk disease 
who wish to defer radical treatment.  
 
The American Society of Clinical Oncology (ASCO) recommend that for most patients 
with low-risk localised prostate cancer AS is the recommended treatment strategy. 
This however, comes with a qualifying statement that accepts due to the 
heterogeneity of the group consideration must be given to young patients (<55yrs), 
higher volume Gleason 6 disease, patient preference and ethnicity. ASCO also 
recommend active treatment for most patients with intermediate risk localised 
disease. However, for patients with low volume intermediate risk disease (Gleason 
3+4) AS may be offered. A further qualifying statement from ASCO suggests only men 
with low volume Gleason pattern 4 or >75 should be considered or AS (Chen et al., 
2016).  
 
Including the total number of positive cores, single core positivity rates and 
parameters such as PSA DT in criteria for enrolment are obviously made with the 
right intent and should undoubtedly aid decision processes. However, in practice 
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having straight forward criteria such as suggested by NICE and ASCO is probably 
beneficial. 
 
The exact follow-up protocols for patients on active surveillance do vary between 
institutions but it is recommended that patients have regular PSA check between 4-
6 monthly and consider repeat MRI at 12-18 months after diagnosis (NICE., 2019). 
This represents an update from previous NICE guidance which recommended a 
restaging TRUS biopsy at 12-18 months rather than an MRI (NICE, 2014). In the 
updated NICE guidance repeat biopsy is suggested if there is a clinical change, PSA 
rise or MRI change. Evidence suggests repeat biopsy acts as a second gateway to 
continued surveillance and reduces the risks of under-staging the disease and 
ensuring there has been no grade progression, although less likely. Re-staging biopsy 
has been shown to be associated with a better outcome in patients on surveillance 
ensuring patients are truly low risk (Dall'Era et al., 2012). The use of MRI in 
surveillance is variable but has been shown to act as a good test for detecting 
clinically significant disease at enrolment although its use in follow-up is less well 
known (Schoots et al., 2015). 
 
It is widely accepted that more long term studies (>10-year follow-up) are needed 
on the outcomes of active surveillance given that it is younger men with a long-life 
expectancy enrolling on such programmes. Dall’Era et al 2012 performed a 
systematic review and compared outcomes from 7 large AS series. It showed 
treatment rates of between 11% at median follow-up of 1.8 years and 33% at 2.7 
years. Longest median follow up was 6.8 years with a treatment rate of 30% although 
this cohort was older at diagnosis. Prostate cancer specific mortality was low across 
all studies although follow up was limited (Dall'Era et al., 2012). The much larger 
PRIAS study with 10 year follow up showed that at 5 and 10 year follow up 52% and 
73% of men, respectively, had discontinued AS with the main reason being protocol 
based re-classification. The PRIAS study then went on to look at the pathological 
features at prostatectomy of men discontinuing AS and found that only Gleason 
upgrading or clinical T3 disease should be used as a trigger for radical treatment. 
They did not use MRI scans in this study (Bokhorst et al., 2016). 
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Deferred treatment strategies provide a key treatment pathway for men with low 
risk disease although many questions remain unanswered as to the optimum follow-
up routine, the timing of re-biopsies and the use of mpMRI in the pathway. With 
surveillance an attractive strategy for younger men it is essential that the risk of 
disease progression is minimised with a robust and effective treatment protocol. 
 
1.10.1.2 Radical prostatectomy 
Radical prostatectomy can be offered to men, in good health, with intermediate and 
high risk localised prostate cancer with greater than 10-year life expectancy. The aim 
being to cure prostate cancer with preservation of continence and minimal impact 
on potency (Mottet et al., 2017a) 
 
The surgical approach can include open, robotic assisted laparoscopic (RALP) 
approach or conventional laparoscopy. To date no one study has proved better 
oncological outcomes with one approach and there remains ongoing debate as to 
which one is superior. One cannot argue, however, that RALP has over taken 
conventional open surgery in becoming the standard approach for radical 
prostatectomy. In England in 2017, RALP accounted for 74% of all prostatectomies 
with only 12% performed open (NPCA., 2018). It is associated with less morbidity, 
often a shorter hospital stay and quicker return to normality. 
 
Post operatively PSA levels are monitored and should be undetectable (<0.1ng/ml). 
The accepted definition for biochemical recurrence (BCR) is 2 or more readings 
>0.2ng/ml and indicates recurrent disease (Mottet et al., 2017b). Predictors of BCR 
include Gleason grade, T-stage and PSA at diagnosis. However, not all patients with 
biochemical recurrence develop clinically apparent disease, with a risk of metastases 
and disease specific mortality. Risk factors for doing so include a PSA doubling time 
of <3 months, pT3b disease or higher, Gleason score 8 or BCR within 3 years of 
radical prostatectomy (Antonarakis et al., 2012, Brockman et al., 2015, Freedland et 
al., 2005).  
 
 44 
1.10.1.3 Radical radiotherapy 
External beam radiotherapy (EBRT), like surgery is offered to men with intermediate 
and high risk localised prostate cancer. Men wanting to avoid the potential side 
effects of surgery may choose EBRT as an alternative option. To date there has been 
no study which has shown superiority of surgery or EBRT over each other in the 
setting of localised prostate cancer. The ProtecT study reported excellent survivals 
rate at 10 years for men having surgery or EBRT (Hamdy et al., 2016). However, it is 
generally accepted that younger men may gain more benefit from surgery given that 
if the disease recurs salvage radiotherapy is more straight forward than the other 
way around of salvage surgery. Radiotherapy also conveys a small risk of secondary 
cancers the longer one lives after treatment. 
 
EBRT is usually given over a 4-week period with neo-adjuvant and adjuvant 
hormones given to patients with intermediate and high risk disease respectively. The 
addition of hormones to EBRT has been shown to improve disease free and overall 
survival (Bolla et al., 2002). After EBRT the PSA level is expected to fall to a low point 
(the nadir), recurrence after treatment is defined as a rise of 2ng/ml above the nadir. 
 
1.10.2 Locally advanced non-metastatic prostate cancer 
Locally advanced disease defines men who have cancer that has spread outside of 
the capsule of the prostate (>T2) but has not metastasised elsewhere. 
 
If the patient is fit, the mainstay of treatment for locally advanced non-metastatic 
prostate cancer is EBRT and long term (3 years) hormone therapy. A number of 
studies have shown improved disease free survival and overall survival with this 
regime (Bolla et al., 2002, Warde et al., 2011). 
 
In more recent years there has been a drive to avoid under-treatment of men with 
locally advanced disease, i.e. offering them radical treatment as opposed to non-
curative treatment with hormonal therapy. Increasingly fit men with non-metastatic 
T3 disease are being offered surgery as the primary treatment accepting the 
possibility of needing additional EBRT, if the disease recurs or if it is not all removed 
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(positive margins and detectable post-operative PSA), as part of a multimodality 
approach. Surgery offers a chance of cure and long term control but at the risk of 
needing additional treatment. To date, the timing of adjuvant EBRT in this setting is 
being evaluated by the RADICALS trial (Parker et al., 2007). Two other trials, EORTC 
22911 and SWOG 8794, compared immediate adjuvant EBRT versus EBRT at the time 
of BCR, in the setting of positive surgical margins and/or T3 disease post RP. Both 
trials showed improved biochemical progression free survival rates, however, only 
SWOG 8794 showed improved overall survival rates at 10 years (Bolla et al., 2012) 
(Thompson et al., 2009). 
 
1.10.3 Metastatic prostate cancer 
The aim of treatment in men with metastases is to control the disease rather than 
to cure. This is achieved via the manipulation of testosterone with the aim of 
reducing it to a castrate level (androgen deprivation therapy). This is done either 
surgically with bilateral sub-capsular orchidectomy, or via medical castration. 
Medical castration, can be achieved via several different methods; the 
hypothalamic-pituitary-testes axis can be turned off with leutinising hormone 
releasing hormone (LHRH) analogues or antagonists, alternatively the androgen 
receptor (AR) can be targeted with anti-androgens. Typically, with ADT the disease 
will be controlled for 12-18 months and then men develop castrate-resistant 
prostate cancer (CRPC) with AR activity returning. At this time, more novel agents 
such as enzalutamide and abiraterone are available and offer small but significant 
survival benefits. Chemotherapy also plays an important role in the management of 
metastatic disease. Traditionally it was used following the failure of first line 
hormonal treatment and offered a 2-3 month survival benefit if used at the time of 
CRPC (Tannock et al., 2004). However, it has now been shown to offer a 10-month 
survival benefit if used upfront i.e. soon after starting ADT (James et al., 2016). 
 
1.11 Use of MDTs 
 
Multi-disciplinary team meetings bring together all expert clinicians involved in the 
individual patients care to discuss results of diagnostic investigations and decide on 
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the correct course of action. They have been mandated in clinical practice in the UK 
for cancer care for over 15 years and discussion at MDT provides reassurance to both 
clinicians and patients alike. The benefits of MDT discussion have been shown to 
improve cancer survival rates in breast cancer and have shown to be financially 
sustainable (Kesson et al., 2012). 
 
MDTs also provide a record for patient care and are a vital source of data collection 
for cancer services which can feed into local and national databases to provide up to 
date and relevant cancer statistics. 
 
In 2014, the National Prostate Cancer Audit was established in England and Wales to 
ensure the care received by men was as recommended by NICE and ensure that care 
was uniform. The main outcomes of the audit were to assess – 
- Service delivery and organisation of care in England and Wales   
- The characteristics of patients newly-diagnosed with prostate cancer   
- The diagnostic and staging process and the planning of the initial treatment 
- The initial treatments that men received   
- The experiences of men receiving care as well their health outcomes 18 
months after diagnosis   
- Overall and disease-free survival  
The use of local MDTs is critical in capturing data required for this and data collection 
was mandated by the government (NPCA., 2017). 
  
1.12 Summary and thesis aims 
 
This thesis will use a prospectively collected database of newly diagnosed cases of 
prostate cancer discussed at a single centre specialist MDT (the EPC MDT) over a 20-
year period to address several clinically relevant questions. The database provides a 
unique insight in to the disease characteristics, presentation trends, staging 
investigations and the treatment of men processed through a large single specialist 
MDT.  
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The aims of the thesis will follow the pathway of a patient through from diagnosis to 
treatment and are as follows: 
  
1. Interrogation of the EPC MDT database, with the specific aims to: 
a. Assess the data quality of the EPC database 
b. Assess patient capture rates post 2014 following the introduction of 
the National Prostate Cancer Audit (NPCA) in Wales. 
c. Present an overview of the data recorded on the EPC database. 
d. Assess trends in symptoms at presentation and their relationship on 
disease stage and the primary treatment undertaken in all cases 
captured by the EPC MDT over a 20-year period. 
e. Assess the impact of family history on disease stage at presentation 
and the primary treatment undertaken in all cases captured by the 
EPC MDT over a 20-year period. 
f. Assess changes in primary treatment patterns over the 20-year period 
of the EPC MDT and compare with national figures. 
 
2. Review the utilisation of bone scan staging, with the specific aims to: 
a. Review bone scan positivity rates in the EPC MDT cohort. 
b. Determine the threshold for requesting a bone scan in newly 
diagnosed intermediate risk localised prostate cancer patients. 
 
3. Review the outcomes of men undergoing radical prostatectomy as a primary 
treatment and assess if the changes in MRI technology and protocols have 
effected upstaging rates. The specific aims are: 
a. Create a radical prostatectomy dataset created from the EPC MDT 
database 
i. Report on the disease characteristics and staging results of all 
men undergoing RP as a primary treatment following EPC 
MDT. 
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ii. Compare the pre-operative staging and grading parameters 
with the prostatectomy pathology. 
iii. Assess predictive markers of biochemical recurrence. 
 
b. Assess the accuracy of MRI staging. 
Compare the staging accuracy of MRI over the time of EPC MDT and effect 
that different MRI technique and timing has had on: 
i. The correlation between a positive MRI (detectable lesion) 
and different associated prognostic features such as Gleason 
score, clinical stage, PSA etc. 
ii. The effect of upstaging after radical prostatectomy. 
 
4. Review the outcomes of men on a deferred treatment strategy for localised 
prostate cancer, with the specific aims to: 
a. Assess the outcome of all patients enrolled on an active monitoring 
or surveillance program. 
b. Assess the outcomes of introducing protocol re-staging in a cohort of 
clinically stable active monitoring patients – defined as Restaging 
Group 1.  
c.  Compare the outcomes of restaging in Restaging group 1 (protocol 
re-staging in a stable cohort of AM patients) with patients having 
both: 
i. Clinical change or triggered re-staging - defined as Restaging 
Group 2,  
and  
ii. Protocol restaging as part of active surveillance - defined as 
Restaging Group 3 
d.  Assess the use of MRI in restaging and its usefulness in the pathway. 
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Chapter 2. The Early Prostate Cancer MDT – a 20-year experience of a 
single centre specialist MDT – results from a prospectively collected 
database 
 
2.1 Introduction 
 
2.1.1 The Early Prostate Cancer (EPC) MDT  
The concept of an MDT meeting was developed to bring together expert opinions 
from different clinicians within the same field of expertise to agree on the optimum 
treatment strategy for each individual patient. It is now the standard of care for 
cancer management within UK practice and has been shown to improve cancers 
outcomes (Kesson et al., 2012). 
 
A specialist MDT was established at the University Hospital of Wales, Cardiff, in 
February 1997 with the aim of discussing all new cases of prostate cancer that were 
suitable for radical treatment. As a result, the MDT was termed the ‘Early Prostate 
Cancer MDT’ or ‘the EPC MDT’ and this term has remained despite evolving in to its 
current form where the aim is to discuss all new cases of prostate cancer. Other 
existing prostate cancer cases are also discussed when management decisions are 
complex and require discussion. From its inception, there has been an aim to 
prospectively record all new cases discussed on an electronic database. This has led 
to the creation of an extremely large cohort of patients managed by the many of the 
same clinicians over a 20-year period and represents a unique insight in to 
presentation trends, as well as the results of staging investigations and the primary 
treatment undertaken. 
 
The EPC MDT is comprised of urologists, an expert uro-pathologist, a radiologist, an 
MDT coordinator from the hospital cancer service department and specialist uro-
oncology nursing staff. The composition has remained constant throughout and so 
have many of the key team members.  
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Data collection has focused on the presenting disease characteristics and planned 
primary treatment. There have three amendments to the data collection pro-forma 
over the period assessed and these reflect changing practice and requirements of 
the MDT. However, staging protocols have not changed significantly with all patients 
suitable for radical treatment having an MRI scan at diagnosis and isotope bone scan 
staging. This level of staging at time of introduction was not routine practice within 
the UK and probably remains the case. We therefore believe that the database of 
EPC patients represents a unique insight in the evolution or presentation and 
management of patients over a 20-year period in a large tertiary referral UK centre 
where staging protocols have remained largely uniform.  
 
This chapter will interrogate the EPC MDT dataset. Specifically, I will focus on the 
assessing quality of data to determine its accuracy and its suitability to answer 
clinically relevant questions addressed later in this thesis. This chapter will provide 
an overview of the EPC dataset. It will also pay attention to the impact that 
symptoms and family history have on presenting disease characteristics and how 
they may influence treatment choices. Also, as discussed previously there is an 
increasing awareness to avoid overtreatment of low risk disease and under 
treatment of high risk disease. I will assess how treatment rates in a contemporary 
UK sMDT have changed over a 20-year period. 
 
It must be acknowledged that some of the aims within this chapter will be subject to 
bias in data collection as prior to 2014 the EPC MDT was not designed to capture all 
new cases of prostate cancer within the health board. Therefore, it must be 
remembered that any conclusions made in this chapter relate to cases discussed at 
a specialist MDT within an evolving case load and are not inclusive of all new cases 
of prostate cancer within the health board over a 20-year period. 
 
2.2 Aims 
The specific aims of this chapter were: 
 
1. Assess the data quality of the EPC database 
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2. Assess patient capture rates post 2014 following the introduction of the 
National Prostate Cancer Audit (NPCA) in Wales. 
3. Present an overview of the data recorded on the EPC database 
4. Assess trends in symptoms at presentation and their relationship on disease 
stage and the primary treatment undertaken in all cases captured by the EPC 
MDT over a 20-year period. 
5. Assess the impact of family history on disease stage at presentation and the 
primary treatment undertaken in all cases captured by the EPC MDT over a 
20-year period. 
6. Assess changes in primary treatment patterns over the 20-year period of the 
EPC MDT and compare with national figures. 
 
2.3 Methods 
 
2.3.1 Service evaluation approval 
The study was granted approval by the service improvement department within the 
surgical department in UHW, Cardiff. Patients were also requested to consent at the 
time of their first appointment, following MDT discussion, for their presenting 
disease statistics to be stored on the database. 
 
2.3.2 Patient population 
As mentioned in the early days of data collection only selected patients with newly 
diagnosed prostate cancer were discussed at the EPC specialist MDT and it was often 
only those that were suitable for radical treatment. Other cases of new diagnosis 
prostate cancer not suitable for radical treatment may have been discussed at a local 
MDT rather than the specialist EPC MDT. 
 
Over the 20 years of data collection, numbers have increased as patient care is 
streamlined though a single MDT with the mandate that all new diagnoses be 
discussed. The most significant change came in 2014 when data collection for the 
EPC MDT was changed to mirror the data required for the upcoming data collection 
for the National Prostate Cancer Audit. It was this move that led to a big drive to 
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discuss all newly diagnosed prostate cancer patients within the local Health Board 
regardless of stage and patient fitness in a single specialist MDT and one which 
continues.  
 
The significant majority of patients that are discussed at the EPC MDT will be new 
diagnosis patients from within the catchment area of the Health Board. However, 
there are a small subset of patients that are referred by a neighbouring health board, 
Cwm Taf, that are also discussed at the EPC MDT. These are patients that have been 
referred for consideration of radical prostatectomy and are subsequently reviewed 
at the MDT prior to review in an outpatient clinic. 
 
2.3.3 Data collection and amalgamation of different data sets 
Data capture for analysis was from February 1st, 1997 to January 31st, 2017.  
 
All data was collected on pre-designed data collection sheets. Data was inputted at 
two different time points, firstly at the time of discussion in the MDT and secondly 
after review and discussion with the patient when the treatment plan has been 
determined in an outpatient clinic. All data was recorded by clinicians. 
 
There have been two changes to the data collection sheets over time, i.e., three 
different forms have been used. The latest change was in 2014 and was introduced 
to enable data collection to match the required data items for the National Prostate 
Cancer Audit (NPCA) which started in Wales in April 2015.  
 
The first data collection sheet used was between 1997 and 2002 (Figure 2.1). It was 
not coded and relied on freehand descriptive input. The first amendment and 
subsequent creation of the second datasheet (Figure 2.2) introduced coded 
descriptions and this was used from 2002 until 2014. The second and most recent 
amendment to create the third datasheet (Figure 2.3) was done to increase the 
number of data items recorded to bring it in line with the NPCA dataset. This 
datasheet has been used since April 2014 and is still currently in use. 
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At the time of review the data had been recorded on two separate excel databases, 
one pre-April 2014 and the other post-April 2014. In order to analyse, the data sets 
were amalgamated to introduce uniformity across data items.  
 
An overview of each data item recorded and amendments made when 
amalgamating data sets is recorded as follows; 
 
1. Patient demographics  
a. Recorded throughout in the same format. 
2. Referral Hospital –  
a. Recorded throughout in the same format 
3. Referral Doctor 
a. Recorded throughout. 
b. Coding changed in 2014 with addition of different consultants. 
4. PSA at diagnosis 
a. Recorded throughout in the same format (ng/ml) 
5. Presentation – how the patient presented.   
a. Recorded throughout. 
b. One addition in 2014 with the addition of symptoms due to 
metastases to correspond to NPCA dataset 
6. TURP -  if patient presented following TURP this documents the percentage 
of positive chips involved.  
a. Recorded throughout in the same format (%). 
7. Family History 
a. Recorded throughout in the same format. 
8. ASA grade 
a. New addition in 2014 to correlate with NPCA dataset. 
9. Performance score  
a. New addition in 2014 to correlate with NPCA dataset. 
10. Referral clinical T stage 
a. Recorded throughout.  
b. Change in 2014 to include stage T2c. 
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11. Referral Gleason 
a. Recorded throughout in the same format. 
12. EPC clinical T stage 
a. Recorded throughout.  
b. Change in 2014 to include stage T2c 
13. Random TRUS biopsy 
a. Recorded throughout.  
b. Change to coding in 2014 to include saturation TRUS biopsy. 
14. Perineal biopsy 
a. New addition in 2014 to correlate with the NPCA dataset. 
15. Additional targeted biopsy 
a. Recorded throughout in the same format. 
16. EPC Gleason 
a. Recorded throughout in the same format. 
17. Tertiary Gleason 
a. New addition in 2014 to correlate with NPCA dataset. 
18. Core features 
a. New addition in 2014 to correlate with NPCA dataset. 
19. Number of positive cores and total number of cores taken 
a. Recorded throughout in the same format. 
20. Maximum positive core length 
a. Recorded throughout in the same format. 
21. Total length of core containing maximum tumour length 
a. New addition in 2014 to correlate with the NPCA dataset 
22. Bone scan 
a. Recorded throughout in the same format. 
23. Further bone imaging 
a. Recorded throughout in the same format. 
24. MRI timing 
a.  New addition in 2014 to correlate with NPCA dataset. 
25. MRI T stage 
a. Recorded throughout.  
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b. Change in 2014 to include stage T2c  
26. MRI N stage 
a. Recorded throughout in the same format 
27. Further biopsy investigation required before final stage 
a. New addition in 2014 
28. Final stage or Consensus stage 
a. Final stage was used until 2014 when this was replaced with 
consensus stage. The recording of final stage up until 2014 was not as 
specific as the updated consensus stage. This considers the clinical 
and MRI stage to provide an agreed TNM stage at the time of MDT. 
29. D’Amico risk classification 
a. New addition in 2014. 
30. Treatment intent 
a. New addition in 2014. 
31. Patient choice or Planned treatment 
a. Recorded up until 2014 and then changed to planned treatment. 
32. Treatment undertaken 
a. Recorded throughout.  
b. Changes in 2014 to add additional treatments and recoding of some 
treatments. 
33. Staging node sampling 
a. Recorded up until 2014. 
34. Androgen deprivation 
a. New addition in 2014. 
35. Other therapies 
a. New addition in 2014. 
36. Trial patient 
a. New addition in 2014. 
37. Data authority signed 
a. New addition in 2014. 
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2.3.4 Data quality assurance 
Prior to analysis a series of measures were taken to ensure accuracy of data. All 
duplicates were identified and removed. All pathology data on the TRUS biopsy 
result was reviewed and checked for accuracy against documented reports on the 
hospital reporting system. Missing items were filled in. The documented treatment 
undertaken was also verified with actual the actual treatment received and this was 
used as the marker of data quality.  
Patient capture at MDT was also assessed prior to the start of data collection for the 
NPCA and compared with the local cancer service records and the national data sets. 
 
2.3.5 National Prostate Cancer Audit 
The National Prostate Cancer Audit commissioned through HQIP was set up in 2014 
in England to capture all new prostate cancer cases. The overriding aims of the audit 
were to assess (NPCA., 2017); 
- Service delivery and organisation of care in England and Wales.   
- The characteristics of patients newly diagnosed with prostate cancer.   
- The diagnostic and staging process and planning of initial treatment.  
- The initial treatments that men received.  
- The experiences of men receiving care and their health outcomes 18 months 
after diagnosis  
- Overall and disease-free survival rates 
Data collection is mandatory and is the responsibility of individual Health Boards in 
Wales to comply. Data collection in Wales started a year later than in England in April 
2015. Prior to this a year of data collection running from April 1st, 2014 to April 2015 
was carried out in UHW, Cardiff, as a pilot to ensure data collection was feasible and 
robust. As part of the project team for the NPCA and NPCA Clinical Research Fellow 
for Wales I ensured data capture was accurate and felt the introduction of the NPCA 
within Wales has had a major impact in ensuring data collection at MDT was 
improved. 
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2.3.6 Data analysis 
The initial datasets were recorded and amalgamated using Microsoft Excel. The final 
dataset was then transferred to IBM SPSS version 23 where all statistical analysis was 
performed.   
Chi square test and multi-variate Poisson regression was used to identify factors 
independently associated with symptomatic presentation and those with family 
history.  
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Figure 2.1. EPC MDT data collection sheet 1. Used from 1997 to 2002. 
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Figure 2.2. EPC MDT data collection sheet 2. Used from 2002 to March 2014. 
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Figure 2.3. Data collection sheet 3. Used from April 2014 to the present day. 
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2.4 Results 
 
2.4.1 Aim 1 - Data quality 
After the exclusion of duplicates and confirmation of biopsy findings, all cases were 
assessed. Data quality was defined as the percentage of cases with an accurate 
recording of the primary treatment undertaken. 
 
3575 new cases of prostate cancer were identified. Incorrect treatment was 
documented in 178 cases accounting for a 5% error rate. The largest area for error 
was in the recording of patients who were recorded as on an active surveillance 
program but were on a watching waiting approach, accounting for just over a quarter 
(28%) of all mistakes. However, this may reflect a change in terminology rather than 
incorrect recording (Figure 2.1). 
 
 Treatment 
received  
AS WW RP RT Brachy ADT TOTAL 
Treatment 
recorded 
        
AS  N/A 50 24 11 1 3 89 
WW  13 N/A 3 16 - 3 35 
RP  7 - N/A 5 - 1 13 
EBRT  6 - 4 N/A - 6 16 
Brachy  2 - 1 2 N/A - 5 
ADT  - - 1 16 - N/A 17 
Focal   - - - - - 1 1 
No record  - - 1 - - 1 2 
TOTAL  28 50 34 50 1 15 178 
Table 2.1. Data quality indicator. Comparison of treatment recorded on the EPC MDT 
data collection sheet versus the actual treatment undertaken for cases where an 
error was detected (n=178). 
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2.4.2 Aim 2 - Accuracy of data capture. 
An assessment was made to determine the quality of patient capture at the EPC 
MDT, i.e., were all new diagnoses being captured and hence, could meaningful 
comparisons be made.  
 
Three separate databases that should theoretically contain the same patients were 
compared; 
 
1. Database 1 (DB1) - The EPC MDT database. Generated by clinical referrals 
2. Database 2 (DB2) – The hospital cancer services database. Generated by 
clinical referrals, MDT discussion and pathology reports 
3. Database 3 (DB3) – The Welsh national cancer registry data (Canisc). 
Generated from all the previous data sources. 
 
The period of analysis was between the 1st April 2014 and 1st April 2015 and aimed 
to mirror the period for the start of the NPCA data collection for England and 
followed the introduction of the new data collection sheet for the EPC MDT. It was 
in effect a trial period of data collection for the NPCA data within UHW and was 
performed to address potential pitfalls in data capture.  
 
The definition for the date of diagnosis did vary between databases and led to 
discrepancies in number of patients for the defined period (Table 2.2). The date of 
diagnosis for the EPC database is derived from the date that the TRUS biopsy 
pathology was reported. However, for hospital cancer services and Canisc the date 
of diagnosis is taken from the date that the biopsy was taken. 
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 DB1 -  
EPC MDT 
database 
DB2 -  
Hospital cancer 
services 
DB3 -  
National registry  
No. of patients 320 448 338 
Inclusion criteria Date of pathology 
report 
Date diagnostic 
biopsy taken 
Date diagnostic 
biopsy taken 
No. of patients 
not on DB1 
N/A 52 50 
No. of patients 
need adding to 
DB1 
N/A 31 31 
Table 2.2. Table to compare patient capture rates on the EPC MDT database, the 
hospital cancer service database and the National cancer registry database for men 
with new diagnosis prostate cancer. Between 1st April 2014 and 1st April 2015. 
 
To account for the discrepancies in patient numbers between each database they 
were cross-referenced. Where cases were not present on each database the 
individual case was reviewed. The discrepancies can be accounted for as follows; 
 
1.DB1 – The EPC dataset 
The EPC database had 320 patients recorded. 
- 37 patients had a biopsy date prior to 1st April 2014 therefore would not 
have been included on DB2 or DB3 
- 19 Patients on DB1 but not on DB2 
o 13 were referrals from peripheral hospital or private 
o 6 were new diagnosis prostate cancer  
▪ 3 of these were not on DB3 
- 74 patients on DB1 but not on DB3 
o 23 of these are on DB2 
o 51 are not on DB2 
 
2 .DB2 – Hospital cancer service dataset 
This database had 448 patients recorded. 
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- 52 patients were not on the EPC 
o 31 needed adding to EPC database 
▪ New diagnosis - 22 patients 
▪ TURP/HoLEP - 5 patients 
▪ Private patients - 4 RRPs in UHW 
o 9 patients already on EPC MDT database prior to April 2014 (AS 
re-biopsy or previous RRP) 
o 1 incorrect coding 
o 2 cystectomies with incidental prostate cancer 
o 3 Swansea patients 
o Other 6 patients – logical reason for non-inclusion on EPC 
database. 
 
3. DB3 – National data registry – Cansic 
This database had 338 patients recorded. 
- 38 patients on database but not on EPC database between time frame. 
However, they are all on EPC post 1-4-15. 
- 50 patients not on EPC (45 are the same patients as highlighted above by 
hospital database. 5 additional ones – 4 are private patients with no data 
and the other was diagnosed in 2009) 
o 31 need adding to EPC database 
▪ New diagnosis - 22 patients 
▪ TURP/HoLEP - 5 patients 
▪ Private patients – 4 RRPs in UHW 
o 7 already on database prior to April 2014 (AS re-biopsy or previous 
RRP) 
o 1 incorrect coding 
o 2 cystectomies with incidental prostate cancer 
o Other 4 patients – logical reason for non-inclusion on EPC 
database  
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In summary: 
Data capture for NPCA 
There were only three patients that would not have been captured by the hospital 
cancer services and hence not entered in to the national prostate cancer audit for 
the pilot year. This equates to an error rate of <1% and represents a robust process 
for data collection for the NPCA. 
Data capture rates for EPC MDT 
There were 31 patients detected by both database 2 and 3 that were missing from 
the EPC database. This equates to a 10% error rate for patient capture on the EPC 
database. 
 
2.4.3 Aim 3 – An overview of EPC data collection 
Number of cases 
A total of 3575 cases were discussed. There was a trend of increasing patient 
numbers over the period with a peak in 2015 of 375 (Figure 2.4). This represents an 
increasing capture rate of all new diagnoses, particularly post 2014, when NPCA data 
collection ensured new cases were discussed. 
 
 
Figure 2.4. Graph showing the number of newly diagnosed patients discussed at EPC 
MDT per year, 1997-2016 (2017 not included as incomplete year). (N=3575) 
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Source of referral 
76.2% of referrals to the MDT were from within our institution. 13.3% were from 
Cwm Taf Health Board with the remaining from other sources including private 
referral. The proportion of external referrals to the MDT has remained very stable 
over the last 8 years (2009 onwards). Prior to this, 20-40% of cases discussed at the 
MDT were external referrals. However, when looking at the actual number rather 
than the proportion one can see that it has not changed dramatically year on year 
(Figure 2.5). 
 
 
Figure 2.5. Graph to show the source of referral for patients discussed at the EPC 
MDT by year of presentation. (N=3575) 
 
Age at diagnosis 
The mean and median age at diagnosis showed a steady rise from the introduction 
of the MDT to the present day (Figure 2.6). In 1997, the mean age was 65.2 years old 
and in 2016 it was 68.5 years. The overall mean was 66.8 with a median of 67 years 
old (range 39 – 100). The increase in age is most likely to account for the inclusion of 
all new cases and patients less appropriate for radical treatment. These patients 
were less likely to have been discussed in the early days of EPC MDT. 
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Figure 2.6. Graph to show the mean and median age at diagnosis by year of 
presentation. (N=3575) 
 
PSA level at diagnosis 
The mean PSA at diagnosis varied dramatically year by year but the overall trend was 
that of an increasing level. During the first three years of the MDT the mean PSA was 
less than 15ng/ml, however, in 2015 and 2016 the level was greater than 100ng/ml. 
The median PSA was more consistent over time as one would expect (Figure 2.7). 
The overall mean PSA was 44.3 and median was 9.2 ng/ml (range 0.2 to 9998ng/ml). 
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Figure 2.7. Graph to show the mean and median PSA at diagnosis by year of 
presentation. Large spikes in mean PSA can be accounted for by individuals with very 
high PSA levels. (N=3575) 
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Symptom Number of cases Percentage (%) 
Asymptomatic raised PSA  1268 35.5 
LUTS and raised PSA 1421 39.7 
LUTS 206 5.8 
Retention 65 1.8 
TURP 62 1.7 
Haematuria  152 4.3 
Haematospermia 38 1.1 
Erectile dysfunction 13 0.4 
Abnormal DRE 52 1.5 
Symptoms of metastases 51 1.4 
Other 164 4.6 
Not known 83 2.3 
Table 2.3. Table to show the range of symptoms that men presented with prior to 
being diagnosed with prostate cancer. (N=3575) 
 
As a percentage of cases presenting each year, from 1997 to 2002, there was a 
significant proportion of men presenting with LUTS alone. From 2002 onwards this 
percentage fell significantly and was replaced by men presenting with a raised PSA 
and LUTS. From 2003 onwards, there were roughly equal numbers presenting 
asymptomatic raised PSA and raised PSA with symptoms. The other most notable 
difference was in men presenting with symptoms of metastases. Almost nobody was 
discussed at MDT with these symptoms prior to 2014, in 2015 and 2016 these 
accounted for between 6-7% of cases (Figure 2.8). 
 
 70 
 
Figure 2.8. Pivot table plot to illustrate the change in presenting symptoms over 20 
years of EPC MDT data collection. (N=3575) 
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have been assessed by one of a variety of clinicians, i.e. general practitioner, nurse 
specialists, urology registrars or a non-EPC MDT consultant (non uro-oncology sub-
specialist). The clinical stage recorded at the EPC MDT is assessed by one of the pelvic 
oncologists in the department and represents an accurate/expert clinical staging. 
 
Overall, the proportions of documented clinical T-stage appeared to be similar 
between referral and EPC MDT (Figure 2.9). The only stage that differed dramatically 
was the number of patients with T2a disease, there appeared to many more patients 
with T2a at referral stage than were recorded at EPC MDT. However, there were 
many more patients who did not have their stage recorded at EPC and this may 
account for this discrepancy.  
 
 
Figure 2.9. Graph showing the overall numbers of clinical T-stage at time of referral 
to and after assessment at the EPC MDT by a pelvic oncology surgeon. (N=3575) 
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concordance with 23.6% upstaged at EPC and 18.2% down-staged, 13.4% were not 
stated. For higher clinical T-stages, there was again poor concordance and a much 
higher rate of T stage not being recorded (Table 2.4). This may be a result of clinicians 
feeling clinical stage was less important to repeat as other diagnostic tests may have 
already confirmed high risk disease. 
 
 EPC 
cT-
stage 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N/R  
T1a 
 
T1b 
 
T1c 
 
T2a 
 
T2b 
 
T2c 
 
T3a 
 
T3b 
 
T4 
Total 
Referral 
Stage 
           
`N/R 23.6% 
(91) 
1.3% 
(5) 
0.3% 
(1) 
29.4% 
(113) 
19% 
(73) 
9.1% 
(35) 
1% 
(4) 
10.9% 
(42) 
3.4% 
(13) 
1.8% 
(7) 
384 
T1a 
 
6.7% 
(3) 
40% 
(18) 
2.2% 
(1) 
37.8% 
(17) 
8.9% 
(4) 
2.2% 
(1) 
0 2.2% 
(1) 
0 0 45 
T1b 
 
18.6% 
(8) 
0 27.9% 
(12) 
32.6% 
(14) 
11.6%  
(5) 
9.3% 
(4) 
0 0 0 0 43 
T1c 
 
7.0% 
(71) 
0.9% 
(9) 
0.2% 
(2) 
72.4% 
(735) 
11.6% 
(118) 
4.4% 
(45) 
1% 
(10) 
2% 
(20) 
0.4% 
(4) 
0.01% 
(1) 
1015 
T2a 
 
13.4% 
(136) 
0.6% 
(6) 
0.7% 
(7) 
16.9% 
(172) 
48.8% 
(497) 
11.4% 
(116) 
1.3% 
(13) 
8.7% 
(89) 
1.8% 
(18) 
0.4% 
(4) 
1018 
T2b 
 
20.9% 
(65) 
0.3% 
(1) 
0.3% 
(1) 
7.1% 
(22) 
11.3% 
(35) 
43.7% 
(136) 
1%  
(3) 
12.9% 
(40) 
2.6% 
(8) 
0 311 
T2c 
 
6.3% 
(4) 
0 0 9.5% 
(6) 
11.1% 
(7) 
3.2% 
(2) 
57.1% 
(36) 
9.5% 
(6) 
1.6% 
(1) 
1.6% 
(1) 
63 
T3a 
 
33% 
(144) 
0 0 1.1% 
(5) 
1.6% 
(7) 
3.2% 
(14) 
0.5% 
(2) 
54.4% 
(237) 
4.1% 
(18) 
2.1% 
(9) 
436 
T3b 
 
72.2% 
(83) 
0.9% 
(1) 
0 1.7% 
(2) 
0 0 0 5.2% 
(6) 
20% 
(23) 
0 115 
T4 
 
44.8% 
(47) 
0 0 1%  
(1) 
1.9% 
(2) 
0 0 1%  
(1) 
1.9% 
(2) 
49.5% 
(52) 
105 
Total  
 
652 40 24 1087 748 353 68 442 87 74 3575 
Table 2.4. Concordance between clinical T stage at referral stage compared with 
clinical T-stage at EPC MDT after review by a pelvic oncology surgeon. 
 
Gleason grade at presentation 
There was a marked increase in the number of Gleason 6 and 7 disease over the 
period of the EPC data collection. Over the last ten years of data collection there has 
been a very similar rise in the number of Gleason 6 and 7 disease. High risk disease 
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(Gleason >7) numbers were relatively stable over the period, however, numbers 
have increased over the past 5 years and probably represent an increased capture 
rate of all new diagnosis cases, including the cases with metastatic disease, that may 
not have previously discussed at the EPC MDT (Figure 2.10). 
 
 
 
Figure 2.10. Graph showing the overall numbers of Gleason score at diagnosis over 
the period of EPC data collection, 1997 - 2016. (N=3441) 
 
 
When reviewing the Gleason score as a percentage of all cases that presented each 
year there appeared to be a decreasing proportion of Gleason 6 disease compared 
to higher risk disease. Between 2002 and 2007 the proportion of Gleason 6 disease 
was between 50-60%, whereas, between 2008 and 2013 the rate was between 40-
50% and for the last 3 years the rate was less than 40% (Figure 2.11). 
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Figure 2.11. Pivot table plot to show the proportions of Gleason disease by year of 
presentation to EPC MDT, 1997 to 2016. (N=3575) 
 
 
As for clinical T stage, a comparison was made between the Gleason score recorded 
at initial diagnosis and the Gleason score after EPC MDT review. Concordance rates 
were very high across all Gleason scores, >94%, apart from Gleason <6 where rates 
were 72.1%. As one would expect, all cases that were discordant were upstaged 
(Table 2.5). This group of Gleason score <6 represent historic practice and it would 
be interesting to review this cohort and rescore them with contemporary 
classification to see how it would change. 
 
Overall, given the high rate of concordance with Gleason scores one could argue the 
benefit of review at MDT as the Gleason scores are already peer reviewed prior to 
publishing a formal report as set out by ISUP guidelines. 
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 EPC  
Gleason 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<6 6 7 8 9 10 Total 
Referral 
Stage 
       
<6 72.1%  
(44) 
26.2% 
(16) 
1.6%  
(1) 
0 0 0 61 
6 
 
0.2%  
(3) 
96.9% 
(1511) 
2.8%  
(44) 
0.1% 
(2) 
0 0 1560 
7 
 
0 1.7% (22) 97.2% 
(1281) 
0.8%  
(11) 
0.3%  
(4)  
0 1318 
8 
 
0 0 4.2%  
(9) 
94.4%  
(204) 
1.4%  
(3) 
0 216 
9 
 
0 0 6 2.6%  
(8) 
95.5% 
(299) 
0 313 
10 
 
0 0 0 0 0 100% (18) 18 
Total 
 
47 1549 1341 225 306 18 3486 
Table 2.5. Concordance between Gleason score at referral compared with Gleason 
score recorded after review at EPC MDT. (N=3486) 
 
Number of cores 
The current standard for TRUS biopsy of the prostate is a 10-12 needle cores. The 
database was reviewed and showed a median number of 10 cores taken with a range 
from 0 to 22 (0 represents a clinical diagnosis of CaP). Median number of positive 
cores was 3 with a mean of 4.1. Median percentage of positive cores was 40% with 
a mean of 46.6% (Table 2.6). 
 
 No. of cores taken No. of positive 
cores 
% of positive cores 
N (missing data) 3411 (164) 3368 (207) 3366 (209) 
Mean 9.1 4.1 46.6 
Median 10 3 40 
Range 0-22 1-14 0-100 
Table 2.6. Table showing numbers of cores taken at TRUS biopsy including positivity 
rates. 
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Staging investigations 
In addition to TRUS biopsy of the prostate, patients also received MRI and isotope 
bone scans as part of staging. 
 
MRI usage 
In total, 80.2% (2813/3506) had an MRI after their TRUS biopsy, 12.1% (424/3506) 
were before the biopsy and 7.7% (269/3506) did not have an MRI. No information 
was available for 69 cases (Figure 2.12). 
 
 
Figure 2.12. Graph showing the timing of MRI compared to TRUS biopsy. (N=3575) 
 
The uptake of pre-biopsy MRI scan increased significantly in the last 3 years of data 
collection, with 88.6% of all those patients having an MRI scan having it before their 
biopsy in 2016 (Figure 2.13). 
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Figure 2.13. Pivot table plot showing the percentage of patients having MRI scans 
and the timing in relation to their TRUS biopsy of the prostate. (N=3575) 
 
More detailed analysis of the outcomes of MRI will be presented in chapter 4. 
 
Bone scan 
In total, 68.7% (2423/3526) had a negative bone scan, 24.0% (845/3526) did not have 
a scan, 5.4% (192/3526) were positive, 1.9% (66/3526) were equivocal. No record 
was present for 49 cases. 
 
Over the period of data collection, there was a marked change in the use of isotope 
bone scans. In more recent years there was a significant increase in the number of 
patients that did not have a bone scan as part of staging. This led to a marked 
reduction in the proportion of negative scans (Figure 2.14). There was also an 
increased rate of positive scans which can probably be accounted to increased 
number of patients with metastatic disease discussed at EPC MDT. 
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Figure 2.14. Pivot table plot to show the outcomes of staging isotope bone scans 
over the period of EPC MDT data collection. (N=3575) 
 
More detailed analysis of the outcomes of isotope bone scans will be presented in 
chapter 3. 
 
D’Amico risk stratification at diagnosis 
Overall, 27.7% (990/3575) of cases were D’Amico low-risk, 34.1% (1219/3575) were 
intermediate risk and 38.0% (1357/3575) were high risk. In the first 6 years of data 
collection there was a relatively low proportion of low risk cases, however, this 
slowly increased and from 2003 until 2016 the proportion of different risk groups 
remained largely similar (Figure 2.15). 
 
For the purposes of data collection at the EPC MDT all cases of node positive cancer 
and metastatic disease were included in the high-risk category. 
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Figure 2.15. Pivot table plot to show the proportion of D’Amico risk classified cases 
at diagnosis. (N=3575) 
 
Treatment received 
Active surveillance was the primary treatment recorded in 23% of cases, 3.8% had 
watchful waiting, 24.6% went on to radical prostatectomy, 32.1% had radical 
radiotherapy and 14.3% had androgen deprivation therapy. Treatment was not 
known in 2.2% of cases (Table 2.7). 
 
Treatment  Number (%) 
Active surveillance 822(23) 
Watchful waiting 135(3.8) 
Radical prostatectomy 880 (24.6) 
Radiotherapy 1146 (32.1) 
ADT 512 (14.3) 
Not known 80 (2.2) 
Table 2.7. Table highlighting the primary treatment choices for men with discussed 
at the EPC MDT. 
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2.4.4 Aim 4 - Trends in symptoms at presentation and the relationship on disease 
stage 
 
2.5.4.1 Symptoms and influence on disease presentation 
Overall, data is available for 3328 patients. 1268 (38.1%) patients were 
asymptomatic at presentation and 2060 (67.9%) were symptomatic. 
 
Age and symptoms 
Asymptomatic men were most numerous in the 60-69-year-old group, the 
proportion of men who were in the <60 years old group was roughly equal to that in 
the >70 years old age group. In symptomatic men, there was a marked difference 
between groups, with a lower proportion of men in the younger than 60 years of age 
group compared to the older age groups. 
 
There was an increase in the number of men presenting with symptoms as age 
increased with 69.1% of men symptomatic in the >70-year-old age group versus 
55.2% in the < 60-year-old group (Table 2.8). 
 
Year of presentation 
When comparing year of presentation, after 2002 the proportion of those presenting 
with symptoms was roughly equal at around 60%. However, between 1997-2001 a 
much higher proportion were symptomatic at 81.6%. This may represent an increase 
in the number of screen detect cases because of increased disease awareness (Table 
2.8). 
 
Route of presentation 
As one might expect there was a slightly higher proportion of symptomatic patients 
presenting via the NHS than privately, 62.5% versus 49.7% (Table 2.8). 
 
Disease characteristics 
Higher Gleason score, PSA level and clinical T stage were all associated with a higher 
rate of symptoms at presentation. For patients with a Gleason score between 8-10 
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or PSA >20 or a clinical T stage T3-4 73% of patient had symptoms compared with 
between 49.7% - 57.6% with symptoms for patients with D’Amico low risk features 
(Gleason <7, or PSA <10, or Clinical T stage <T2a) (Table 2.8).  
 
Only age at diagnosis was independently associated with symptomatic presentation 
with older men having more symptoms. Earlier period of presentation, higher 
Gleason score, and more aggressive clinical stage did appear to be related associated 
with higher rates of symptomatic presentation but these were not statistically 
significant associations (Table 2.8). 
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 Whole 
cohort 
 No 
symptoms 
% of those 
without 
symptoms 
% of 
those c 
charact. 
Symptoms % of those 
with 
symptoms 
% of 
those c 
charact. 
Factors associated 
with symptoms at 
presentation. 
 N % N % % N % % IR 95% 
CI 
p-
value 
TOTAL 3328 100 1268 38.1  2060 67.9     
            
AGE  
(N=3323) 
           
<60 643 19.3 288 22.7 44.8 355 17.3 55.2 0.79 0.68-
0.92 
0.002 
60-69 1483 54.7 608 48.0 40.8 875 42.5 59.2 0.86 0.77-
0.96 
0.010 
>70 1197 36.0 370 29.2 30.9 827 40.2 69.1 1 - - 
PERIOD  
(N=3323) 
           
1997-2001 326 9.8 60 4.7 18.4 266 12.9 81.6 1.35 0.93-
1.96 
0.119 
2002-2006 697 21.0 292 20.7 41.9 405 19.7 58.1 1.00 0.86-
1.14 
0.957 
2007-2011 875 26.3 343 27.1 39.2 532 25.9 60.8 1.05 0.93-
1.18 
0.411 
2012-2016 1425 42.9 571 45.1 40.1 854 41.5 59.9 1 - - 
NHS/PRIVATE 
(N=3321) 
           
NHS 3172 95.5 1191 94.1 37.5 1981 96.4 62.5 1.18 0.93-
1.50 
0.175 
PRIVATE 149 4.5 75 5.9 50.3 74 3.6 49.7 1 - - 
GL SCORE 
(N=3276) 
           
<7 1512 46.2 641 50.8 42.4 871 43.2 57.6 0.90 0.76-
1.07 
0.218 
7 1249 38.1 485 38.4 38.8 764 37.9 61.2 0.90 0.77-
1.04 
0.057 
8-10 515 15.7 136 10.8 26.4 379 18.8 73.6 1 - - 
PSA LEVEL 
(N=3328) 
           
<10 1784 53.6 761 60.0 50.3 1023 49.7 49.7 0.94 0.81-
1.09 
0.392 
10-20 837 25.2 321 25.3 38.4 516 25.0 61.6 0.89 0.76-
1.04 
0.136 
>20 707 21.2 186 14.7 26.3 521 25.3 73.7 1 - - 
C T-STAGE 
(N=2725) 
           
T1A-T2A 1781 65.4 786 71.5 44.1 995 61.2 55.9 0.88 0.76-
1.03 
0.103 
T2B-C 394 14.5 166 15.1 42.1 228 14.0 57.9 0.87 0.73-
1.04 
0.121 
T3-4 550 20.2 148 13.5 26.9 402 24.7 73.1 1 - - 
D’AMICO 
(N=3322) 
           
LOW 927 27.9 428 33.8 46.2 499 24.3 53.8 - - - 
INT. 1134 34.1 485 38.3 42.8 649 31.6 57.2 - - - 
HIGH 1261 37.9 353 27.9 30.0 908 44.2 70.0 - - - 
 
Table 2.8. Table showing the distribution of patients with and without symptoms at 
presentation and the association with disease characteristic (age, year of 
presentation, etc.) and patient demographics. Factors associated with symptoms at 
presentation was assessed with Poisson regression with all co-variates entered 
simultaneously. D’Amico risk classification was not assessed given co-linearity. 
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2.4.4.2 Symptoms and influence on treatment 
The effect of whether symptoms influenced primary treatment decision was 
assessed. Patients were divided according to D’Amico risk and age at presentation 
and the presence of symptoms. 
 
D’Amico risk group 
Treatment patterns differed significantly between D’Amico risk groups at referral. 
 
Low risk – the presence of symptoms did not appear to affect the decision to have 
radical treatment or enter surveillance with roughly equal numbers choosing each 
treatment (Table 2.9). 
 
Intermediate risk – the presence of symptoms did not appear to affect the decision 
to enter a deferred treatment strategy. A higher proportion of asymptomatic 
patients underwent radical prostatectomy. Similar numbers had radical 
radiotherapy, although slightly more symptomatic patients received this (Table 2.9). 
 
High risk – overall, a higher proportion of patients had radical radiotherapy rather 
than radical prostatectomy. The presence of symptoms did not appear to affect the 
treatment decision although a slightly higher proportion of asymptomatic patients 
had radical prostatectomy than those with symptoms (Table 2.9). 
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RISK GROUP 
–  
SYMPTOMS 
 
PRIMARY 
TREATMENT 
LOW (N =927) 
 
NO           YES 
N=428     N=499 
INT. (N=1134) 
 
NO           YES 
N=485     N=649 
HIGH (N=1261) 
 
NO           YES 
N=353     N=908 
AS                 234         282 
54.7%    56.5% 
83            135 
17.1%     20.8% 
11            22 
3.1%        2.4% 
 
WW 2              9 
0.5%       1.8% 
24            42 
4.9%        6.5% 
11            41 
3.1%        4.5% 
 
RP 125         130 
29.2%     26.1% 
203          201 
41.9%     31.0% 
60            87 
17%         9.6% 
 
RT 40           64 
9.3%       12.8% 
151          228 
31.1%     35.1% 
177          424 
50.1%     46.7% 
 
ADT 17           10 
4%          2% 
13            29 
2.7%       4.5% 
86            311 
24.4%     34.3% 
 
NOT KNOWN 10           4 
2.3%      0.8% 
11            14 
2.3%       2.2% 
8              23 
2.3%       2.5% 
 
CHI SQUARE 
P VALUE 
 
0.018 
 
0.007 
 
<0.001 
Table 2.9. Table showing the effect of symptoms on primary treatment received 
according to D’Amico risk classification. 
 
Age group 
Treatment patterns differed significantly between age groups at referral. Overall, as 
one would expect there were higher numbers choosing watchful waiting and 
receiving radiotherapy and ADT in the >70-year-old age group. There were also 
fewer men having radical prostatectomy. 
 
Less than 60 years old – in those choosing either surgery or radiotherapy, those with 
symptoms had a higher rate of radical radiotherapy and a lower rate of 
prostatectomy. The proportion having deferred treatment was equal (Table 2.10). 
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60-69 years old – again those with symptoms had a higher rate of radical 
radiotherapy and a lower rate of prostatectomy and similar rates of deferred therapy 
(Table 2.10). 
 
70 years old and above – for older men they were less likely to choose active 
surveillance if they were symptomatic at presentation. Treatment rates were similar 
for radical treatment regardless of whether men were symptomatic or not (Table 
2.10). 
 
AGE GROUP –  
 
SYMPTOMS 
 
PRIMARY 
TREATMENT 
<60 (N =643) 
 
NO           YES 
N=288     N=355 
60-69 (N=1483) 
 
NO           YES 
N=608     N=875 
≥ 70 (N=1197) 
 
NO           YES 
N=370     N=827 
AS 66           77 
22.9%    21.7% 
156          224 
25.7%     25.6% 
108          141 
29%         17% 
 
WW 0             1 
0%          0.3% 
3              3 
0.5%       0.3% 
34            88 
9.2%        10.6% 
 
RP 151         147 
52.4%     41.4% 
205          225 
33.7%     25.7% 
31            44 
8.4%        5.3% 
 
 
RT 46            98 
16%         27.6% 
189          318 
31.1%      36.3% 
133          300 
35.9%      36.3% 
 
ADT 18            27 
6.3%        7.6% 
35            88 
5.8%       10.1% 
62            235 
16.8%     28.4% 
 
NOT KNOWN 7              5 
2.4%       1.4% 
20            17 
3.3%        1.9% 
2              19 
0.5%        2.3% 
 
CHI-SQUARE 
P-VALUE 
 
 
0.007 
 
0.001 
 
<0.001 
Table 2.10. Table showing the effect of symptoms on primary treatment received 
according to age at presentation. 
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2.4.5 Aim 5 - Impact of family history on disease stage and treatment undertaken 
 
2.4.5.1 Family history and effect on presentation 
In 16.6% (593/3575) of cases family history was not known. Of the men where it was 
known, 85.8% did not have documented evidence of a family history of PCa, 5.8% 
had a history of disease affecting their father and 5.4% their brother, 3.0% had 
disease affecting another close relative or a history of breast cancer.  
 
The rate of patients presenting with a positive family history fluctuated from around 
2% to 22% but did not follow a definite trend over the period of data collection 
(Figure 2.16). 
 
 
Figure 2.16. Pivot table plot showing the proportion of patients with a positive family 
history at presentation. (N=3575) 
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When comparing the proportion of men with a positive family history and disease 
characteristics at presentation there was a higher rate of family history associated 
with lower PSA score, 17.4% of patients with a PSA <10 versus 8.3% with a PSA >20. 
This was also seen for Gleason score, with a positive family history seen in 16.8% of 
patients with Gleason score <7 versus 7.8% in those with Gleason >8. Higher clinical 
T stage was also associated with a lower rate of family history compared with lower 
clinical stage. Overall, 21.1% of patients with D’Amico low risk disease had a positive 
family history compared with, 14.8% of intermediate risk disease and 9.4% of high 
risk disease (Table 2.11).  
 
Poisson multivariate analyses highlighted that only Gleason score had a significant 
correlation with family history. Men with a Gleason score <7 were 1.8 times more 
likely to have a positive family history than Gleason score 8-10 (p-value 0.011) and 
men with Gleason 7 disease were 1.64 times more likely than those with a score 8-
10 (P-value 0.025). No statistically significant associations were observed for PSA or 
clinical stage at diagnosis (Table 2.11). 
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 FHX     FACTORS ASS. WITH FH AT 
PRESENTATION 
 None Brother Father Other  FHx 
combined 
IR 95% CI p-value 
PSA         
<10 
N=1627 
1343  
(82.5%) 
105  
 
126  53 284  
(17.4%) 
1.27 0.89-
1.81 
0.192 
10-20 
N=751 
661 
(88%)  
40  33  17 90 
(11.2%) 
1.09 0.74-
1.60 
0.673 
>20 
N=604 
554  
(91.7%) 
16  13  21  50 
(8.3%) 
1 - - 
TOTAL 
N=2982 
2558 161 172 91  - - - 
GLEASON SCORE 
OF BX 
        
<7 
N=1382 
1150  
(83.2%) 
90  92  50  232 
(16.8%) 
1.81 1.15-
2.86 
0.011 
7 
N=1117 
959  
(85.9%) 
58  66  34  158 
(14.1%) 
1.64 1.07-
2.52 
0.025 
8-10 
N=437 
403 (92.2%) 13  14  7  34 
(7.8%) 
1 - - 
TOTAL 
N=2936 
2512 161 172 91     
CLINICAL STAGE         
T1-2A 
N=1636 
1357 
(82.9%) 
103  119  57  279  
(17.1%) 
1.1 0.75-
1.62 
0.620 
T2B-C 
N=346 
290  
(83.8%) 
23  18  15  56  
(16.2%) 
1.25 0.82-
1.9 
0.311 
T3-4 
N=483 
439 (90.1%) 12  19  13  44  
(9.9%) 
1 - - 
TOTAL 
N=2465 
2086 138 156 85     
D’AMICO RISK         
LOW 
N=832 
665 (79.9%) 63  68  36  147 (21.1%) - - - 
INTERMEDIATE 
N=1024 
872 
(85.2%) 
62 67 23 132 (14.8%) - - - 
HIGH 
N-1120 
1015 
(90.6%) 
36 37 32 105 
(9.4%) 
- - - 
TOTAL 
N=2976 
2552 161 172 91     
Table 2.11. Table to highlight the association of family history with presenting 
disease characteristics, with combined family history and individual previously 
affected. Factors associated with symptoms at presentation was assessed with 
Poisson regression with all co-variates entered simultaneously. D’Amico risk 
classification was not assessed given co-linearity. 
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2.4.5.2 Family history and presence of symptoms 
When comparing men with and without symptoms and the correlation between 
family history and D’Amico risk classification at diagnosis it can be seen that for 
asymptomatic men with a family history there is much higher proportion of low-risk 
disease than for those men with symptoms. For men with symptoms and a family 
history there is a roughly equal divide of risk groups, whereas, if there is no family 
history there is double the number of high risk cases compared to low-risk (Table 
2.12). For both men with and without symptoms there is a significant difference in 
the proportion of men with the same D’Amico risk group with more low risk in men 
with family history and a lower rate of high risk disease. 
 
 Low risk Intermediate 
Risk 
High risk Total  
Asymptomatic men (Chi square test – P value <0.001) 
No FHx 299 
(32.2%) 
360 
(38.7%) 
270 
(29.1%) 
929 
FHx 91  
(47.6%) 
66 
(34.5%) 
34 
(17.8%) 
191 
Total 390 426 304 1120 
Symptomatic men (Chi-square test – P value <0.001) 
No FHx 338 
(22.4%) 
474  
(31.5%) 
694 
(46.1%) 
1506 
FHx 70 
(32.6%) 
78 
(36.3%) 
67 
(31.2%) 
215 
Total  408  552 761 1721 
Table 2.12. Table showing correlation between family history and disease risk 
classification in a/symptomatic men at presentation. 
 
2.4.5.3 Family history and influence on treatment 
The effect of whether symptoms influenced primary treatment decision was 
assessed. Patients were divided according to D’Amico risk and age at presentation 
and the presence of symptoms. 
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D’Amico risk group 
Significant difference in treatment chosen was only seen in the low and high risk 
groups. 
Low-risk - for men with low risk disease and a positive family history less men had 
active surveillance and more men had a radical prostatectomy, than those without 
a family history (Table 2.13). 
Intermediate risk – slightly less men with a positive family history chose surveillance 
and slightly more had radical prostatectomy although the difference was not as 
much as that seen in low risk disease (Table 2.13). 
High risk disease – for men with a family history there was a higher rate of radical 
treatment (both surgery and radiotherapy) and a lower rate of ADT (Table 2.13). 
 
Risk group –  
 
FHx 
 
Primary 
treatment 
Low (n =832) 
 
No           Yes 
n=665     n=177 
Int. (n=1024) 
 
No           Yes 
n=872     n=152 
High (n=1120) 
 
No           Yes 
n=1015   n=105 
AS                 386          81 
58%         45.8% 
168           24 
19.3%      15.8% 
27            3 
2.7%        2.9% 
 
WW 6              0 
0.9%       0% 
45             7 
5.2%         4.6% 
40            1 
3.9%        1% 
 
RP 174          64 
26.2%     36.2% 
 
318           63 
36.5%      41.4% 
124          23 
12.2%     21.9% 
RT 76            15 
11.4%     8.5% 
 
299           49 
34.3%      32.2% 
476          58 
46.9%     55.2% 
ADT 22            1 
3.3%        0.6% 
 
31             4 
3.6%        2.6% 
322          18 
31.7%      17.1% 
Not known 1              6 
0.2%       3.4% 
11             5 
1.3%        3.3% 
26            2 
2.6%       1.9% 
Chi-square p-
value 
 
<0.001 
 
0.340 
 
0.004 
Table 2.13. Table showing the effect of family history on primary treatment received 
according to D’Amico risk classification. 
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Age Group 
Significant difference was only seen in the <60 years and 60-69 year groups. The 
treatment chosen in men older than 70 was not different in men with and without 
family history. 
Less than 60 years old – for those men with a positive family history there was a 
higher rate of men having radical prostatectomy and less men receiving radical 
radiotherapy than those without family history. Similar numbers had active 
surveillance (Table 2.14). 
60-69 years old – treatment for this was very similar between men with and without 
family history. The only difference noted was a lower number having radiotherapy 
in those with a family history (Table 2.14). 
70 years old and above – a positive family history was associated with a slightly 
higher rate of radical prostatectomy and a lower rate of ADT (Table 2.14). 
 
AGE GROUP  
 
FHX 
 
PRIMARY 
TREATMENT 
<60 (N =605) 
 
NO           YES 
N=665     N=177 
60-69 (N=1358) 
 
NO           YES 
N=1161   N=227 
≥70 (N=1017) 
 
NO           YES 
N=917     N=100 
AS                 105          23 
15.8%     13% 
287           59 
24.7%      26%   
 
194         26 
21.1%     26% 
WW 1              0 
0.2%  
4                0 
0.3% 
 
86            8 
9.4%        8% 
 
RP 218         75 
32.8%    42.4% 
339           62 
29.2%      27.3% 
 
58            12 
6.3%        12% 
RT 115         21 
17.3%    11.9% 
402           62 
34.6%      27.3% 
335          39 
36.5%     39% 
ADT 37           3 
5.6%      1.7% 
109           6 
9.4%         2.6% 
229          14 
25%         14% 
 
NOT KNOWN 3             4 
0.5%      2.3% 
20             8 
1.7%         3.5% 
15            1 
1.6%        1% 
CHI-SQUARE 
P-VALUE 
 
0.004 
 
0.008 
 
0.067 
Table 2.14. Table showing the effect of family history on primary treatment received 
according to age. 
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2.4.6 Aim 6 - Change in treatment patterns  
 
2.4.6.1 Treatment of different D’Amico risk groups. 
Low risk patients – Between 1997 and 2007 at least half of all low risk patients were 
receiving radical treatment as a primary treatment. However, there were low 
numbers of men with low risk disease and meaningful assessment is difficult. From 
2011, there was a continual reduction in the proportion of men having radical 
treatment, and in 2016 84% of men choose active surveillance as a primary 
treatment. There also appeared to be a reduction in the proportion of men having 
radical prostatectomy and a more marked reduction in men choosing radical 
radiotherapy (Figure 2.17). This reduction in the proportion of men having radical 
treatment is largely due to an increased number of men diagnosed with low disease 
and captured by the MDT. 
 
 
Figure 2.17. Pivot table plot showing the primary treatment low risk patients 
received, 1997-2016. (N=990) 
 
Intermediate risk – For men with intermediate risk disease there appeared to less 
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a reduction in the use of androgen deprivation therapy and a reduction in the 
proportion of men having radical radiotherapy (Figure 2.18). 
 
Figure 2.18. Pivot table plot showing the primary treatment received by 
intermediate risk patients. 1997-2016. (N=1219) 
 
High risk – When looking at primary treatment for all high-risk patients there does 
not appear to be appear any distinct patterns over the period of EPC (Figure 2.19). 
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Figure 2.19. Pivot table plot showing the primary treatment received by high risk 
patients, 1997-2016. (N=1357) 
 
To further, sub-divide the high-risk group (1357 cases) all cases with a positive bone 
scan, evidence of nodal disease on MRI or a PSA > 200 were excluded. This left 1048 
high risk cases that could be considered high risk non-metastatic and therefore 
eligible for radical treatment. The treatment patterns of this subgroup were 
reviewed. There did not appear to be a significant change in treatment rates for men 
with high risk disease. Although from 2014, similar proportions of men were 
receiving radical treatment, with 76% in 2016. (Figure 2.20). 
 
 
Figure 2.20. Graph showing what primary treatment a subgroup of high risk patients 
received (all high-risk patients with positive bone scan, PSA>200, or nodal disease on 
MRI were excluded) (N=1048) 
 
2.4.6.2 Active Surveillance 
To further assess changes in treatment patterns the D’Amico risk classification of 
patients that were entered in to an active surveillance program were reviewed. From 
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prostate cancer. The high proportion of high risk patients that were enrolled in the 
early years of EPC MDT may have been incorrectly coded as AS rather than watchful 
waiting. Prior to 2004, the sample sizes per year were also small and therefore 
difficult to compare with later years. 
 
 
Figure 2.21. D’Amico risk classification of patients entering active surveillance as a 
primary treatment, 1997-2016. (N=813) 
 
2.4.6.3 Radical prostatectomy 
The changes in D’Amico risk classification of patients undergoing radical 
prostatectomy was also reviewed. As seen with AS there was a steady decline in the 
proportion of low risk patients having radical treatment. From 2003, the proportion 
of low risk patients having dropped from over 50% to just over 15% in 2016 (Figure 
2.22). Over the same period there was also an increase in the number of high risk 
patients having surgery which again would correlate with the drive to not under-
treat high disease. This change can also be accounted for by a higher number of men 
with intermediate and high risk disease having surgery, thereby reducing the 
apparent proportion of men with low risk disease. 
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Figure 2.22. D’Amico risk classification of patients having radical prostatectomy a 
primary treatment, 1997-2016. (N=872). 
 
 
2.5 Discussion 
 
This chapters reports on the use of a large and prospectively collected dataset for 
patients with newly diagnosed prostate cancer over a 20-year period. It provides 
detailed information on how presentation and treatment trends at a specialist MDT 
have changed over this period and provides valuable insight in to changing 
managements strategies. It also provides useful information as to how men with 
symptoms and family history present and how this may influence disease stage and 
subsequent primary treatment. 
 
2.5.1 Data quality and capture rates 
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better than others with reported error rates in clinical databases up to 27% 
(Goldberg et al., 2008).  
 
The accuracy of data on clinical databases is of vital importance to correct 
interpretation and to enable one to draw meaningful conclusions. Errors occur from 
either the non-entry of data items or from inaccurate entry. It is often easier to 
correct and review missing data retrospectively as it is easily identifiable. However, 
incorrect data is much harder to account for and correct without laborious 
intervention. Within this study, the accuracy of the recorded primary treatment 
received was used as a simple quality indicator. Within this field, only a very small 
number of cases were missing and many of the errors were due to incorrect data 
entry and probably related more to a change in the naming and meaning of the 
treatment rather than a true data error (watchful waiting as opposed to active 
surveillance in the early days of deferred treatment). Aside from the TRUS biopsy 
pathology data, where each individual record was checked for accuracy against 
hospital record, other data items within the EPC MDT database were not checked as 
vigorously and this is a weakness of the analysis. It must also be remembered that 
with the most recent data collection form (2014 onwards) there are over 50 data 
items which must be recorded at MDT by hand and then later inputted on to the 
electronic database. It is inevitable that errors will occur but within the data field 
assessed for quality in this study I have demonstrated a low error rate of 5%. 
Certainly, if data is missing from other data items this poses less of a risk in analysing 
the data accurately than if incorrect data is entered.  
 
As discussed previously the data present from the EPC specialist MDT database 
represents a real-time analysis over the last 20 years and only since 2014 was there 
an attempt to capture all new diagnoses of prostate cancer at the MDT. Prior to this 
some new cases may have been discussed at the hospitals smaller local MDT, these 
would often have been clinical diagnoses of CaP or incidental following intervention 
such as TURP, management would often have been considered straight forward and 
therefore not referred to a specialist MDT. The introduction of the NPCA to Wales in 
2015 mandated changes to data collection at the EPC MDT and an emphasis that all 
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new cases be discussed from 2014 onwards. The creation of an NPCA data record 
was through one of three sources, either from discussion at MDT, generation of a 
positive pathology report or via local hospital cancer services. Through comparison 
of these data sets it was noted that in 2014 EPC MDT missed 10% of all new 
diagnoses cases of prostate cancer. This figure is likely to be higher for previous years 
but it hoped that for the years after 2014 it is lower, given that this was the first year 
of mandated data collection. One can therefore assume that post 2014 the data is 
more representative of all new cases of cancer than prior to this and must remember 
this when interpreting the data. 
 
It is also worth noting that the data collection for the NPCA in Wales was piloted in 
UHW in 2014, prior to national implantation in 2015. The data capture results for the 
NPCA pilot were very encouraging with <1% of all new diagnoses not identified by 
the process that generates a NPCA patient record. Within Wales once a NPCA case 
note is generated the data collection system for that case note differs significantly 
to that in England and is worthy of mentioning. Within Wales all data items required 
by the NPCA are both automatically and manually uploaded on to an electronic 
database. These case notes are then individually validated and subsequently signed 
off by a clinician before being automatically uploaded to generate a report for each 
individual health board. If data items are missing the report will not be able to be 
validated, hence ensuring high levels of data completeness. This process has resulted 
in excellent captures rates and data completeness rates of >98% across all health 
boards for Wales. This same process is not in place in England and completeness 
levels for the same datasets in England ranges from 31-73% (NPCA., 2017). This has 
emphasised the importance of how data is captured and processed. 
 
2.5.2 EPC data  
The data presented here represents an accurate history of a very contemporary UK 
MDT practice. The raw data itself is not unique and represents routine patient 
demographics and disease characteristic at presentation. However, it has many 
strengths in that many of the clinicians involved with data collection and assessment 
have remained the same. Staging investigations have remained relatively 
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homogenous with a high number having both MRI and bone scan at diagnosis and 
the reporting of TRUS biopsies have remained the same but up to date with current 
reporting practice.  
 
Over the period of the EPC MDT we have shown that the workload of a specialist 
MDT has increased dramatically to keep up with modern practice and the increasing 
number of patients diagnosed. The introduction of the NPCA to England and Wales 
and the mandate that all patients with new diagnosis cancer should be discussed at 
MDT has led to not only a higher number of patients discussed each year, but has 
also resulted in an older population, with a higher mean PSA going through the EPC 
MDT. These increases can be accounted for by the higher proportion of patients with 
more advanced disease that may not previously have been discussed at an sMDT or 
even a MDT at all in the early years of data collection. It is also interesting to note a 
declining number of patients presenting with Gleason 6 disease with a reduction 
from around 60% in 2004 to around 30% in 2016. It must be proposed that this drop 
is in part related to the changes in how Gleason is reported. 
 
When reviewing so many patients at MDT it is important to review the process to 
see if time is used wisely and if one can make the process more efficient. One could 
question the use of DRE at the time of referral given such poor correlation between 
referral stage and that after review at the EPC MDT. One could also question the 
need for pathology review at MDT given that in most cases there was >95% 
concordance between the Gleason grade at diagnosis and at review at the sMDT. As 
TRUS biopsies are peer reviewed at the time of reporting does this process need to 
be repeated at MDT? 
 
The use of imaging over the time of the MDT has also changed with a significant shift 
towards pre-biopsy MRI in line with recent evidence highlighting its benefits in 
targeting abnormal lesions (Ahmed et al., 2017). In 2016, 88.6% of MRI were pre-
biopsy and over the period of EPC 92.3% of patients received an MRI as part of 
staging. In a cohort of this size this represents a unique data set given that prior to 
updated NICE guidance in 2014 there were no recommendations considering the use 
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MRI as part of staging in UK practice (NICE, 2014). The high usage of bone scan in 
this large cohort will also enable valuable questions to be answered as to the most 
appropriate people to stage with this investigation. 
 
2.5.3 Effect of symptoms on disease characteristics and treatment  
There is mixed evidence suggesting men with symptoms have a higher rate of 
aggressive cancer with some studies suggesting there is a higher rate (Arsov et al., 
2015, Miller et al., 2003) and others reporting no association(Martin et al., 2008). 
 
Our findings largely agree with an Australian study of a similar nature with a slightly 
larger cohort. Fewer men are presenting with symptomatic disease than they did 
over 15 years ago. This may be due to an increased awareness of the disease and a 
higher incidence of PSA testing. However, it may be also due to the skew in data 
presented in this study with patient capture rates different in the early years of the 
EPC MDT compared to later years. Within this study, it appeared that age at 
diagnosis was the only the independent factor associated with men presenting with 
symptoms, with older men more likely to be symptomatic. Whilst men with a higher 
Gleason grade, clinical stage and PSA had a higher chance of presenting with 
symptoms this was not found to be statistically significant. This was also highlighted 
in the Australian study where only age, earlier diagnostic time of presentation and 
public-sector management were independently associated with symptomatic 
presentation (Beckmann et al., 2017). The Australian study also found that with 
multi-variate analysis the risk of having intermediate and high risk disease (NCCN 
criteria), Gleason 7 disease or PSA 10-20 was lower in men with symptoms. The 
reasons for this finding were not clear but this study does not support these findings 
as no statistical significance was highlighted. 
 
This study also supported the findings that men with symptoms are less likely to 
undergo radical prostatectomy than those men without symptoms. This may be a 
result of men with symptoms wanting a greater chance of symptom relief rather 
than radical treatment which may add to symptoms burden. 
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Unfortunately, unlike the Australian study our study did not have survival outcome. 
They found that men presenting with symptoms were shown to have a worse disease 
specific survival at 10 years. This, rather surprisingly, was independent of differences 
in age, disease characteristics and treatment received. Several reasons were 
postulated; men with symptoms have more advanced disease, under staging of 
disease at diagnosis, disparities in treatment of men with and without symptoms and 
the potential effect of inflammation on disease progression (Beckmann et al., 2017). 
Whatever the reason it is important to note that men presenting with symptoms 
may be an independent predictor of worse disease specific survival. Within our study 
cohort it would be interesting to obtain survival outcome data to determine if the 
same findings apply. 
 
2.5.4 Effect of family history on disease characteristics and treatment 
As discussed in chapter 1, the risk of developing prostate cancer is higher if one has 
first degree relatives affected by the disease. It is also increased in presence of 
germline mutations and can be more aggressive with specific BRCA 2 mutations 
(Castro et al., 2013). 
 
Several studies have reported that cases of hereditary prostate cancer often present 
earlier, however, clinical characteristics are like those of sporadic cases (Bratt et al., 
2002, De Visschere et al., 2016, Roehl et al., 2006). The earlier presentation of men 
with hereditary prostate cancer, must be due to many different factors, firstly 
increased awareness of the disease through personal experience and potential 
earlier PSA testing and secondly national guidance programs have advocated 
screening men with significant family disease. There is also debate as to the effect of 
family history on outcomes of radical treatment for localised disease. Several studies 
have failed to show a difference in both the survival rates and difference in 
biochemical recurrence (BCR) free rates in men undergoing radical prostatectomy 
for localized disease for those with and without family history (Heck et al., 2012, 
Bratt et al., 2002). There is also some evidence to suggest that men with hereditary 
prostate cancer have a higher rate of BCR after prostatectomy although this is older 
data (Bratt et al., 2002). 
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In this study, we have shown that men with a family history of prostate cancer 
present with a lower Gleason grade. For men with no symptoms, family history has 
a significant impact on the D’Amico risk group that men have at presentation with a 
much higher proportion of men having low risk disease if they have a positive family 
history. A similar pattern can be seen for men with symptoms; there is a much lower 
proportion of men with high risk disease and have a positive family history.  
 
The presence of a family history also has a significant impact on treatment in men 
with low and high risk disease and in those men younger than 70 years of age. There 
appeared to be higher rates of radical prostatectomy in men with low and high risk 
disease with a positive family history. There was also a lower rate of surveillance in 
the low risk group with family history. This pattern was also seen in younger men 
with family history choosing radical prostatectomy.  
 
Despite a lack of outcome data for our cohort we have shown that men with a 
positive family history are presenting with a lower grade of disease which few studies 
have shown previously. This is encouraging given the evidence that when these men 
have radical treatment for localised disease the outcomes are similar to men without 
familial disease. Obviously, this study has not defined family history more specifically 
than brother, father or other and therefore it is difficult to draw any further 
conclusions. Whether patients with germline mutation that present at an early stage 
do equally well remains to be seen. However, it is important in these men with 
germline mutations that disease detection is early. 
 
2.5.5 Changing patterns of treatment 
The changes seen in treatment patterns very much echo what is happening 
elsewhere in the treatment of prostate cancer. With continued evidence supporting 
active surveillance as the primary treatment for low risk cancer there is a real drive 
to avoid over treatment of such cases. In this study in 2016, 84% of low risk men 
chose active surveillance as their primary treatment. However, this is lower than the 
92% reported in the NPCA for England for the same time period, and lower than 88% 
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reported for the previous year in England (NPCA., 2017, NPCA., 2018). It will be 
interesting to note how this figure compares with data from other Health Boards in 
Wales as this data has yet to be published in previous reports and it is known that 
the English data is not as complete as the Wales data. We have also seen a significant 
reduction in the number of intermediate risk patients enrolling on a surveillance 
program and in the number of low risk men undergoing radical prostatectomy which 
between 10-15 years ago was between 40-50% of patients having surgery. 
 
For men with high risk disease there is also a move away from treating men with 
long term hormones towards radical treatment with survival benefit seen even in 
patients having radiotherapy in patients with small volume metastatic disease 
(Parker et al., 2018). Within our cohort in 2016, 74% of patients with high risk disease 
received radical treatment. This compares well with the 73% seen in NPCA data for 
England for the same year, an improvement from 61% the previous year (NPCA., 
2018).  
 
2.5.6 Limitations 
The EPC MDT dataset represents the evolution of a contemporary UK specialist MDT. 
When analysing the data presented one must remember that prior to 2014 not all 
new cases of prostate cancer were captured. Therefore, there may be bias towards 
fitter patients with potentially lower risk disease that are more suitable for radical 
treatment particularly in the earlier years of data collection. Also, the dataset 
includes external referrals for men to be considered for radical prostatectomy and 
this will undoubtedly skew some figures towards higher proportions of localised 
disease. Nonetheless, this dataset represents the workload of a large tertiary sMDT. 
When reporting on the changes in treatment rates this is specific to disease risk 
classification and therefore the source of referral is not relevant. Also, one can see 
that the rate of referral has remained relatively stable over the period.  
 
Unfortunately, the dataset lacks survival data. This would be a significant 
undertaking to retrospectively obtain but would add significant value to reporting 
on disease specific outcomes. 
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2.5.7 Summary 
As discussed already the EPC MDT dataset is a large and contemporary record of an 
sMDT within the UK. We have shown that the data present within the database has 
low rates of error and in recent years, post 2014, is an accurate reflection of all cases 
of new diagnosis prostate cancer for Cardiff and the surrounding geographical area. 
The uniqueness of the dataset should allow meaningful questions to be answered in 
later chapters. 
 
Within the limitations of early data capture in mind, analysis of the dataset in this 
chapter has shown how presentation trends have changed over 20 years and how 
treatment strategies have also changed to reflect new evidence. With an increasing 
weight of evidence driving the avoidance of over-treatment of low risk disease and 
the under treatment of high risk disease we have shown that the results from this 
database reflects this change. 
 
Particularly when looking at men with symptoms and family history at presentation 
we have shown that age was the only independent factor associated with men 
presenting with symptoms, however, the presence of symptoms did significantly 
affect the choice of primary treatment. When looking at men with a family history, 
it appears that these men present with a lower grade of disease and are more likely 
to have their primary treatment choice affected by the presence of a positive family 
history if they have low or high risk disease or are younger than 70 years of age.  
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Chapter 3. Refining the use of isotope bone scan in the staging of 
intermediate risk prostate cancer 
 
3.1 Introduction 
 
In England and Wales in 2016, 16% and 13% of men respectively, presented with 
metastatic disease (NPCA., 2018). The most common sites for metastases are the 
lymphatics and bones with around 3% of all newly diagnosed cases of prostate 
cancer having bone metastases at presentation. The detection of metastatic disease 
is not only important in accurate staging but also in directing specific treatment to 
limit specific skeletal related events which may cause significant morbidity. 
 
Isotope bone scan (BS) is the most commonly used staging test to determine the 
presence of bony metastatic disease with sensitivity and specificity rates of around 
80% (Shen et al., 2014). MRI, CT and PET/CT are used in certain settings and have the 
potential to overtake the use of bone scan in staging. However, given the cost and 
practical benefits that bone scan has over the alternative imaging techniques it 
remains the most commonly used tool and it is essential that one can accurately 
define which patients require staging with a bone scan. 
 
In 2016, there were several international guidelines providing inconsistent advice. 
The AUA’s best practice policy do not suggest performing BS routinely in men with a 
PSA <20ng/ml, unless there is a suspicion of bony metastases and recommend that 
BS be considered in men with Gleason 8 or higher or cT3 disease or higher, even if 
PSA is less than 10ng/ml (AUA., 2013). The UK NICE guidelines recommend BS prior 
to deferring hormonal therapy in asymptomatic men on a watchful waiting program 
with a high chance of developing bony complications. NICE also recommend against 
the use of routine bone scanning in men with low risk localised prostate cancer (as 
defined by D’Amico risk group) but do not offer any recommendations for men with 
intermediate risk disease or high risk non-metastatic disease (NICE, 2014). ESMO 
(the European Society for Medical Oncology) guidelines recommend BS for all 
 106 
intermediate and high risk patients (Parker et al., 2015).  The Royal College of 
Radiologists within the UK recommends performing BS in all high risk patients and in 
intermediate risk patients when bone symptoms are present (RCR, 2013). The CART 
(classification and regression tree) risk stratification tool developed initially for 
patients who are candidates for radical prostatectomy by Briganti el al suggests BS 
in patients with a Gleason score greater than 7 or a PSA greater than 10 and a clinical 
T stage T2c or higher (Briganti et al., 2010). Finally, the EAU guidelines recommend 
BS in men with high-risk disease, and in men with intermediate risk disease and a 
primary Gleason grade of 4 or greater (Mottet et al., 2017a). 
 
Guideline  Recommendation 
AUA (AUA., 2013) Gleason  8 or T3. 
Suggestion of bony involvement. 
NICE (NICE, 2014) In watchful waiting patients at risk of bony metastases. 
Not for low-risk patients. 
NCCN (NCCN, 2016) Gleason 8 or, cT>2 or, cT1 and PSA >20 ng/ml or cT2 with PSA 
>10 ng/ml or symptomatic. 
ESMO (Parker et al., 
2015) 
All intermediate and high-risk groups. 
RCR (RCR, 2013) In all high-risk patients and those with bony symptoms. 
CART (Briganti et 
al., 2010) 
Asymptomatic patients and Gleason 8, or, PSA >10ng/ml and 
cT2c. 
EAU (Mottet et al., 
2017a) 
All high-risk patients and intermediate risk with primary Gleason 
pattern 4 (ISUP grade ≥3) 
Table 3.1. Comparison of different guidelines on the use of isotope bone scanning 
in the staging of newly diagnosed prostate cancer. 
 
The guidelines are generally consistent regarding low risk and high risk patients. Low 
risk patients should not have BS unless clearly symptomatic as the BS is unlikely to 
offer any additional information; it may however be of detriment to both patient 
safety and mental well-being and convey an additional cost to the service provider. 
The guidelines concur that BS or equivalent should be performed in high risk patients 
as the risk of bone metastases is much higher. The guidelines are less consistent and 
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clear in defining the variables which should trigger the use of BS in the intermediate 
risk patients. In this chapter, we study the data present in the EPC MDT dataset to 
determine bone scan positivity rates, paying attention to the intermediate risk 
group, to more accurately define which patients would benefit from BS staging 
investigation. 
 
3.2 Aims 
 
The aims of this chapter were: 
 
1. Review bone scan positivity rates in the EPC MDT cohort. 
2. Determine the threshold for requesting a bone scan in newly diagnosed 
intermediate risk localised prostate cancer patients. 
 
3.3 Methods 
 
3.3.1 Service evaluation 
This study was approved as part of service evaluation by the surgical directorate, 
UHW, Cardiff.  
 
3.3.2 Patient population and analysis 
As discussed in chapter 2, the EPC MDT database analysed in this thesis contains 
patients presenting with newly diagnosed prostate cancer between 1997 and 2017 
discussed at a single centre specialist MDT. All patient demographics and staging 
investigations, including TRUS biopsy results, MRI results and bone scan results were 
recorded prospectively. All intermediate and high risk classified patients had a bone 
scan as part of staging unless contra-indicated. In some cases, low-risk patients 
would have had a BS but this was often decided on a case by case basis. 
 
All isotope bone scans performed were technetium (99mTc)-methylene 
diphosphonate with planar imaging without single-photon emission. If the BS was 
equivocal a variety of additional imaging techniques were used as thought best at 
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the time by the radiologist. These included plain radiograph, CT, SPECT (Single-
Photon Emission Computed Tomography) or MRI.  
 
To address aim 1 the database was analysed between 2002 and 2015. Patients prior 
to 2002 were not analysed due to missing data items and the poor availability of 
radiology images to review, if required, in equivocal cases. Cases post 2015, were 
excluded as this study was carried in late 2016 and hence a full year of data was 
included up to the end of 2015. 
 
In equivocal cases, these may have been discussed and reviewed at the time of EPC 
MDT and a definitive decision made and recorded as such. If it was equivocal even 
after EPC MDT review it would have recorded as such and it these cases that were 
subsequently reviewed by a radiologist to address aim 1 and 2. Further statistical 
analysis carried out in relation to association of PSA, Gleason score and clinical T-
stage was done using the whole EPC cohort 1997-2017 and excluded equivocal cases, 
including only positive and negative results.    
 
All patients were D’Amico risk classified. Analysis was done in Microsoft Excel and 
IBM SPSS version 22. 
 
3.4 Results 
 
3.4.1 Results from EPC cohort between 2002 and 2015 
Between 2002 and 2015, 2720 new cases of prostate cancer were discussed at the 
EPC specialist MDT and bone scan positivity rates analysed. There were 858 low-risk 
cases, 976 intermediate risk cases and 886 high-risk cases. Of the intermediate risk 
patients, 10.1% (99/976) were primary Gleason pattern 4, i.e. Gleason 4+3, and the 
remainder were Gleason 3+4. 
 
Overall, 78.9% (2145/2720) patients in this cohort had a bone scan of which 6.2% 
(133/2145) were positive. Of the positive bone scan results only one patient was 
previously classified as having intermediate risk disease; he had primary Gleason 
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pattern 4 and no men with Gleason 3+4 and intermediate risk disease (PSA <20 and 
clinical T stage <T2c) had a positive bone scan. The remaining 99% of men with a 
positive bone scan all had high-risk disease (Table 3.2). 
 
D’AMICO RISK 
GROUP 
NO. OF MEN 
(%TOTAL) 
NO. WHO HAD 
A BONE SCAN 
(% OF RISK 
GROUP) 
NO. WITH A 
POSITIVE BS 
BS POSITIVITY 
RATE 
LOW RISK 858 (31.5%) 351 (40.9%) 0 - 
INTERMEDIATE 
RISK - GL 3+4 
877 (32.2%) 816 (93%) 0 - 
INTERMEDIATE 
RISK – GL 4+3 
99 (36.4%) 99 (100%) 1 1% 
HIGH RISK 886 (32.6%) 879 (99.2%) 132 15% 
TOTAL 2720 2145  133 6.2% 
Table 3.2 Bone scan positivity rates in the EPC MDT cohort of newly diagnosed 
prostate cancer cases, 2002 to 2015. 
 
There were 61 patients with intermediate risk disease with Gleason 3+4 histology 
who did not have a bone scan. Further analysis of this cohort, identified that only 3 
of the 61 patients were classified as intermediate risk on histology alone. 25 of the 
61 were intermediate risk on clinical stage alone and 33 men were classified as 
intermediate risk based purely on a PSA reading at diagnosis between 10-20ng/ml. 
Of these 33 men classified intermediate risk on PSA, 24 had a PSA reading between 
10-12ng/ml. These would imply that a clinical decision was made on the usefulness 
of bone scan at the time and not thought necessary given that these patients were 
very much towards the low risk end of intermediate risk disease. Analysis of these 
61 patients has shown no evidence of metastatic disease on most recent follow-up 
imaging (treatment of disease was not taken in to account and was purely an 
observation to emphasise no adverse outcomes of not scanning these patients). For 
the 7 men with high risk disease that did not have a bone scan, all had investigation 
for metastases with alternatives imaging modalities. 
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Of the 886 men with high risk disease, 146 were classified as high-risk based on 
clinical T-stage alone, i.e., all had PSA <20ng/ml and Gleason score <8 but clinical T 
stage T2c. Of these 146 patients, 5.4% (8/146) had positive bone scans and they all 
had Gleason 4+3 disease. In many of the guidelines mentioned criteria for 
recommending BS do specify clinical stage as a specific indicator, however, if these 
patients had not been clinically staged and as a result not been deemed high risk a 
significant proportion of patients may have been under staged. 
 
Given that clinical stage may be affected by subjectivity and also omitted in certain 
clinical scenarios, such as nurse led clinics or MRI led diagnostics clinics, BS positivity 
rates were analysed according to PSA level and Gleason score alone. 148 patients 
had both Gleason 4+3 and a PSA <20 ng/ml and 6.1% (9/148) of these had a positive 
scan. There were no positive bone scans in patients with Gleason 3+4 and PSA<20 
ng/ml. Extrapolating these results to men with Gleason 3+4 disease and a PSA <20 
ng/ml produces a negative predictive value of 100% and therefore suggesting that 
only men with a PSA >20 or a Gleason grade with a primary pattern of 4 require an 
isotope bone scan. 
 
3.4.2 Extended results from EPC cohort between 2002 and 2017 -  statistical 
analysis 
As previously described the previous study time frame (2002-2015) was chosen to 
enable analysis of equivocal scans and answer the initial question that was asked 
prior to locking out the EPC database for final analysis in 2017. With this additional 
2-year period I have again reviewed positivity rates to further assess the significance 
of PSA, Gleason group and clinical stage had on rates of positivity. Binomial logistic 
regression and chi square tests were performed and for this analysis all equivocal 
scans that had not been clarified were excluded. 
 
Expanding the date range produced very similar results with only one intermediate 
risk patient identified as having a positive scan. This was the same patient as 
previously mentioned in analysis from 2002-2015. As expected D’Amico risk group, 
PSA level, Clinical T-stage and Gleason grade all had a significant impact on the rates 
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of bone scan positivity with P values all <0.001 (Table 3.3). Low-risk patients had a 
positivity rate of 0%, intermediate risk was 0.1% and high risk patients had a rate of 
16.9%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 112 
Clinical Parameter Isotope bone scan results Total 
Negative Positive  
(% of sub-group) 
D’Amico risk group    
Low 330 0 (0%) 330 
Intermediate 912 1 (0.1%) 913 
High 878 179 (16.9%) 1057 
Total 2120 180 (7.8%) 2300 
Chi-square test P <0.001   
    
PSA level    
<10 982 15 (1.5%) 997 
10 to 20 632 17 (2.6%) 649 
>20 505 148 (22.7%) 653 
Total 2119 180 (7.8%) 2299 
Chi-square test P <0.001   
    
Clinical T-stage    
T1-T2a 1121 12 (1.1%) 1133 
T2b 287 9 (3.0%) 296 
T2c 49 3 (5.8%) 52 
T3 394 102 (20.6%) 496 
T4 23 39 (62.9%) 62 
Total 1874 165 (8.1%) 2039 
Chi-square test P <0.001   
    
ISUP grade group    
Group 1  698 2 (0.3%) 700 
Group 2 794 12 (1.5%) 806 
Group 3 258 24 (8.5%) 282 
Group 4 157 22 (12.3%) 179 
Group 5 203 85 (29.5%) 288 
Total 2110 145 (6.4%) 2255 
Chi-square test P <0.001   
Table 3.3. Effect of PSA, ISUP grade group, Clinical T-stage and D’Amico risk group on 
BS outcome. 
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For the binomial logistic regression analysis PSA level was as recorded as a 
continuous variable, ISUP grade group was recorded as a categorical data and clinical 
stage was divided in to T2 or greater than T2 (to create a dichotomous categorical 
variable). As one would expect, PSA level, ISUP grade group score and Clinical T-stage 
were all significant independent predictors of bone scan positivity. A higher ISUP 
grade group is associated with an increased chance of bone scan positivity with ISUP 
grade group 3 having a 9.8 times higher risk of positivity compared to ISUP group 1 
and ISUP grade 5 29.5 times more likely. Men with cT3 or 4 have a 3.2 times higher 
chance of positivity compared to men with organ confined disease (Table 3.4). 
 
Disease parameter 
 
P-value Odds ratio 95% CI 
PSA level  <0.001 1.014 1.010 - 1.018 
ISUP Group 1 <0.001 - - 
ISUP Group 2 0.209 2.691 0.575-12.585 
ISUP Group 3 0.003 9.776 2.171-44.020 
ISUP Group 4 0.001 12.704 2.771-58.247 
ISUP Group 5 <0.001 29.530 6.818-127.894 
Clinical stage 
(T2 or >T2) 
<0.001 3.220 1.896 – 5.468 
Table 3.4. Outcome of binomial logistic regression to assess if PSA level (continuous), 
ISUP grade group (categorical) and clinical stage (expressed as categorical variable, 
T2 or >T2) were independently associated with increased risk of bone scan positivity. 
  
During the initial period of this study, 2002 to 2015, there were 1784 patients with 
intermediate and high-risk disease who underwent a bone scan (Table 3.1). If only 
patients with high risk or intermediate risk disease with primary pattern 4 had been 
imaged 816 patients could have avoided an unnecessary scan. This equates to 
around 60 scans per year that were not required and would have had both a 
psychological impact on patients and a financial and time impact on the service 
provider. 
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Following this study, it was recommended in our centre that only high risk patients 
or intermediate risk patients with primary pattern 4 or PSA > 20ng/ml undergo BS 
staging. When reviewing rates of bone scan use it is clear that before this 
recommendation came in to force that an increasing number of patients were not 
undergoing BS and as a result the rate of negative scan was decreasing. In 2006, only 
2.6% of patients discussed at the EPC MDT had a positive bone scan, 90.1% had a 
negative scan and 7.3% did not have a scan. Compare this to 2016, when 9.4% had a 
positive scan, 41.5% had a negative scan and 49.1% did not have a scan (Figure 3.1). 
Despite this apparent change in the use of bone scan over this time it is reassuring 
that local evidence justifies this change. As discussed, it is important to both patients 
and healthcare providers that staging scans are appropriate. 
 
 
Figure 3.1. Graph to show the outcome of the isotope bone scan of patients 
discussed at the EPC MDT between 2006 and 2016. N=2546 (Equivocal scans and 
missing data not recorded). 
 
3.5 Discussion 
 
To date, the results from this study represent the largest single centre review of 
bone scan positivity rates in the UK. In men with intermediate risk disease only 
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0.1% were found to have a positive BS and this was only associated with ISUP grade 
group 3, no men classified as intermediate risk with ISUP grade <3, or men with low 
risk disease had a positive BS. These results support the guidelines published from 
the European Association of Urologists and recommend that BS be used in all 
newly diagnosed high risk men and those men with intermediate risk disease with 
ISUP grade 3.  
 
The successful uptake of a classification or guideline is dependent upon relevance, 
accuracy and ease of use. The D’Amico classification remains the most widely used 
means of classifying newly diagnosed prostate cancer largely due to these factors. 
Despite many other risk classifications existing D’Amico remains the preferred 
choice in many national guidelines and research publications. Some of the 
guidelines recommending the use of staging BS do not include clearly defined risk 
groups and can therefore be hard to remember and implement. When reviewing 
the different guidelines on BS usage (Table 3.1) EAU are the most specific regarding 
the high-risk group and a specific sub-group of intermediate risk patients.  
 
When making recommendations based on clinical stage it must be remembered 
that this can be very subjective and hence unreliable (Reese et al., 2011). There has 
been debate regarding the subgroups within clinical T2 disease as across this group 
all three D’Amico risk categories are represented. There is evidence to suggest that 
T2c disease should be re-classified as representing intermediate risk disease given 
that it behaves like this in the context of no other high risk features (Klaassen et al., 
2015). There has also been debate as to whether or not clinical stage alone is an 
independent predictor of BS positivity (Al-Ghazo et al., 2010), however, we have 
shown along with a number of other UK studies that it is an independent predictor 
(Ayyathurai et al., 2006, O'Sullivan et al., 2003). In this study, when the clinical 
stage was excluded, and only patients that were defined by Gleason  8 or PSA 20 
had had a bone scan, a significant percentage of men with primary pattern 4 
disease with a positive BS that would have been missed (around 6%). If clinical 
stage was factored in, and D’Amico classification used, then this dropped to 1%. 
This goes against the results from the previous largest study within the UK that 
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reported a 100% negative predictive value for a positive bone scan when the 
Gleason score was less than 8 and the PSA was <20 ng/ml (McArthur et al., 2012). 
Other UK based studies, on a smaller scale, suggested not doing a BS for men with 
Gleason score <8, clinical stage < T4 and PSA < 20 ng/ml unless primary pattern 4 
which is some way towards what our findings suggest but eliminating T3 disease 
may exclude men with high-risk disease (O'Sullivan et al., 2003, Ayyathurai et al., 
2006) Our results suggest the uses of D’Amico classification which obviously 
includes clinical T-stage as an essential parameter. 
 
Previous studies that have compared the effectiveness of the various guidelines 
have yielded encouraging results regarding their accuracy. Briganti et al compared 
EAU, AUA, NCCN and AJCC guidelines with their own CART analysis model. The 
CART model, or risk stratification tool, divided patients up in to different risk 
groups and the likelihood of a positive scan. The low risk group included was 
subdivided into 2 groups; the first with a Gleason score of 7 and cT1 disease giving 
a 0.2% chance of BS positivity and the second, with same Gleason score, but 
including cT2-3 disease with a PSA 10 giving a 1.3% chance of positive BS. The 
intermediate risk group was again Gleason 7, cT2-3 but a PSA > 10 and conferred 
an 8.3% chance of a positive BS. The high-risk group included Gleason 8 and 
conferred a risk of 16.9% positive BS. They concluded it was more accurate than 
the guidelines assessed with a higher sensitivity. It did, however, include two low 
risk groups, one of which included patients with clinical T3 disease and was tested 
in men being considered for radical prostatectomy so therefore must be viewed 
with caution (Briganti et al., 2010).  
 
Further, external validation of the CART model by De Nunzio, compared CART to 
EAU guidelines and reported on slightly better accuracy for the CART model but 
encouragingly excellent negative predictive values of 97% for CART and 98% for 
EAU. It must also be said that the EAU guidelines compared were from 2011 and 
did not specify clearly the distinction that intermediate risk patient with primary 
pattern 4 be scanned (Abdollah et al., 2015). Further studies comparing the CART 
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model to other national guidelines, this time the AUA and NCCN guidelines, again 
highlighted similar results and concluded that criteria for performing a BS of PSA 
>20 and a Gleason score of >7 would lead to fewer negative scans being 
performed.  
 
Currently BS remains the most common imaging modality. However, whole body 
MRI does have superior sensitivity over BS (Gutzeit et al., 2009) and is more 
sensitive and specific than BS combined with plain radiography and CT images 
(Pasoglou et al., 2014). MRI detects early changes within the haemopoeitic 
compartment of the bones where normal cells and associated fat cells are replaced 
by tumour cells (Tombal and Lecouvet, 2012). This change is prior to the 
osteoblastic reaction that is identified on BS and plain radiographs and hence 
provides MRI imaging with an advantage over BS. The main issues with remain MRI 
cost, availability of the technology on a wide enough scale and operator time. BS 
remains a relatively simple procedure to perform whereas multi-sequence MR can 
be more complex and take longer to perform. This however, should not be the 
main driver behind a change to a more sensitive and specific test. Also, as MRI is 
now offered pre-biopsy, if one is to avoid repeated MRI scans men will need to be 
triaged appropriately as to the risk of metastatic disease to determine whether 
they undergo upfront whole body MRI or pelvic MRI.  
 
Choline PET/CT has also been shown to have a higher specificity for bone 
metastases than BS but it is not clear if it is more sensitive. Perhaps, most 
promising is PSMA PET/CT which potentially has sensitivity and specificity levels 
approaching 100% (Mottet et al., 2017a). Unfortunately, little evidence exists to 
confirm if the effect that these different imaging modalities has on the detection of 
metastatic disease affects outcomes and how best to treat these men with 
potentially low volume metastatic disease. Although recent evidence from the 
Stampede trial may be encouraging to men with low volume metastatic disease 
(Parker et al., 2018) with survival advantage to men who received radiotherapy to 
prostate in addition to standard of care hormone therapy. 
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Despite encouraging new imaging modalities, it is clear is that within current UK 
practice local MRI staging and bone scan +/- CT imaging remain the most 
commonly used modalities for the investigation of suspected metastatic disease. At 
present NICE guidelines do not currently recommend the use of PET CT in routine 
clinical practice or whole body MRI (NICE., 2019) and with this in mind, this study 
has provided essential further evidence to support the use of BS in a select 
population. 
 
This study does have some limitations. The presence of metastases has not been 
histologically confirmed. There may also be a small margin of error in reporting but 
this will be hopefully minimised by the fact that all cases have been discussed and 
reviewed at a specialist MDT. As discussed in chapter 2, we report on the data from 
a large MDT database with a low data quality error rate and therefore believe that 
these findings are truly representative. In positive BS cases, all parameters have 
been reviewed and are correct. It must also be remembered that the data has been 
collected on a prospective basis over 20 years, at a single centre specialist MDT, 
with many senior clinicians remaining the same throughout and it is the single 
largest UK study reporting BS positivity rates to date. 
 
3.5.1 Conclusion  
In summary, we have shown that BS can be safely omitted for men with 
intermediate risk disease with ISUP grade group 2. However, for intermediate risk 
disease with ISUP grade group 3 and high risk disease BS should be performed. This 
is in line with and supports the recommendations of the current EAU guidelines. 
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Chapter 4. Has improved MRI technology and protocol improved the 
accuracy of pre-operative staging and subsequent rate of upstaging at 
radical prostatectomy 
 
4.1 Introduction 
Pathological grading and staging following radical prostatectomy (RP) provides the 
most accurate assessment of local disease status and the outcome of such can have 
a significant impact on the risk of disease recurrence and subsequent long-term 
survival.  
 
As discussed previously the use of MDTs has been shown to improve cancer 
outcomes providing consensus expert opinion and hence improving diagnostic 
accuracy and treatment decisions. 
 
Over the period of 20 years of the EPC MDT there have been changes in the staging 
and grading of prostate cancer. Advances in MRI technology have brought about 
changes in how it used in the diagnostic pathway, with transition from not providing 
MRI in may centres to the present day where it is recommended all patients be 
imaged with mpMRI; with recent evidence suggesting possible safe omission of 
prostate biopsies in patients with a low risk of harbouring significant prostate cancer. 
 
In the 20 years of the EPC MDT all appropriate patients have been offered MRI 
staging and all have been reviewed at MDT providing contemporary expert 
radiological staging. Initial MRI scans were standard T2 weighted (T2W) and were 
performed post biopsy, in 2012 this changed to bi-parametric MRI (bpMRI) with T2W 
and diffusion weighting (DWI), and in 2014 MRI was introduced prior to prostate 
biopsy.  
 
All diagnostic parameters and post-surgical pathology reports have been MDT 
reviewed and therefore analysis of this dataset provides important information as to 
the outcomes of men undergoing surgery for newly diagnosed prostate cancer. 
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4.2 Aims  
The aims of the chapter are - 
 
1. Review the radical prostatectomy dataset 
 
a. Report on the disease characteristics and staging results of all 
men undergoing RP as a primary treatment following EPC MDT. 
b. Compare the pre-operative staging and grading parameters with 
the prostatectomy pathology. 
c. Assess predictive markers of biochemical recurrence. 
 
2. Assess the accuracy of MRI staging 
 
Compare the staging accuracy of MRI over the time of EPC MDT and effect 
that different MRI technique and timing has had on: 
 
a. The correlation between a positive MRI (detectable lesion) and 
different associated prognostic features such as Gleason score, 
clinical stage, PSA etc. 
b. The effect of upstaging after radical prostatectomy. 
 
4.3 Methods 
 
4.3.1 Service evaluation 
This study was approved as part of service evaluation by the surgical directorate, 
UHW, Cardiff.  
 
4.3.2 Patient population 
A separate database of prostatectomy patients was created using the EPC database 
to identify all men undergoing surgery as a primary treatment for newly diagnosed 
CaP. All cases with a planned treatment of radical prostatectomy were included for 
analysis. All prospectively collected pre-operative staging data from the EPC 
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database was included for analysis. Prostatectomy pathology data and post-
operative PSA record was obtained from clinical reports available on the hospital 
results reporting system. The need for adjuvant treatment was also based upon 
information available on the hospital results system and CANSIC (the all Wales 
Cancer Network database). 
 
All cases recorded between 1997 and February 1st, 2017 were reviewed. 878 patients 
were recorded as having had a prostatectomy. 91 cases were excluded from analysis 
for reasons as explained in Table 4.1. Therefore, 787 cases were analysed. 
 
No prostatectomy pathology reports  69 
Awaiting surgery 12 
Surgery elsewhere 6 
No pre-operative staging data 2 
Prostatectomy abandoned 2 
Total excluded 91 
Table 4.1 Reasons for excluded cases not included in overall analysis. 
 
UHW, Cardiff was a recruitment centre for the ProtecT study. These patients were 
excluded from analysis to avoid any potential bias. Only patients discussed at the 
EPC sMDT and recorded as having radical prostatectomy as the primary treatment 
were included in this study. 
 
4.3.3 Data analysis 
All staging and grading data was as recorded on the EPC database. For radiological 
staging PIRADS or LIKERT scores were not recorded and the radiological T-stage 
reported in this study is as was recorded at the time of MDT discussion. For clinical 
and pathological T-stage, clinical T-stage was subdivided as per TNM classification, 
however, for pT2 disease it was not subdivided as very few pathological reports 
included this detail. Margin status was reported as positive and negative as reported 
length of margin status was again not included in many cases. The dominant tumour 
was classified as largest tumour irrespective of Gleason grade. In cases when the 
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dominant tumour was not the area with the highest Gleason grade this was 
recorded. Biochemical recurrence was defined as per EAU guidelines as two 
consecutive PSA rises 0.2ng/ml and the time to this was defined by the second 
elevated reading (Mottet et al., 2017b). 
 
Data was collected on using an excel database and transferred to SPSS for statistical 
analysis. 
Chi-square tests were used to analyse differences between groups and binomial 
logistic regression was performed where appropriate to assess for significant 
independent variables. 
 
The PROMIS trials definitions of clinically significant and non-significant cancer were 
used to subdivide groups for comparison. Definition 1 of clinically significant cancer 
is Gleason ≥4+3 or MCCL ≥6mm. Definition 2 of clinically significant cancer is Gleason 
≥3+4 or MCCL ≥4mm (Ahmed et al., 2017). 
 
4.4 Results 
 
4.4.1 Prostatectomy data set 
 
4.4.1.1 Pre-operative staging data 
As discussed, 787 cases are presented. There was a general rising trend for the 
number of prostatectomies performed each year with a peak of 100 cases in 2015. 
This is important to note when understanding follow-up time and reflects an 
increasing surgical practice within our centre (Figure 4.1).  
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Figure 4.1. Graph to show the number of radical prostatectomies performed each 
year, 2000 to 2016. (N= 787). 
 
The median age of men having surgery was 62 years (range 39-77), with a median 
PSA of 7.3. There were very similar numbers of men with clinical T1 and T2 disease 
with only 2.5% of men having T3 disease. Again, there were similar numbers of men 
with Gleason 6 and 7 disease with very few men having surgery with Gleason 8,9 or 
10 disease. Most men had ISUP grade group 1 or 2 disease with only 11.6% having 
grade group 3 or higher. Median maximum cancer core length (MCCL) was 6mm 
(range 1-25mm). In total, 33.9% of men had D’Amico low risk disease, 51.5% were 
intermediate-risk and 14.6% were high-risk (Table 4.2).  
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Number of patients 787 
Age (years)  
Mean 61.6 
Median 62 
Range 39 to 77 
PSA  
Median 7.3 
Range 0.6 to 70 
Clinical T stage (%)  
T1 353 (44.9%) 
T2 339 (43.1%) 
T3 20 (2.5%) 
Not known 75 (9.5%) 
MRI T stage (%)  
T1 273 (34.7%) 
T2 472 (60%) 
T3 22 (2.8%) 
Not done 20 (2.5%) 
ISUP grade group (%)  
1 395 (50.2%) 
2 301 (38.2%) 
3 51 (6.5%) 
4 17 (2.2%) 
5 23 (2.9%) 
% of positive cores  
Median 37.5% 
Range 5-100% 
Maximum core length (MCCL)  
Median 6mm 
Range 1-25mm 
Range 4-100% 
D’Amico risk classification (%)  
Low 267 (33.9%) 
Intermediate 405 (51.5%) 
High 115 (14.6%) 
Table 4.2 Presenting patient demographics and disease features of men undergoing 
radical prostatectomy for newly diagnosed prostate cancer, 2000 to 2016. 
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Men were also defined according to the PROMIS study criteria for significant cancer 
using both definition 1 and definition 2. Using these definitions, 53.9% (408/757) 
men were defined as having significant cancer according to definition 1 and 75.6% 
(572/757) were defined as having significant disease based on definition 2. There 
were significant differences between the relationship ISUP grade groups and MCCL. 
This was seen when MCCL was defined as significant at  4 or 6mm, with much lower 
rates of higher Gleason grades when MCCL was less than 4 or 6mm (Table 4.3 and 
4.4).   
 
ISUP Grade Group Maximum cancer core length Total 
<6mm 6mm 
1 263 118 381 
2 86 200 286 
3 16 35 51 
4 4 13 17 
5 3 19 22 
Total 372 385 757 
Chi square P <0.001 
No. with PROMIS definition 1 – 408 (with both criteria available) 
No. with PROMIS definition 1 – 409 (with at least one criteria present) 
Table 4.3. Table to identify the number of men with significant prostate cancer, as 
defined by PROMIS definition 1. 
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ISUP Grade Group Maximum cancer core length Total 
<4mm 4mm 
1 185 196 381 
2 37 249 286 
3 9 42 51 
4 1 16 17 
5 1 21 22 
Total 233 524 757 
Chi square P <0.001 
No. with PROMIS definition 2 – 572 (with both criteria available) 
No. with PROMIS definition 2 – 588 (with at least one criteria present) 
Table 4.4. Table to identify the number of men with significant prostate cancer, as 
defined by PROMIS definition 2.  
 
4.4.1.2 Post-operative staging data 
Overall, a quarter of radical prostatectomies were performed robotically with the 
remainder via an open procedure. Most (83.8%) were classified as either ISUP grade 
1 or 2 with a roughly equal proportion between the two groups. Only 12.1% were 
ISUP group 3 and 4.6% were ISUP group 4 and 5. 59.3% of tumours were 
pathologically staged as T2 and 40.7% were staged as T3 (Table 4.5). 
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Type of prostatectomy (%)  
Robotic 202 (25.7%) 
Open 585 (74.3%) 
Gleason score  
5 5 (0.6%) 
6 312 (39.6%) 
7 432 (54.9%) 
8 14 (1.8%) 
9 23 (2.9%) 
 Total 786 (1 missing) 
ISUP grade group  
1 317 (40.3%) 
2 337 (42.8%) 
3 95 (12.1%) 
4 14 (1.8%) 
5 23 (2.9%) 
Total 786 (1 missing) 
Pathological T stage  
T2 466 (59.3%) 
T3a 268 (34.1%) 
T3b 52 (6.6%) 
T4 1 (0.1%) 
Table 4.5. Table to highlight the pathological grading (Gleason and ISUP grade group) 
and staging of men having radical prostatectomy between 1997-2017, n=787.  
 
4.4.1.3 Upstaging and upgrading rates 
The rate of upstaging and upgrading between diagnostic investigations and 
prostatectomy specimen was also reviewed. The rate of concordance between pre-
operative grading and prostatectomy grading was between 29.4% and 72%. The best 
rates were achieved for ISUP grade group 2 where concordance was 72% with a very 
similar number being upgraded and downgraded. The rate of upgrading for Gleason 
grade group 1 was around 30.7%. As one might expect there was much lower rates 
of concordance for ISUP group 4, as this group includes 3+5, 5+3, 4+4 and is more 
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prone to change when whole specimen is available for analysis. Within this group 
just over a third were downgraded to ISUP group 2 (Table 4.6). 
 
Diagnosis 
ISUP grade 
group 
Pathological ISUP grade Total 
1 2 3 4 5 
1 278 
(70.3%) 
104 
(26.3%) 
12 
(3%) 
1 
(0.4%) 
0 395 
2 36 
(12%) 
216 
(72%) 
42 
(14%) 
5 
(1.7%) 
1 
(0.3%) 
300 
3 3 
(5.9%) 
11 
(21.6%) 
30 
(58.8%) 
3 
(5.9%) 
4 
(7.8%) 
51 
4 0 6 
(35.3%) 
5 
(29.4%) 
5 
(29.4%) 
1 
(5.9%) 
17 
5 0 0 
 
6 
(26.1%) 
0 17 
(73.9%) 
23 
Total 318 337 95 14 23 786 
Table 4.6. Table to compare the difference between pre-operative ISUP grade group 
from TRUS biopsy to ISUP grade group from radical prostatectomy specimen, n=786 
(1 patient did not have record of prostatectomy grading). 
 
When comparing the rate of upstaging, from clinical T stage at diagnosis compared 
to pathological stage, there was an overall rate of 74.9% (533/712). This rate is high 
and does not factor in MRI staging and a MDT consensus stage (i.e. combined MRI 
and clinical stage). There were many men with clinical T1 disease and obviously, this 
accounts for the large number of cases of upstaging. When looking at just cT2 disease 
or higher there was an upstaging rate of 52.2% (177/339) (Table 4.7). 
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Clinical 
T-stage 
Pathological T-stage Total 
T2 T3a T3b T4 
N/A 54 19 3 0 75 
T1 244 91 14 0 353 
T2a 115 97 17 0 231 
T2b 38 39 10 0 89 
T2c 5 8 5 1 19 
T3a 3 13 3 0 19 
T3b 0 1 0 0 1 
Total 466 268 52 1 787 
Table 4.7. Table to compare the clinical stage at diagnosis with the pathological T 
stage. Pathological stage was just recorded as T2 and not further sub-divided. N/A = 
not recorded on the database.  
 
4.4.1.4 Tumour characteristics 
Further analysis was performed detailing tumour characteristic and prostate size and 
relationship with tumour. Just under two-thirds of men had multifocal tumours. The 
dominant tumour was defined as the tumour with the largest volume (95% of these 
tumours correlated with the area of highest Gleason grade i.e. the largest tumour 
was also the highest grade). The median volume of dominant tumour was 1.9cc with 
median total tumour volume just higher at 2.2cc. Ratio of tumour volume was also 
calculated and can be seen in Table 4.8. 
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Tumour multi-focality 
 
Yes 491 (62.4%) 
No 296 (37.6%) 
Length of Gleason dominant tumour  
N 772 (15 missing) 
Median 22mm (5 to 84.5) 
Volume of Gleason dominant tumour  
N 772 (15 missing) 
Median 1.9cc (0.1 to 34.0) 
Total tumour volume  
N 723 (64 missing) 
Median 2.2cc (0.1 to 34.0) 
Prostate weight  
N 775 (12 missing) 
Median 44g (16 to 165) 
Dominant tumour volume to prostate 
weight ratio 
 
N 761 (26 missing) 
Median 0.043 (0.01 to 0.861) 
Total tumour volume to prostate weight 
ratio 
 
N 713 (74) 
Median 0.05 (0.01 to 0.861) 
Table 4.8. Tumour characteristics within the prostatectomy pathological analysis. 
 
4.4.1.5 Margin status 
80.1% (630/787) of men had negative surgical margins and 19.6% (154/787) were 
reported positive. There were 3 (0.4%) equivocal reports. As one would expect, there 
was a statistically significant difference between the pathological T stage and margin 
positivity rates. There was a 12.9% positivity rate for men with T2 disease, 28.4% for 
men with T3a disease and 32.7% for men with T3b disease, or 29% for T3 disease 
(Table 4.9).  
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Pathological stage Margin positivity rates  
T2 12.9% (60/466) 
T3a 28.4% (76/268) 
T3b 32.7% (17/52) 
T4 100% (1/1) 
Chi-square P value <0.001 
Table 4.9 Margin positivity rates according to pathological T-stage. 
 
When comparing the margin positivity rates between different pre-operative 
disease parameters we see similar rates for clinical and radiological T-stages with T1 
disease conveying a 15% risk and this rising consistently with a higher T stage. Clinical 
T3 disease conveys a 50% risk and is higher than that seen radiologically. A low risk 
PSA level conveys a similar risk of margin positivity to that of clinical and radiological 
T1 disease at 16% and 1 in 3 men with a PSA of greater than 20 had positive surgical 
margins. The difference in positivity rates between clinical and radiological T stages 
and PSA groups were significant and as expected saw higher rates with more 
aggressive disease. Interestingly this statistical significance was not seen for ISUP 
grade group although higher rates were seen with more aggressive disease (Table 
4.10). 
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cT-stage Pos.rate MR T-
stage 
Pos.rate PSA 
group 
Pos.rate ISUP 
group 
Pos.rate 
N/R 13.3% No MRI 15.8% 0-9.9 16.5% 1 18% 
T1 15% T1 15% 10-20 23.8% 2 19.9% 
T2a 21.2% T2a 16.3% >20 33.3% 3 23.5% 
T2b 27% T2b 27.7%   4 29.4% 
T2c 42% T2c 36.6%   5 26% 
T3a 52.6% T3a 38.9%     
T3b 0% T3b 50%     
Overall  19.6%  19.6%  19.6%  19.6% 
Chi-
square 
<0.001  <0.001  0.004  0.585 
Table 4.10. Pre-operative diagnostic parameters and their associations with margin 
positive resection at radical prostatectomy. 
 
The margin positive rates between different risk groups was assessed. When 
defining patients according to the PROMIS study criteria similar rates of positivity 
were similar for significant cancer whether using definition 1 (Gleason 4+3 or MCCL 
6mm) or 2 (Gleason 3+4 or MCCL 4mm). If one were to define patients by 
D’Amico risk similar rates were seen between low and intermediate-risk disease but 
as one might expect high-risk cases had a much higher rate at nearly 1 in 3 men 
(Table 4.11). 
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PROMIS  
Def. 1 
Pos.rate PROMIS  
Def. 2 
Pos.rate D’Amico  
group 
Pos.rate 
No 
significant 
Cancer 
17.1% No 
significant 
Cancer 
14% Low 16.9% 
Significant 
cancer 
21.5% Significant 
cancer 
21.1% Intermediate 18.8% 
    High 31.3% 
Overall  19.6%  19.6%  19.6% 
Chi-square 0.134  0.035  0.002 
Table 4.11. Pre-operative disease classification as per D’Amico or PROMIS 1 or 
PROMIS 2 criteria for significant cancer and association with positive margins. 
 
The effect of post-operative pathological markers on margin positive rates was also 
assessed. Interestingly the rate of positivity for pathological T3a disease was only 
28.4% compared with 52.6% for clinical T3a disease. Although I suspect this can be 
attributed to the lack of patients being assigned clinical T3b disease and if one is to 
think of T3 as one group comparative positivity figures would be 52.6% versus 61.1% 
for cT3 and pT3 disease respectively. Again, there was no significant difference seen 
between different ISUP grade groups although higher rates were seen for groups 4 
and 5. Both pT-stage and volume of dominant tumour were shown to have 
statistically significant different rates of positivity between the different groups. As 
one would expect higher T-stage and larger tumours were associated with higher 
rates. No difference was seen between the surgical approach (Table 4.12). 
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pT-stage Pos.rate ISUP 
group 
Pos.rate Dom. 
TV (ml) 
Pos.rate Method Pos.rate 
T2 12.9% 1 17% <0.5 6.5% Robotic 20.3% 
T3a 28.4% 2 19.9% 0.5-
0.99 
10.1% Open 19.3% 
T3b 32.7% 3 22.1% 1-1.99 16.7%   
T4 100% 4 35.7% 2-4.99 19.3%   
  5 30.4% >5 37.7%   
        
        
Overall  19.6%  19.6%  19.6%  19.6% 
Chi-
square 
<0.001  0.219  <0.001  0.762 
Table 4.12. Post-operative staging parameters and association with positive margins. 
 
4.4.1.6 Biochemical recurrence rates 
The rates of biochemical recurrence were reviewed. As discussed BCR was defined 
as two separate PSA readings 0.2ng/ml. Of the patients with a recorded post-
operative PSA level (778 of 787 patients) 5.1%  had a detectable PSA (≥0.1ng/ml) at 
the first check (at least 6 weeks after the operation).  
 
Of the total cohort, 8.9% of patients had immediate adjuvant therapy. Excluding 
patients who had a detectable PSA and/or immediate adjuvant therapy, there were 
680 that were assessed for true BCR. 11.6% (79/680) of patient developed BCR (Table 
4.13). Median time to follow-up was 4.4 years (Table 4.14).  
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First post-op PSA (n=778, 9 missing)  
Less than 0.1 738 (93.8%) 
0.1 or greater 40 (5.1%) 
Immediate adjuvant treatment (n=771, 16 missing) 
Yes 70 (8.9%) 
No 701 (89.1%) 
Biochemical Recurrence (n=784, 3 missing)  
No 601 (76.7%) 
Yes 79 (10%) 
Yes, but post-adjuvant treatment  20 (2.5%) 
No, but post-adjuvant treatment  38 (4.8%) 
Not known 46 (5.8%) 
Table 4.13. First post-operative PSA reading, number of patients receiving 
immediate adjuvant treatment and biochemical recurrence rates amongst men who 
underwent radical prostatectomy. 
 
Time to follow-up  
Mean 4.8 years 
Median 4.4 years 
Range 0.1 to 15.4 years 
Table 4.14. Time to follow-up following radical prostatectomy. 
 
4.4.1.7 Pre-operative predictors of BCR 
Clinical and radiological T-stage, PSA level at diagnosis and ISUP grade group at 
biopsy were reviewed to assess association with BCR rates. As one would expect 
clinical T-stage, PSA level and ISUP grade group were all associated with significant 
differences between subgroups with more aggressive disease showing higher rates 
of BCR. BCR rates for different radiological T-stages was not significantly different 
and the rate of BCR for T3 disease was nearly half that of clinical T3 disease. Rates of 
BCR for radiological and clinical T2c are very low compared to other T2 disease and 
which is surprising given that a high percentage (68.4%, Table 4.7) of clinical T2c was 
upstaged at prostatectomy (Table 4.15). 
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cT-stage BCR rate MR T-
stage 
BCR rate PSA 
group 
BCR rate ISUP 
group 
BCR rate 
N/R 6% No MRI 0 0-9.9 9.3% 1 7.5% 
T1 7% T1 9.4% 10-20 16.5% 2 16.7% 
T2a 16.6% T2a 14% >20 15.6% 3 11.8% 
T2b 14.1% T2b 13.6%   4 10% 
T2c 7.1% T2c 3.4%   5 28.6% 
T3a 50% T3a 27.3%     
T3b 0 T3b 0     
Overall  11.6%  11.6%  11.6%  11.6% 
Chi-
square 
<0.001  0.079  0.032  0.003 
Table 4.15. Pre-operative diagnostic and staging results and the effect on rate of 
biochemical recurrence (BCR). Clinical and radiological T-stage, PSA level 
(represented as 3 different groups) and ISUP grade group. Chi-square tests 
performed to assess variation between groups. 
 
BCR rate was also assessed on pre-operative risk group. Patients were categorised 
according to both PROMIS definition 1 and definition 2 and D’Amico risk group. As 
one would expect there was a significant difference between BCR rates between the 
significant and insignificant cancer groups for both PROMIS definitions and between 
the different D’Amico risk groups with higher rates seen for significant cancer and 
higher risk groups. The BCR rate for significant cancer was near identical for both 
PROMIS definition at 14% and 13.2%, for definition 1 and 2 respectively. This 
percentage was like that seen for D’Amico intermediate risk patients but was lower 
than the 18.2% seen for high risk disease (Table 4.16). 
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PROMIS  
Def. 1 
BCR rate PROMIS  
Def. 2 
BCR rate D’Amico  
group 
BCR rate 
No significant 
cancer 
9.4% No significant 
cancer 
7.2% Low 5.5% 
Significant 
cancer 
14% Significant 
cancer 
13.2% Intermediate 14.5% 
-  -  High 18.2% 
Overall  11.6%  11.6%  11.6% 
Chi-square 0.065  0.031  <0.001 
Table 4.16. Pre-operative risk classification according to PROMIS definition 1 and 
PROMIS definition 2 and D’Amico risk group and associated BCR rate. 
 
Binomial logistic regression was performed to assess for independent pre-operative 
predictors for BCR. Only clinical T-stage was found to be significant (P-value 0.016) 
when compared ISUP grade group, PSA level, percentage of positive cores, MCCL and 
age. For men with cT2a disease their risk of BCR was found to be twice that of men 
with cT1 disease and for men cT3 disease there was found to be an 8 times higher 
chance of BCR compared to men with cT1 disease (Table 4.17). 
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Clinical feature P-value Odds Ratio 95% CI 
cT stage T1 0.016 - - 
cT stage T2a 0.023 1.958 1.097 – 3.493 
cT stage T2b 0.616 1.251 0.521 – 3.000 
cT stage T2c 0.448 0.436 0.051 – 3.716 
cT stage T3a 0.006 8.236 1.838 – 37.133 
ISUP group 1 0.225 - - 
ISUP group 2  0.058 1.795 0.981 – 3.284 
ISUP group 3 0.897 1.092 0.289 – 4.124 
ISUP group 4 0.517 2.055 0.233 – 18.153 
ISUP group 5 0.078 3.703 0.862 – 15.913 
PSA 0 – 9.9 0.117 - - 
PSA 10 - 20 0.058 1.746 0.980 – 3.110 
PSA >20 0.230 1.938 0.657 – 5.715 
% pos. cores 0.032 1.013 1.001 – 1.026 
MCCL 0.334 0.960 0.885 – 1.042 
Age 0.393 1.019 0.976 – 1.064 
Table 4.17. Binomial logistic regression to determine pre-operative predictors of 
BCR. Clinical T-stage, ISUP grade group, PSA level, percentage of positive cores, 
maximum cancer core length and age were compared.  
 
 
4.4.1.8 Post-operative pathological predictors of BCR 
Post-prostatectomy pathological markers were also used to compare BCR rates. T-
stage, ISUP grade group and margin status were compared. All 3 of these parameters 
were found to have significantly different BCR rates between their sub-groups. As 
one would expect higher T-stage, higher ISUP grade and margin positivity were all 
associated with higher rates of BCR. The size of the dominant tumour volume also 
affected BCR rates with low rates for very small tumours and much higher rates seen 
for larger tumours (Table 4.18).  
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pT-stage BCR rate ISUP 
group 
BCR rate Dom. 
TV (ml) 
BCR rate Margins BCR 
rate 
T2 8% 1 5.3% <0.5 4.4% Positive 24.5% 
T3a 15.9% 2 16.4% 0.5-
0.99 
8% Negative 9.1% 
T3b 39.1% 3 12.5% 1-1.99 12.7%   
T4 0 4 37.5% 2-4.99 11.5%   
  5 26.7% >5 20%   
        
        
Overall  11.6%  11.6%  11.6%  11.6% 
Chi-
square 
<0.001  <0.001  0.011  <0.001 
Table 4.18. Post-operative pathological features and association with biochemical 
recurrence rates. 
 
Binomial logistic regression was also performed to assess for independent post-
operative pathological predictors of BCR. Positive surgical margins, ISUP grade group 
and pathological T-stage were all significant independent predictors of BCR. The 
volume of the dominant tumour did not significantly affect the BCR rate. Men with 
a positive surgical margin were 3.5 times more likely to have BCR than those with 
negative margins. In those men with ISUP grade group 2 (Gleason 3+4) the risk of 
BCR was 3 times higher than for men with grade group 1 and was 17.5 times higher 
for men with grade group 4. For men with pT3a disease the risk of BCR was only 
marginally higher compared to those with T2 disease, however, men with T3b 
disease has just over 5 times increased risk of BCR (Table 4.19).  
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Pathological  
feature 
P-value Odds Ratio 
 
95% CI 
Margin Positive <0.001 3.509 1.966 – 6.263 
ISUP group 1 0.001 - - 
ISUP group 2 0.001 2.983 1.573 – 5.657 
ISUP group 3 0.214 1.844 0.703 – 4.837 
ISUP group 4 0.002 17.457 2.92 – 104.369 
ISUP group 5 0.016 5.295 1.365 – 20.533 
T stage – T2 0.015 - - 
T stage – T3a 0.620 1.160 0.645 – 2.085 
T stage – T3b 0.001 5.192 1.880 – 14.339 
T stage – T4 1.000 0 0 
DT vol. <0.5ml 0.697 - - 
DT vol. 0.5-0.99 0.627 1.368 0.387 – 4.842 
DT vol. 1 – 1.99 0.423 1.603 0.505 – 5.086 
DT vol. 2 – 4.99 0.657 1.303 0.406 – 4.181 
DT vol. >5ml  0.255 2.020 0.602 – 6.733 
Table 4.19. Binomial logistic regression to determine post-operative pathological 
predictors of BCR. Margin status, T-stage, ISUP grade group and volume of dominant 
tumour (DT vol.) were compared. 
 
The median time to BCR was 3.1 years with a range of 0.3 years to 12.3 years. When 
assessing the time to biochemical recurrence only pathological T-stage was a 
significant factor with higher stage related to an earlier time of recurrence (p-value 
0.040) (Graph 4.1). Although ISUP grade group and margin status predicted BCR they 
did not affect when it occurred. However, this is likely to be due to relatively small 
sample sizes of men with higher Gleason grades and/or a PSA of >20 rather than a 
true lack of significance. The dominant tumour size and overall tumour volume, 
multi-focality, age or PSA at diagnosis did not affect timing of BCR (Graphs 4.2-8).  
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Graph 4.1. Kaplan-Meier curve assessing pathological T-stage and influence on time 
to BCR. T-stage significantly affected time to recurrence with log rank P-value 0.040. 
 
 
Graph 4.2. Kaplan-Meier curve assessing post-operative pathological ISUP grade 
group and its effect on time to BCR. No significant difference was found between the 
different groups and time to BCR. Log rank p-value 0.159. 
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Graph 4.3. Kaplan-Meier curve assessing radical prostatectomy margin status and 
impact on time to BCR. No significant difference was seen between the groups. Log 
rank p-value 0.597. 
 
Graph 4.4. Kaplan-Meier curve assessing effect on dominant tumour volume on time 
to BCR. No significant difference was seen between the different tumour size groups. 
Log rank p-value 0.391. 
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Graph 4.5. Kaplan-Meier curve assessing effect on total tumour volume and time to 
BCR. No significant difference was seen between the groups. Log rank p-value 0.173. 
 
 
Graph 4.6. Kaplan-Meier curve assessing effect of tumour multi-focality on time to 
BCR. No significant difference was seen between solitary or multifocal tumours. Log 
rank p-value 0.465. 
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Graph 4.7. Kaplan-Meier curve assessing effect of PSA at diagnosis on time to BCR. 
No significant difference was seen between the PSA groups. Log rank p-value 0.187. 
 
 
Graph 4.7. Kaplan-Meier curve assessing effect of age at diagnosis on time to BCR. 
No significant difference was seen between the age groups. Log rank p-value 0.985. 
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4.4.2 MRI staging data 
As with the prostatectomy dataset 787 patients were assessed, 20 patients who had 
undergone radical prostatectomy did not have an MRI scan. Therefore, 767 men who 
had received an MRI scan as part of pre-operative staging were included for analysis. 
Overall, 459 (59.8%) men had a post-biopsy non-bpMRI, 224 (29.2%) had a post-
biopsy bpMRI and 85 (11.1%) men had a pre-biopsy bpMRI (Table 4.20). 
 
Bi-parametric MRI MRI timing Total 
Pre-biopsy Post-biopsy 
No 0 458 (67.1%) 458 
Yes 85 (100%) 224 (32.9%) 309 
Total 85 682 767 
Table 4.20. Type of MRI staging scan performed and timing with respect to TRUS 
biopsy in all men who then went on to receive radical prostatectomy as primary 
treatment. 
 
When assessing the overall upstaging rates across all patients 65.6% were noted to 
have radiological upstaging (comparison of radiological T-stage with pathological T-
stage). This is lower than the rate of 74.9% for clinical upstaging. Around 40% of 
those patients who were upstaged were from radiological T1 disease (a normal scan) 
to pT2. Around 1 in 3 men were accurately staged and only 0.5% of men were down 
staged after surgery (Table 4.21 and 4.22). 
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MRI T-stage Pathological T-stage Total 
T2 T3a T3b T4 
Not done 15 3 2 0 20 
T1 203 63 7 0 273 
T2a 148 122 24 0 294 
T2b 84  43 10 0 137 
T2c 12 23 5 1 41 
T3a 3 13 2 0 18 
T3b 0 1 3 0 4 
Total 464 268 53 1 787 
Table 4.21. Comparison of pre-operative radiological (MRI) T-stage compared with 
pathological T stage at radical prostatectomy. 
 
Change in T-stage from MRI to pT stage Frequency 
Same T stage 260 (33.9%) 
Upstaged 503 (65.6%) 
- Upstage from T1 to pT2   203  
- Significant upstage   300 
Downstage 4 (0.5%) 
Total 767 
Table 4.22. Overall change from pre-operative radiological T-stage compared to 
pathological T-stage at radical prostatectomy. Significant upstage was classified as 
from cT1 to pT3 or higher, or from cT2 to pT3 or 4. There were no cases of upstaging 
for cT3 disease. 
 
The rate of upstaging was compared across the three different groups who had 
received either a post biopsy non-bpMRI (defined as group 1), a bpMRI scan post-
biopsy (group 2), or a pre-biopsy bpMRI (group 3). Those men in group 1 had a lower 
overall rate of upstaging (63.5%) compared with Group 2 and 3 which very similar at 
around 68%. The rate of upstaging from T1 to T2 disease fell from Group 1 where it 
was 31%, to 21.9% in group 2 and 14.1%. There was a higher rate of disease 
upstaging from T2 to higher stage for men in group 3 compared to group 2 and group 
1 (54.1%, versus 46.9% versus 32.5% respectively). If one were to exclude the 
patients upstaged from T1 to T2 the overall rates of significant upstaging, from T2 to 
greater, in groups 1, 2 and 3 would still be significantly different with rates of 47%, 
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60% and 63% respectively (chi-square p-value <0.001). The rate of no change was 
roughly equal men between the 3 groups at 30 to 36% (around 1 in 3 men) (Table 
4.23). 
 
MRI type 
and timing 
Change from MRI T-stage to Pathological T stage Total 
Downstage T1 to T2 Significant 
upstage 
No change 
Group 1 2 (0.4%) 142 (31%) 149 (32.5%) 165 (36%) 458 
Group 2 1 (0.4%) 49 (21.9%) 105 (46.9%) 69 (30.8%) 224 
Group 3 1 (1.2%) 12 (14.1%) 46 (54.1%) 26 (30.6%) 85 
Total 4 203 300 260 767 
Table 4.23 Comparison of radiological T-stage and post-prostatectomy pathological 
T-stage and effect that timing and type of MRI scan had on rate of upstaging. Chi-
square P-value <0.001. 
 
Given the significant difference in rates of upstaging in from both T1 to T2 disease 
and from T2 to higher (significant upstaging) the three different MRI groups were 
compared according to PROMIS 1 and 2 definitions of significant cancer. Again, there 
were higher rates of men with significant cancer in Group 1 for men that were 
upstaged from T1 to T2 disease. There was also a higher rate of men that were 
upstaged from T2 disease to higher in Group 3 compared to Groups 2 and 1, with the 
rate of significant upstaging again lowest in group 1 (Table 4.24). 
 
 % of significant PROMIS 1 def. % of significant PROMIS 2 def. 
 Upstage 
T1 to T2 
Upstage 
T2 to 
higher 
No 
change 
Upstage 
T1 to T2 
Upstage 
T2 to 
higher 
No change 
Group 1 14.2% 50% 35.3% 21.6% 40.5% 37.3% 
Group 2 10.7% 57% 32.2% 16.1% 50.5% 32.8% 
Group 3 9.4% 60.9% 28.1% 14.1% 55.1% 29.5% 
Table 4.24. Proportion of men with significant cancer at diagnosis according to 
PROMIS definitions 1 and 2 and the rates of upstaging of disease from pre-operative 
MRI to pathological T-stage. Grouped according to MRI timing and protocol. 
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Binomial logistic regression was performed to assess for independent predictors of 
upstaging in the three different MRI groups. Only men that were upstaged from 
radiological T2 to ≥pT2 post-prostatectomy were analysed. For both men that had a 
post-biopsy non bpMRI (group 1) or a pre-biopsy bpMRI scan (group 3) there were 
no significant predictors of upstaging (Table 4.25 and 4.27). However, for men that 
a post-biopsy bpMRI scan both clinical T-stage and MCCL were predictors of 
upstaging. Men with cT2a and cT2b were 3.3 and 4.2 times more likely, respectively, 
to have radiological upstaging of disease (Table 4.26). 
 
Clinical parameter P-value Odds Ratio 
 
95% CI 
PSA at diag. 0.082 1.043 0.995-1.094 
cT1 0.768 - - 
cT2a 0.411 0.683 0.276-1.693 
cT2b 0.404 0.554 0.139-2.216 
T3a 0.999 0.000 0.000- 
ISUP group 1 0.489 - - 
ISUP group 2 0.948 1.030 0.422-2.514 
ISUP group 3 0.673 1.436 0.268-7.699 
ISUP group 4 0.161 7.532 0.447-127.015 
ISUP group 5 0.223 4.723 0.390-57.256 
MCCL 0.371 1.057 0.936-1.193 
Table 4.25. Binomial logistic regression to assess predictors of upstaging from 
radiological T-stage to pathological T-stage in men who received a post-biopsy non-
bpMRI scan. Men who were upstaged from T1 to T2 disease were excluded from 
analysis. 
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Clinical parameter P-value Odds Ratio 
 
95% CI 
PSA at diag. 0.606 1.011 0.970-1.054 
cT1 <0.001 - - 
cT2a <0.001 3.307 1.847-5.923 
cT2b 0.001 4.255 1.771-10.222 
cT2c 0.534 1.540 0.395-6.033 
cT3a 0.576 1.522 0.349-6.640 
ISUP group 1 0.395 - - 
ISUP group 2 0.800 1.081 0.592-1.972 
ISUP group 3 0.235 1.926 0.653-5.678 
ISUP group 4 0.496 1.647 0.392-6.931 
ISUP group 5 0.106 5.908 0.685-50.988 
MCCL 0.011 1.107 1.023-1.197 
Table 4.26. Binomial logistic regression to assess predictors of upstaging from 
radiological T-stage to pathological T-stage in men who received a post-biopsy 
bpMRI scan. Men upstaged from T1 to T2 disease were excluded from analysis. 
 
Clinical parameter P-value Odds Ratio 
 
95% CI 
PSA at diag. 0.798 0.989 0.910-1.075 
cT1 0.760 - - 
cT2a 0.303 1.888 0.564-6.324 
cT2b 0.370 0.445 0.076-2.609 
cT2c 0.845 1.189 0.210-6.746 
cT3a 0.624 0.442 0.013-13.236 
cT3b 1.000 - 0.000 -  
ISUP group 1 0.779 - - 
ISUP group 2 0.505 1.492 0.460-4.833 
ISUP group 3 0.586 0.553 0.066-4.648 
ISUP group 4 1.000 - 0.000- 
ISUP group 5 0.729 0.642 0.052-7.878 
MCCL 0.059 1.145 0.995-1.318 
Table 4.27. Binomial logistic regression to assess predictors of upstaging from 
radiological T-stage to pathological T-stage in men who received a pre-biopsy bpMRI 
scan. Men who were upstaged from T1 to T2 disease were excluded from analysis. 
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The results of radiological staging were also reviewed with respect to prevalence of 
detectable lesion on MRI, i.e. radiological T≥2, and how this changed over the period 
of changes in protocol. The proportion of men with detectable lesions increased 
from Group 1 at 56.9%, to 70.1% of men in group 2 and 75.3% of men in group 3 
(Table 4.28). 
 
MRI lesion MRI group Total 
Post-biopsy 
non-bpMRI 
Post-biopsy 
bpMRI 
Pre-biopsy 
bpMRI 
No 185 (40.4%) 67 (29.9%) 21 (24.7%) 273 
Yes 273 (59.6%) 157 (70.1%) 64 (75.3%) 494 
Total 458 224 85 767 
Table 4.28. Proportion of MRI scans with detectable lesions according to type and 
timing of scan. 
 
The presence of a detectable lesion on MRI was then reviewed with respect to 
diagnostic staging parameters and pathological parameters to determine if there 
were any independent predictors of a detectable lesion and how this varied between 
the three MRI groups. 
 
For men who had a post-biopsy non bpMRI (group 1) both diagnostic PSA and clinical 
T-stage were significant independent factors in detecting a lesion on MRI. Men with 
clinical T2 disease had a significantly higher chance of having an identifiable lesion 
than those with cT1 disease, cT2b was nearly 5 times more likely than cT1 disease to 
have radiological T≥2. ISUP grade group and MCCL did not significantly predict a 
lesion although men with ISUP grade 3 did have a significantly higher chance than 
those with grade group 1 (Table 4.29). When reviewing pathological markers T-stage 
and total tumour volume were significantly associated with an MRI T stage ≥2. Again, 
neither ISUP grade group or margin positivity was significant (Table 4.30).  
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Clinical parameter P-value Odds Ratio 95% CI 
PSA at diag. 0.048 0.952 0.907-1.000 
cT1 0.008 - - 
cT2a 0.038 1.812 1.035-3.174 
cT2b 0.002 4.807 1.770-13.058 
cT3a 0.399 2.878 0.247-33.590 
ISUP group 1 0.286 - - 
ISUP group 2 0.313 1.353 0.752-2.437 
ISUP group 3 0.042 5.176 1.063-26.196 
ISUP group 4 0.999 0.000 0.000- 
ISUP group 5 0.553 2.176 0.166-28.463 
MCCL 0.066 1.085 0.995-1.183 
Table 4.29. Binomial logistic regression to assess diagnostic clinical predictors of an 
identifiable lesion on MRI (T≥2) for men who had a post-biopsy non-bpMRI (group 
1). 
 
Pathological 
parameter 
P-value Odds Ratio 
 
95% CI 
Margin pos. 0.074 1.991 0.934-4.244 
pT2 <0.001 - - 
pT3a <0.001 0.043 0.012-0.156 
pT3b 0.999 0.000 0.000-  
ISUP group 1 0.284 - - 
ISUP group 2 0.598 0.862 0.497-1.496 
ISUP group 3 0.085 2.343 0.890-6.168 
ISUP group 4 0.999 - 0.000- 
ISUP group 5 0.255 5.351 0.298-96.050 
Total TV <0.5ml <0.001 - - 
TTV 0.5-0.99ml 0.427 0.705 0.297-1.671 
TTV 1-1.99ml 0.005 3.098 1.417-6.769 
TTV 2-4.99ml 0.001 3.652 1.685-7.912 
TTV >5ml 0.367 1.536 0.605-3.898 
Table 4.30. Binomial logistic regression to assess post-prostatectomy pathological 
predictors of an identifiable lesion on MRI (T≥2) for men who had a post-biopsy non-
bpMRI (group 1). 
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For men in group 2 (post-biopsy bi-parametric MRI) MCCL and clinical T-stage was 
also significantly associated with a detectable lesion on MRI with cT2 disease having 
at least a 6 times higher chance of an MRI stage ≥T2 than men with cT1 disease. 
Neither PSA of ISUP grade group were significant (Table 4.31). When reviewing 
pathological markers, as for group 1, pT-stage was a predictor of an MRI with a 
detectable lesion. However, total tumour volume was not a significant predictor and 
neither was ISUP grade group or men with positive margins (Table 4.32). For men 
who in group 3, who had received a pre-biopsy bi-parametric MRI scan, PSA at 
diagnosis, cT-stage, ISUP grade group and MCCL at biopsy were not significantly 
independent predictors of a detectable MRI lesion (Table 4.33). Also, within group 3 
no post-prostatectomy pathological markers were significant predictors with a 
detectable lesion on staging MRI (Table 4.34). 
 
 
Clinical parameter P-value Odds Ratio 95% CI 
PSA at diag. 0.882 0.996 0.945-1.049 
cT1 <0.001 - - 
cT2a <0.001 6.532 2.946-14.481 
cT2b 0.002 24.847 3.173-194.586 
cT2c 0.103 6.067 0.693-53.131 
cT3a 0.998 - 0.000-  
ISUP group 1 0.683 - - 
ISUP group 2 0.317 1.468 0.692-3.113 
ISUP group 3 0.536 1.505 0.413-5.478 
ISUP group 4 0.999 - 0.000- 
ISUP group 5 0.434 0.470 0.071-3.118 
MCCL 0.016 1.130 1.023-1.247 
Table 4.31. Binomial logistic regression to assess diagnostic clinical predictors of an 
identifiable lesion on MRI (T≥2) for men who had a post-biopsy bpMRI (group 2). 
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Path. parameter P-value Odds Ratio 95% CI 
Margin pos. 0.222 1.802 0.701-4.636 
pT2 <0.001 - - 
pT3a <0.001 8.365 3.788-18.475 
pT3b 0.008 8.971 1.788-45.021 
ISUP group 1 0.311 - - 
ISUP group 2 0.495 1.311 0.603-2.851 
ISUP group 3 0.089 3.362 0.833-13.574 
ISUP group 4 0.382 0.427 0.063-2.874 
ISUP group 5 0.651 0.662 0.110-3.963 
Total TV <0.5ml 0.491 - - 
TTV 0.5-0.99ml 0.108 3.143 0.778-12.697 
TTV 1-1.99ml 0.895 1.086 0.321-3.674 
TTV 2-4.99ml 0.600 1.362 0.429-4.318 
TTV >5ml 0.590 1.469 0.362-5.955 
Table 4.32. Binomial logistic regression to assess post-prostatectomy pathological 
predictors of an identifiable lesion on MRI (T≥2) for men who had a post-biopsy 
bpMRI (group 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 154 
Clinical parameter P-value Odds Ratio 95% CI 
PSA at diag. 0.475 1.060 0.904-1.242 
cT1 0.809 - - 
cT2a 0.131 3.154 0.710-14.003 
cT2b 0.999 - 0.000- 
cT2c 0.999 - 0.000- 
cT3a 0.999 - 0.000- 
cT3b 1.000 2.277 0.000- 
ISUP group 1 0.958 - - 
ISUP group 2 0.421 0.565 0.140-2.271 
ISUP group 3 0.999 - 0.000- 
ISUP group 4 1.000 0.261 0.000- 
ISUP group 5 0.999 - 0.000- 
MCCL 0.092 1.175 0.974-1.416 
Table 4.33. Binomial logistic regression to assess diagnostic clinical predictors of an 
identifiable lesion on MRI (T≥2) for men who had a pre-biopsy bpMRI (group 1). 
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Path. parameter P-value Odds Ratio 95% CI 
Margin pos. 0.653 1.375 0.343-5.520 
pT2 0.953 - - 
pT3a 0.761 1.214 0.348-4.238 
pT3b 0.878 1.266 0.062-25.773 
ISUP group 1 0.932 - - 
ISUP group 2 0.362 1.847 0.494-6.913 
ISUP group 3 0.600 1.884 0.176-20.163 
ISUP group 4 0.999 - 0.000- 
ISUP group 5 0.999 - 0.000- 
Total TV <0.5ml 0.300 - - 
TTV 0.5-0.99ml 0.434 3.228 0.172-60.607 
TTV 1-1.99ml 0.502 2.456 0.178-33.985 
TTV 2-4.99ml 0.098 12.478 0.626-248.738 
TTV >5ml 0.204 6.742 0.356-127.878 
Table 4.34. Binomial logistic regression to assess post-prostatectomy pathological 
predictors of an identifiable lesion on MRI (T≥2) for men who had a pre-biopsy bpMRI 
(group 1). 
 
 
4.5 Discussion 
 
This chapter reports on the outcomes of a large series of men who have undergone 
radical prostatectomy as a primary treatment for newly diagnosed prostate cancer 
over a 20-year period. Surgical outcomes and the accuracy of staging is reported on 
patients all discussed at the same single specialist MDT.  
 
4.5.1 Aim 1 - Prostatectomy outcomes 
 
Overall cohort characteristics 
As discussed in chapter 2, there are an increasing number of men undergoing radical 
prostatectomy as a primary treatment for prostate cancer within our institution. 
Within this surgical cohort analysed just over half had D’Amico classified 
 156 
intermediate risk disease, however, there were a significant number of men with low 
risk disease at 33.9% and only 14.6% were classified as high risk. As again discussed 
in chapter 2, in more recent years we have seen a move away from the treatment of 
low risk disease with surgery and an increase in its use in men with high risk disease. 
Within the UK in 2015-2016 only 8% of men with low-risk disease underwent radical 
prostatectomy (NPCA., 2018) while for men in this study in 2016 16% had surgery for 
low risk disease, compared with just under 50% in 2006 (Figure 2.22). In the earlier 
years of the EPC MDT there was a lower proportion of men presenting with low risk 
disease probably a result of lower rates of PSA testing (Figure 2.15). In 2003, the 
proportion of men presenting with low risk dramatically increased (Figure 2.15) and 
this is mirrored in the increase percentage of men having surgery with low risk. It 
then slowly falls, year on year, to the present time. Prior to this relatively few men 
presented with low-risk disease and it was certainly common place within UK 
practice to offer these men radical treatment. The eagerness to offer low risk men 
surveillance was significantly lower than the present day. It must also be 
remembered that Gleason grading changed in 2005 and this may have effected some 
men that would historically have been graded as Gleason 6 (low risk) but with new 
criteria were Gleason 7 (intermediate risk). 
 
Therefore, the high number of men with low-risk disease within this cohort probably 
reflects the changing surgical management of prostate cancer within the UK over 20 
years, and we have shown a marked reduction in the number of low risk men in this 
cohort having surgery in the more recent years.  
 
It is also interesting to note that within this cohort only a quarter of cases were 
performed robotically. Current practice within the England and Wales would suggest 
that that at the time of analysis 88% and 75% of cases respectively, were performed 
robotically (NPCA., 2018). This itself should not have an effect when interpreting the 
results as to date no oncological benefit has been proven between the two different 
techniques (Mottet et al., 2017a). 
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Comparison of Biopsy Gleason grade with prostatectomy Gleason grade 
Accurate Gleason grading at the time of diagnostic biopsy is vital in ensuring patients 
choose the most appropriate treatment pathway. Errors in sampling, pathology 
reporting and borderlines grades are known as potential reasons for changes in 
grading. Within this study, the rate of upgrading from ISUP group 1 disease at biopsy 
was just under 30% with most these upgraded to ISUP group 2 (26.3%). These figures 
compare well a large series of nearly 8000 men reviewed by Epstein et al, although 
in this series there was a slightly lower rate of upgrading in men with Gleason 6 
disease on biopsy (25.1% versus 29.7% in this study)(Epstein et al., 2012). 
Encouragingly there was a high rate of concordance at 72% for ISUP group 2 with a 
roughly equal split of patients downgraded and upgraded, with very few upgrades 
more than ISUP group 3. This compared favourably to around 50% with Epstein at 
al. (Epstein et al., 2012) The low rate of men downgraded is important as men 
downgraded from Gleason 7 on biopsy to 6 at prostatectomy have a higher rate of 
BCR compared to Gleason 6 disease on both (Ham et al., 2017). 
 
Poor concordance was seen for ISUP group 4 with around a third the same and 
roughly the same proportion downgraded to both ISUP group 2 and 3 equally. 
Concordance with higher grade groups range between around 30%-60% (Moussa et 
al., 2009, Imamoto et al., 2010) and it is widely appreciated that concordance is 
lower for higher grade disease. Possible explanations for this include under sampling 
and needle biopsy sampling tertiary disease that is not subsequently reported 
(Epstein et al., 2012).  
 
Factors associated with upgrading include higher PSA, larger tumour volume and 
presence of perineural invasion, T-stage, age, PSA density and smaller prostates 
(Epstein et al., 2012, Alchin et al., 2016, Moussa et al., 2009). It is, of course, 
important to be able to predict who has a higher risk of upgrading as ISUP grade 
group is an important prognostic feature but to date being able to predict upgrading 
is somewhat down to clinical acumen.  
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Comparison of staging 
Excluding those men that had clinical T1 disease the overall rate of upstaging after 
surgery was 52.2%, this is a lower rate than that of radiological upstaging, but still 
reflects a large rate of change. There has been debate as to usefulness of clinical T-
stage given the advances in imaging technology, however, this study has shown that 
clinical T-stage remains an important significant predictor of both margin positivity 
and biochemical recurrence, unlike radiological T-stage and therefore should remain 
a vital part of the diagnostic pathway. 
 
Predictors of margin positivity 
With an overall margin positivity rate of 19.6%, with 12.9% for pT2 disease and 29% 
for pT3 disease this compares favourably with an overall margin positive rate of 31% 
for patients in England and Wales undergoing radical prostatectomy in 2015-16 
(NPCA., 2018). This itself may reflect the higher proportion of low risk patients in the 
study cohort.  
 
As expected there was significantly different rates of margin positivity for clinical T-
stage, PSA level at diagnosis and ISUP grade group with more aggressive disease 
associated with higher rates. When assessed with logistic regression only clinical T-
stage was a significant independent predictor of margin positivity. This study did not 
assess the impact of nerve sparing on margin rates and it must be remembered that 
this may have had an effect. 
 
Interestingly, the PROMIS study definition of significant cancer, be that definition 1 
or 2, carried the same rate of margin positivity as D’Amico intermediate risk disease 
and there was no significant difference in rates of positivity between significant and 
non-significant cancer when using definition 1. However, there were significant 
differences between the subgroups for both PROMIS definition 2 and D’Amico 
classification. 
 
As highlighted positive surgical margin status has, in this study, and other series been 
predictive of BCR (Karakiewicz et al., 2005, Stephenson et al., 2014). However, there 
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is evidence to suggest that positive surgical margins alone are not an independent 
predictor of metastases, or indeed prostate cancer specific mortality (Stephenson et 
al., 2014, Mithal et al., 2016). Adjuvant treatment based on positive surgical margins 
alone is not recommended and results from RADICALS trial aims to address this 
important question (Parker et al., 2007). 
 
Surgical experience is also an important factor on the rate of positive surgical 
margins. For this study cohort, rates are not presented on an individual surgeon 
basis. Data on site and length of margin positivity are also not presented and this 
may have had an effect when assessing the significance of margin positivity on BCR 
rates. 
 
Predictors of BCR 
Excluding those patients that had immediate adjuvant treatment the biochemical 
recurrence rate was 11.6% with a median follow-up of 4.4 years. Biochemical 
recurrence post-prostatectomy is seen in around a quarter to a half of all men 
(Mottet et al., 2017b). Whilst a rising PSA post-surgery almost always represents 
disease progression it is not always associated with metastatic disease. A shorter 
interval to BCR, a higher ISUP grade group, higher T-stage and increasing age are all 
associated with worse outcomes in the setting of BCR (Mottet et al., 2017b). 
 
This study noted that there were significant differences in rates of BCR between 
subgroups for clinical T-stage, PSA and ISUP grade group at diagnosis. It was 
interesting to note that this was not the case for radiological T-stage. It must also be 
noted that clinical T3 conveys a much higher risk of BCR than that of radiological T-
stage, with the rate nearly double for clinical disease, 50% vs 27%. 
 
It was again noted that the BCR rates for significant cancer, whether defined by 
PROMIS definitions 1 or 2, had almost the same rates as that of D’Amico 
intermediate risk disease. Again, there was not a statistically significant difference 
between the rates of BCR between non-significant and significant cancer as per 
PROMIS definition 1 but there was for definition 2 and when using D’Amico 
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classification. When reviewing the results of logistic regression, it again highlights 
the importance of clinical T-stage as this was the only significant independent 
predictor of BCR from pre-operative staging parameters. Increasing ISUP grade did 
have a strong association with BCR but did not reach statistical significance. 
 
As one would expect when reviewing post-op parameters significant difference were 
seen within sub-groups for pathological T-stage, ISUP grade group, size of tumours 
and margin positivity. However, only positive margins, higher T-stage and ISUP grade 
group were significant independent predictors of BCR. Tumour volume was not 
associated with BCR. When reviewing the time to BCR only pT-stage was a significant 
factor in time to BCR with higher stages associated with a shorter time to recurrence. 
A lower proportion of men with high risk disease may have affected results for ISUP 
grade group and PSA level at diagnosis. 
 
4.5.2 Aim 2 MRI staging outcomes 
 
MRI imaging of the prostate has improved dramatically in recent years to the extent 
where recent evidence and updated NICE guidance (NICE., 2019) suggests possible 
omission of diagnostic TRUS biopsy in cases where the MRI is reported as normal 
(Ahmed et al., 2017, Kasivisvanathan et al., 2018). Studies assessing the accuracy of 
MRI at diagnosis often use template mapping biopsies as the reference point. 
However, to truly analyse the accuracy of a diagnostic test it widely accepted that 
comparison with the pathological specimen obtained post-surgery represents the 
most accurate tool for comparison. This study reports on the accuracy on MRI 
staging over a 20-year period of a specialist MDT and how the rate of upstaging has 
changed.  
 
As previously discussed mpMRI includes T2 weighted imaging, diffusion weighted 
imaging (DWI) and dynamic contrast enhanced (DCE) phases, whereas bpMRI omits 
DCE and in doing reduces time to scan and avoids potential risks of giving contrast. 
DCE can help to differentiate equivocal PIRADS 3 lesions in the peripheral zone 
(Bayne et al., 2016) however its role has been debated since introduced (Weinreb et 
 161 
al., 2016a). Numerous studies have compared the accuracy of bpMRI to mpMRI and 
found the two to be comparable (Alabousi et al., 2019, Van Nieuwenhove et al., 
2019). 
 
A large meta-analysis assessing accuracy of MRI for local staging demonstrated 
sensitivity rates of 58% and specificity rates of 88% for detecting T3 disease with 
similar sensitivity rates for detecting extra-capsular extension but higher rates for 
detecting seminal vesical invasion at 91% (de Rooij et al., 2016). The use of DWI and 
higher field strengths (3-Tesla vs 1.5T magnets) improved sensitivity (de Rooij et al., 
2016). 
 
Within this study cohort patients received either T2W MRI alone or bpMRI and the 
timing of scans changed from post-biopsy to pre-biopsy following updated NICE 
guidance in 2014. Overall, there was a general increase in the rate of upstaging from 
men who received a post-biopsy non-bpMRI compared to those that that had a post-
biopsy bpMRI and indeed the highest rate of upstaging was seen with men who had 
a pre-biopsy bpMRI.  
 
As shown men with a post-biopsy non-bpMRI had a lower rate of detectable lesions 
and this can be assumed to be the reason why there was a higher rate of upstaging 
of men from radiological T1 disease to T2 disease. However, even when these 
numbers are excluded from analysis there is still a significant difference in the rate 
of upstaging with more men being upstaged with pre-biopsy bpMRI compared with 
post-biopsy non-bpMRI. This rate of upstaging was still apparent even when risk 
adjusted to significant and non-significant cancer according to PROMIS 1 and 2 
definitions. 
 
It was highlighted in this study that the rate of detectable lesions on non-bpMRI was 
lower than with more modern pre-biopsy bpMRI. With post-biopsy, non-bpMRI both 
higher clinical and pathological T-stage, PSA at diagnosis, larger tumour volume were 
all significantly associated with detectable lesion on MRI. For men with a post-biopsy 
bpMRI again both clinical and pathological T-stage were significantly associated with 
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a lesion on MRI and maximum cancer core length. For the most recent regime of pre-
biopsy bpMRI there were no significant associations for either diagnostic or 
pathological disease parameters. One may postulate that the reason that for this is 
that the more modern MRI regime and technology is able to identify lesions of a 
lower grade and aggressiveness making the association with palpable disease, of a 
larger volume and potentially more aggressive (higher PSA) less significant. This is of 
course important in disease detection at the time of biopsy but as this study results 
have shown relying on the accuracy of MRI staging must still be viewed with caution. 
This study has again highlighted that the sensitivity of MRI for accurately staging 
prostate cancer has not changed significantly over time. It has however, shown that 
very few patients are downgraded following surgery and this has not changed over 
time. This study would support evidence that T2 weighted imaging is most beneficial 
for the staging of disease and diffusion weighted images are more useful as a 
diagnostic tool. 
 
When using MRI T-staging as part of the decision-making process it is essential that 
other clinical parameters be considered as well and it can be suggested that clinical 
T-staging remains a more significant predictor of disease outcome following surgery. 
 
Within the PROMIS trial, patients were risk stratified according to different 
definitions of significant cancer. The subsequent risk of detecting ‘significant cancer’ 
on TRUS biopsy was dependent upon mpMRI PIRADs score. In this study, the rates 
of BCR were very similar for significant cancer when using either PROMIS definition 
1 or 2 and these mirrored results for D’Amico classified intermediate risk disease. 
However, patients with non-significant cancer as defined by definition 1 had nearly 
double the rate of BCR compared with the D’Amico low risk group and the rate of 
BCR was not significantly different to those that had significant cancer. This 
information must be considered when counselling patients regarding treatment or 
indeed whether to have a biopsy. It also highlights that D’Amico classification 
remains more sensitive at predicting BCR than PROMIS definitions of significant 
cancer. 
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4.5.3 Limitations 
Unfortunately, no long-term outcome data is available with a skew in the data with 
larger numbers having surgery more recently. When interpreting the MRI results the 
reduced numbers in group 3 (men who had a pre-biopsy bpMRI) may also have had 
an impact in reducing the significance levels particularly for associations with 
detectable lesions. It would be interesting to repeat this analysis when the cohort 
has matured. 
 
4.5.4 Conclusions 
This study has highlighted encouraging surgical outcomes for a large cohort of men 
treated through a single specialist MDT.  
 
Despite changes in protocol and technology MRI remains an investigation with a low 
sensitivity for accurately staging prostate cancer. The use of other clinical 
parameters remains essential in identifying those patients that have a higher chance 
of disease recurrence and indeed requirement for additional treatment post-
surgery. It also highlights the importance of risk stratification of disease of significant 
disease and how this can impact on disease recurrence figures. 
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Chapter 5. Deferred treatment strategies for men with low-risk 
localised prostate cancer - outcomes from a large contemporary UK 
series of active monitoring/surveillance, the role of protocol restaging 
in a stable cohort of active monitoring patients and the use of bi-
parametric MRI in restaging men on active surveillance. 
 
5.1 Introduction 
With the introduction of widespread PSA testing the incidence of prostate cancer 
has increased (CRUK, 2015). The rise in screen detected prostate cancer cases has 
led to a higher number of cases that are potentially ‘clinically insignificant’, i.e. may 
not impact on a patient’s quality of life or life expectancy. As a result, there is an 
increasing awareness to avoid over-treatment and prevent subsequent morbidity. 
Encouragingly, figures from contemporary UK data demonstrate a decreasing 
number of low risk patients receiving radical treatment (NPCA., 2018). 
 
Deferred treatment or surveillance for low risk localised prostate cancer has long 
been a recognised treatment strategy and it is now the standard of care, however, 
terminology for such regimes is evolving as are the entry criteria. Watchful waiting, 
active monitoring and active surveillance are all surveillance strategies with the 
intention to avoid treatment when appropriate. However, there are significant 
differences between these three groups and it is vital to appreciate this. 
 
Watchful waiting (WW) 
In contemporary practice, watchful waiting is a treatment strategy for men with 
prostate cancer who wish to avoid treatment and the side effects of such for as long 
as possible. It is reserved for men who are generally not fit enough for radical 
treatment or whose life expectancy is less than 10 years. Treatment is commenced 
when men become symptomatic or develop metastases and is based on disease 
control rather than cure. As such surveillance whilst on a watchful waiting program 
is less intensive and invasive and usually involves a PSA blood test at regular 
intervals.    
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Active monitoring (AM) 
This term was introduced by the ProtecT study that was designed to investigate the 
outcomes of immediate radical treatment (surgery or radiotherapy) versus deferred 
treatment for low to intermediate risk localised prostate cancer in screen detected 
patients aged 50 to 69 years old (Hamdy et al., 2016).  
 
After enrolment on an AM programme patients only undergo restaging (further 
prostate biopsy or imaging) if clinical progression was suspected either by a rise in 
PSA level or a clinical change such as a change in the clinical stage on DRE. Treatment 
was offered if disease progression was noted, but equally could also be triggered at 
patients request or if a clinical change was noted without undergoing restaging. The 
AM protocol used for patients in this study was adapted from the ProtecT study 
protocol (Hamdy et al., 2016) and can be seen in Figure 5.1. 
 
AM monitoring differs to WW in that if disease progression is noted men are offered 
treatment with the intent to cure rather than to palliate. AM differs to AS because it 
does not include protocol based restaging as part of surveillance, i.e., when men are 
stable repeat imaging or biopsies are not offered to assess for silent disease 
progression. They are however, monitored with regular PSA tests and DRE. 
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Figure 5.1. Follow-up protocol used for patients on an active monitoring programme 
(adapted from ProtecT study). 
 
Active surveillance (AS) 
This term is now widely accepted and is the preferred terminology for fit patients 
choosing a deferred treatment strategy. As for AM, men on an AS program are 
offered radical (curative) treatment if disease progression is noted and hence they 
are men with a good performance status and a life expectancy of at least 10 years. 
 
Prior to 2014, there were no formal statements in the UK NICE guidance regarding 
who should be offered active surveillance. Updated NICE guidance in 2014 
recommended that all patients with low risk organ confined prostate cancer, suitable 
for radical treatment, be offered active surveillance (NICE, 2014). For those 
diagnosed with intermediate risk cancer not willing to undergo immediate treatment 
AS should also be considered. High risk patients should not be offered AS. In patients 
enrolling on an active surveillance program the following protocol was suggested 
and was the first attempt to introduce a nationwide uniform follow-up programme 
(Table 5.1). 
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Timing Tests 1 
At enrolment in active surveillance Multi-parametric MRI if not previously 
performed 
Year 1 of active surveillance Every 3–4 months: measure PSA2 
Throughout active surveillance: monitor 
PSA kinetics3 
Every 6–12 months: DRE4 
At 12 months: prostate re-biopsy 
Years 2–4 of active surveillance Every 3–6 months: measure PSA2 
Throughout active surveillance: monitor 
PSA kinetics3 
Every 6–12 months: DRE4 
Year 5 and every year thereafter until active 
surveillance ends 
Every 6 months: measure PSA2 
Throughout active surveillance: monitor 
PSA kinetics3 
Every 12 months: DRE4 
1 If there is concern about clinical or PSA changes at any time during active surveillance, reassess 
with multi-parametric MRI and/or re-biopsy. 
2 May be carried out in primary care if there are agreed shared-care protocols and recall systems. 
3 May include PSA doubling time and velocity. 
4 Should be performed by a healthcare professional with expertise and confidence in performing 
DRE. 
Table 5.1. Follow-up protocol for patients on an active surveillance programme as 
recommend by NICE CG175 (NICE, 2014). 
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The aim of protocol restaging, particularly the first restage after diagnosis, is to 
ensure the disease has not been under-staged at diagnosis and to assess for disease 
progression. It is a method of ensuring continued optimum patient selection for 
deferred therapy and reduces the risk of the disease progressing and missing the 
opportunity for radical treatment. Protocol led restaging is the major difference 
between AM and AS. 
 
In 2014, the updated NICE guidance recommended the use of MRI as part of 
restaging only if there were changes in clinical parameters and its use as re-staging 
tool in stable disease, as a checkpoint, rather than a repeat biopsy was not discussed. 
The use of MRI in this setting is still not clear but potentially very promising as any 
measure that can avoid a repeat biopsy, without compromising patient safety, would 
be welcome. 
 
5.2 Aims 
 
The aim of this study was four-fold. 
 
1. Firstly, to assess the outcome of all patients enrolled on an active monitoring 
or surveillance program. 
 
2. Secondly, to assess the outcomes of introducing protocol re-staging in a 
cohort of clinically stable active monitoring patients – defined as Restaging 
Group 1.  
 
3. Thirdly, to compare the outcomes of restaging in Restaging Group 1 with 
patients having both – 
 
a. Clinical change or triggered re-staging - defined as Restaging Group 2,  
 
and  
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b. Protocol restaging as part of active surveillance - defined as Restaging 
Group 3 
 
4.  Fourthly, assess the use of MRI in restaging and its usefulness in the 
pathway. 
 
5.3 Methods 
 
5.3.1 Service evaluation 
This study was approved as part of service evaluation by the surgical directorate, 
UHW, Cardiff.  
 
5.3.2 Patient population 
As discussed in chapter 2, all patients with a new diagnosis of prostate cancer from 
1997 onwards were discussed at the EPC MDT.  Data collection sheets were 
uploaded to an Excel database on a prospective basis. All patients that were 
recorded as commencing on an active monitoring or active surveillance programme 
following the EPC MDT were identified to create a new database of active 
monitoring/surveillance patients.  
 
Prior to 2014, patients in the EPC MDT cohort were followed up based upon an active 
monitoring protocol adapted from the ProtecT study as described (Figure 6.1) and 
would not have been offered protocol restaging unless there were pre-defined 
triggers. 
 
Following the introduction of updated NICE guidance in 2014 (NICE, 2014) all new 
patients entering a deferred treatment strategy, and suitable for radical treatment 
if required, were defined as on active surveillance (AS) and were offered protocol 
restaging in line with guidance i.e. at 12 months after diagnosis. Additional to the 
recommendation by NICE, all patients on AS after 2014 in UHW were offered a re-
staging MRI pre-biopsy at 12 months’ post diagnosis. This MRI scan was not multi-
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parametric, but included T2W sequences and diffusion weight imaging (DWI), i.e., 
bi-parametric (bpMRI). Contrast enhanced imaging was not included.  
 
Prior to 2014 the entry criteria for AM was based on ProtecT inclusion criteria and 
included low to intermediate D’Amico risk stratified patients. Entry, may also have 
been at the discretion of the clinician or MDT and criteria was not as clearly defined 
as some published institutional surveillance strategies. Post 2014, entry criteria to 
AS was based on NICE guidance and was offered to all newly diagnosed cases of low 
risk cancer as recommended and to intermediate risk patients who chose to defer 
radical treatment.  
 
It must be noted that UHW was a recruitment centre for the Protect study, but none 
of these patients are included in this study. 
 
Therefore, the four study groups highlighted in the aims are as follows; 
 
1. The overall cohort of all patients on an AM or an AS program over the period 
of the EPC MDT.  
 
2. Restaging Group 1 - Men that were on active monitoring up to 2014 and had 
not previously been restaged with either a biopsy or an MRI. Therefore, these 
men were theoretically stable and ‘restaging naïve’. Protocol based restaging 
was performed to bring them in line with the active surveillance program 
recommended by NICE guidance.  
 
3. Restaging Group 2 - Men that were on AM or AS but had undergone triggered 
staging based upon a clinical change (rise in PSA, DRE change) indicating 
possible disease progression. 
 
4. Restaging Group 3 - Men that were on an active surveillance program and 
had undergone their first protocol restaging as recommended by NICE 
guidance (CG175) 12-18 months after diagnosis. 
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5.3.3 Data collection and analysis 
Results were collected in Microsoft Excel and transferred to SPSS for analysis. For 
reporting of overall results follow up time was defined as date of diagnosis to date 
of last clinical encounter. If the patient was lost to follow-up, follow-up was again 
recorded up to time of last clinical encounter. Radical treatment was defined as 
treatment with intent to cure.  
 
For comparison of the restaging outcomes clinical progression was defined as 
upstaging of the clinical T stage documented at diagnosis versus at restaging. MRI 
progression was defined by the reviewing the official radiologist report and defining 
that a scan showed progression if the radiologist had stated as such, if there was a 
new lesion present or if the radiological T staging was higher. Grade progression was 
defined as a Gleason grade on restaging higher than that at diagnosis. Volume 
progression was defined as having a higher number of positive cores at restage than 
at diagnosis. 
 
Kaplan-Meier Survival curves and Chi-Square tests were performed using SPSS and 
all table and graphs were created with either Microsoft Excel or Microsoft Word. 
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5.4 Results 
 
5.4.1 Aim 1 - Outcomes of patients enrolled on an active monitoring or surveillance 
program 
 
Number of cases 
Between 1st February 1997 and 1st February 2017 811 were enrolled on an active 
surveillance or active monitoring program. 101 cases were excluded from analysis as 
the date of diagnosis was after January 1st, 2016, hence, excluding patients with less 
than 12 months’ follow-up. Therefore, 710 cases are presented. A general increasing 
trend in the number of patients entering active surveillance year on year (Figure 5.2). 
 
 
Figure 5.2.  Graph showing the number of cases enrolled on an AM or AS program 
by year of diagnosis, 1997-2015 (n=710). 
 
Source of referral 
85% of cases were from the University Hospital of Wales. 10% of cases were from 
Cwm Taf Health board and 5% were from other sites. 
 
Mode of presentation 
There was an equal number of patients presenting who were asymptomatic with a 
raised PSA and presenting with a raised PSA and symptomatic LUTS. Other modes of 
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presentation were generally lower. There was not a significant difference in 
symptoms at presentation between patients choosing a deferred treatment strategy 
and the whole EPC population (Figure 5.3) 
 
Figure 5.3. Graph showing how men presented at diagnosis, including a comparison 
of the AS/AM cohort with the whole EPC MDT population (n=710 and n =3575 
respectively), 1997-2017. 
 
Age at diagnosis 
Mean and median age at diagnosis was 66 years old. Range 42 - 85 years of age. 
 
PSA at diagnosis 
Mean PSA was 7.6ng/ml. Median was 7 ng/ml. Range was 0.4 – 38. 
 
Gleason score at diagnosis 
85.9% of cases were Gleason 6 at diagnosis and 11.1% were Gleason 7. 1.6% of cases 
were Gleason 5 or lower (Table 5.2). 
Gleason score Number of cases Percentage of cases 
 5 12 1.6% 
6 610 85.9% 
7 79 11.1% 
Not recorded 9 1.3% 
Table 5.2. Gleason grade of diagnosis of all patients enrolled on an AS or AM 
treatment strategy, 1997-2015 (n=710). 
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Clinical stage at diagnosis 
Clinical stage was recorded at the time of EPC MDT. 3.6 % of cases were T1a or T1b. 
50.3% of cases were clinical stage T1c. 22.8% were T2a. 6.1% were T2b. 0.8% of cases 
were T2c or higher. 16.5% of cases were not recorded, in these cases the clinical 
stage at time of referral will have been used to determine D’Amico classification 
(Figure 5.4) 
 
 
Figure 5.4. Graph showing the clinical T stage at presentation and entry in to AS or 
AM (n=710). 
 
MRI timing and MRI T stage at diagnosis 
3.8% (27/710) patients did not have an MRI as part of staging. 6.5% (46/710) had a 
pre-biopsy MRI and the remaining 89.7% (637/710) patients had a staging MRI 
following TRUS biopsy. 
 
All staging MRI scans were reviewed at the EPC MDT and staging documented. 53.5% 
were staged at T1. 25.2% were T2a and 15.8% were T2b. 1.7% of cases were staged 
at T2c or higher (Figure 5.5). 
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Figure 5.5. Graph showing the MRI stage at presentation and entry in to AM/AS, 
1997-2015 (n=710) 
 
Maximum cancer core length (MCCL) and percentage of core of maximum tumour 
length 
MCCL was 3.6mm with a range from 1 to 16mm. Mean percentage of core with 
maximum tumour length was 22.2% with a range from 1 to 100% (Table 5.3). 
 
 MCCL % of core with max. tumour 
length 
Number 644  
(46 not known) 
578 
(132 not known) 
Mean 3.6mm 22.2% 
Median 3.0mm 17% 
Range 1-16mm 1-100% 
Table 5.3. Table showing the TRUS biopsy core characteristics at diagnosis and entry 
in to AS/AM program, 1997-2015 (n=710). 
 
D’Amico risk classification at diagnosis 
72.4% of patients were classified a low risk at diagnosis, 25.6% were intermediate 
risk and 2.0% were high risk. 
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Follow-up time 
Follow-up time was calculated from date of diagnosis to last documented follow-up. 
Information was not available for 10 patients; therefore, data was for 700 patients. 
Mean time was 4.7 years and a median of 3.7 years. Range was 0-18.9 years.  
 
Still on an AS/AM program 
At the time of undertaking this study 39.4% (280/710) of patients were still on an 
AS/AM program. 52.8% (375/710) were known to have stopped. 5.6% (40/710) were 
known to have been followed up elsewhere and information regarding outcome was 
not known. There was no information available for 2.1% (15/710) of patients (Figure 
5.6). Therefore, accurate follow-up data on outcome is available for 655 patients. 
 
 
Figure 5.6.  Chart to show proportion of patients still on AS or AM at the time of 
review, 1997-2015 (n=710). 
 
Treatment received  
Of the 655 patients with known follow-up 42.7% (280/655) were still on an active 
surveillance/monitoring program and 57.3% (375/655) had stopped. Of the patients 
that stopped 60.8% (34.8% of the total cohort) went on to have radical treatment 
(21.6% had surgery and 39.2% radiotherapy), 20.5% moved to watchful waiting, 4.5% 
No Yes Follow-up elsewhere Not known
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started hormonal therapy, 13.3% died and information was not known for 0.8% 
(Figure 5.7). 
 
 
Figure 5.7. Graph showing the treatment pathway of patients stopping active 
monitoring/ surveillance, 1997-2015 (n=655). 
 
In total, 37.6% (246/655) had received treatment (radical treatment or hormones) 
and 62.4% (409/655) had not. 
 
Time to treatment 
Mean time to treatment was 3.3 years (median was 2.4 years) with a range of 0.2 to 
15.2 years. Patients with at least 5 years follow up had a 28.3% (77/272) treatment 
rate and those with at least 10 years’ follow-up had a 39.4% treatment rate (28/71). 
The rate of treatment by year of follow-up was roughly 5% per year up to five years 
follow up (Figure 5.8 and Table 5.4). This rose to just over 10% at 10 years’ follow-up 
and 25% at >15 years (i.e. 25% of the total number of patients with that had reached 
more than 15 years’ follow-up had received treatment). 
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Figure 5.8. Graph showing the percentage of patients that had received treatment 
based on their year of follow-up, i.e., 4.6 % of patients had treatment in their 4-5th 
year of follow-up and 18.3% of patients had treatment in their 10-11th year of follow-
up. 
 
No. to reach F/U time 
F/U Time 
(yrs) No. treated % treated by year of F/U 
710 0-1 29 4.1 
620 1-2 40 6.5 
489 2-3 28 5.7 
403 3-4 22 5.5 
327 4-5 15 4.6 
272 5-6 22 8.1 
225 6-7 18 8.0 
171 7-8 15 8.8 
130 8-9 11 8.5 
98 9-10 11 11.2 
71 10-11 13 18.3 
44 11-12 6 13.6 
31 12-13 3 9.7 
21 13-14 2 9.5 
16 14-15 4 25.0 
8 >15 2 25.0 
Table 5.4. Table showing the number and percentage of patients that had received 
treatment based on the number of years follow up. 
 
Of all the patients that had received treatment, just over 70% had received it by 5 
years and only 11% patients remained untreated at 10 years follow up (Figure 5.9). 
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Figure 5.9. Kaplan-Meier plot showing time to treatment in the AS/AM cohort. 
 
 
Reason for change in treatment course 
The reason for change in treatment was due to rising PSA in 40.5% of cases, 19.3% 
of cases was due to patient choice and a request to stop surveillance, 7.8% was due 
to a change in other clinical parameters separate from PSA and 20.9% was due to 
patient co-morbidities (i.e. transferred to watchful waiting as not fit for radical 
treatment). The reason was not clear in 11.5% of cases (Figure 5.10). 
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Figure 5.10. Pie chart showing reason for change in treatment of patients stopping 
AM/AS. 
 
Effect of initial diagnostic parameter on outcome of AS 
Chi-square tests were run to see if there were differences in the rate of treatment 
between different D’Amico risk groups, clinical T-stage sub-groups, Gleason grades, 
and maximum cancer core length (defined as MCCL - <6mm or 6mm). There were 
significant differences observed between all of these groups, apart from Gleason 
grade, with more advanced disease associated with higher rates of treatment (Table 
5.5)  
 
For time to treatment only higher Gleason grade was a significant factor with a 
shorter time to treatment (Figure 5.11). Time to treatment was shorter for higher 
D’Amico risk groups, clinical T-stage and patients with a core length 6mm but this 
was not significant (Figure 5.12-4). The significance of D’Amico risk group may not 
have been demonstrated due to the low sample size for high risk patients. 
 
 
PSA rise Patient choice Clinical progression Patient comorbidities Not clear
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Clinical Parameter Treatment 
YES  NO 
Gleason grade   
3+3 201 (34.7%) 378 
3+4 26 (37.7%) 43 
Chi-square p-value 0.625  
Clinical T stage   
T1 116 (32.1%) 245 
T2a 63 (43.4%) 82 
T2b 20 (45.5%) 24 
Chi-square P-value 0.023  
MCCL   
<6m 166 (34.7%) 313 
≥6mm 69 (50.4%) 68 
Chi-square P-value 0.001  
D’Amico risk   
Low 165 (35.1%) 315 
Intermediate 77 (47.5%) 85 
High  4 (30.8%) 9 
Chi-square P-value  0.010  
Table 5.5. Table to assess the effect of Gleason grade, clinical T-stage, MCCL and 
D’Amico risk group on rate of treatment for men enrolled on an AM/AS program. 
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Figure 5.11. Kaplan-Meier plot to assess effect of Gleason score on time to 
treatment. P-value 0.001. 
 
 
Figure 5.12 Kaplan-Meier plot to assess effect of D’Amico risk group on time to 
treatment. P-value 0.15. 
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Figure 5.13 Kaplan-Meier plot to assess effect of clinical T-stage on time to 
treatment. P value 0.187. 
 
 
Figure 5.14 Kaplan-Meier plot to assess effect of maximum cancer core length on 
time to treatment. P value 0.217. 
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Restaging 
Restaging classified as either an MRI, biopsy or both was performed in 57.2% of 
patients. A third of patients were not restaged. Of the patients that were restaged 
the majority were protocol driven (i.e. no change in clinical parameters), the 
remainder were either a result of a rise in PSA or other clinical change (Table 5.6). 
Very few patients were restaged by request although it is difficult to accurately 
assess this retrospectively. 
 
Reason Number Percentage 
Not done 236 33.3% 
Protocol 262 36.8% 
PSA rise 135 19% 
Other clinical change 6 0.8% 
Patient request 4 0.6% 
Not known 67 9.4% 
Table 5.6. Table showing the number and percentage of men undergoing restaging 
investigations whilst on AM/AS (n=710). 
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5.4.2 Aim 2 – Restaging Group 1 - Outcomes of introducing protocol re-staging in a 
cohort of clinically stable active monitoring patients. 
 
Number of cases 
Between 2014 and 2016, 144 cases were identified as having been enrolled on an 
active monitoring programme and had had restaging based on updated NICE 
guidance (CG175). All patients were suitable for radical treatment and had not 
previously undergone restaging in the form of either an MRI or a TRUS biopsy or 
both. 
 
5.4.2.1 Characteristics at diagnosis 
Median was 64.8 years of age (range 42.1 to 78.2 years). Median PSA was 5.7ng/ml. 
(range 0.5 to 18.2 ng/ml. 1 patient had Gleason 5 disease and 1 had Gleason 3+4=7 
at diagnosis. The remaining 98.6% had Gleason 6 disease. Clinical and radiological T-
stage, number of positive cores and MCCL can be seen in Table 5.21.  
 
93.8% of cases had a post-biopsy MRI at diagnosis. Only 2.8% had a pre-biopsy 
bpMRI and 1.4% patients did not have an MRI. The timing was not known for 2.1% 
of patients. 
 
88.2% of cases were low risk and 11.8% were intermediate risk at diagnosis. 
 
5.4.2.2 Outcomes of restaging  
Time to restage 
Mean time to restage was 3.7 years and median time was 2.6 years. The range was 
1.0 to 12.6 years. 
 
MRI timing at restaging 
All restaging MRI scans were bi-parametric with T2W and DWI sequences. 93.1% of 
patients had pre-biopsy MRI at restaging. 4.2% were performed following TRUS 
biopsy, 2.1% did not have an MRI and 0.7% (1 patient) did not have a biopsy. 
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Change in PSA 
Mean PSA at restage was 6.9ng/ml and median was 6.5. The mean change in PSA 
was 0.7 with a range from an 11.4 decrease to an increase of 12.5. 
 
Gleason grade at restage 
14.9% (21/141) of patients demonstrated grade progression at restage. There were 
no cases that were a higher grade than Gleason 3+4. 25.6% of patients had a negative 
biopsy and 60.3% demonstrated no change in grade (Table 5.7). 
 
GLEASON GRADE AT DIAGNOSIS AT RESTAGE 
NEGATIVE 0 36 
5 1 0 
3+3 142 85 
3+4 1 22 
NO BIOPSY 0 1 
Table 5.7. Table to show the Gleason grading at diagnosis and re-staging in men who 
underwent protocol restaging in a stable AM cohort (n=144). 
 
Of the patients with grade progression, 5/21 (23.8%) demonstrated radiological 
progression, 12/21 (57.1%) demonstrated clinical stage progression and 13/21 (62%) 
had an increased number of positive cores (Table 5.8). 
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 GRADE PROGRESSION NO GRADE PROGRESSION 
RADIOLOGICAL PROGRESSION 
(4 NO MRI TO COMPARE)  
  
YES 5 (23.8%) 14 (11.8%) 
NO 16 (76.2%) 105 (88.2%) 
VOLUME PROGRESSION   
YES 13 (62%) 34 (27.6%) 
NO 8 (38%) 89 (72.4%) 
CT STAGE PROGRESSION   
YES 12 (57.1%) 12 (9.8%) 
NO 9 (42.9%) 111 (90.2%) 
Table 5.8. Table to highlight the association between those with grade progression 
and appearance on MRI, clinical staging and presence of volume progression in men 
who underwent protocol restaging in a stable AM cohort. 
 
MRI stage at restage 
2.8% of cases did not have an MRI for comparison. 59.7% had stable appearances on 
restaging. 24.3% had improved appearances and were staged lower than at 
diagnosis. Only 13.2% of cases had documented progression on MRI at restaging. 
 
When comparing MRI T stage at diagnosis to restage marginally fewer numbers of 
T1c, T2a and T2c were seen at diagnosis. The biggest change was seen in the staging 
of T2b cancers with very few being seen at restage compared to diagnosis. This may 
be attributed to resolution of post-biopsy haemorrhage (Figure 5.15). Improved MRI 
diagnostics may also contribute given the introduction of bpMRI whilst these 
patients were on surveillance. 
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Figure 5.15. Graph to compare MRI stage at diagnosis and at re-stage in men who 
underwent protocol restaging in a stable AM cohort. 
 
When comparing all restaging MRI scans, 34.8% (49/141) of men had a scan with a 
visible lesion i.e. T2a. Of the 49 patients with a visible lesion, 23 (46.9%) had 
additional targeted biopsies at TRUS biopsy, i.e. biopsies taken in addition to the 
standard systematic biopsy. Of the remaining 26 patients with visible lesions, 2 had 
MRIs that were taken post biopsy and one patient did not have a biopsy. These 3 
men were excluded from analysis, therefore, the remaining 23 patients all had 
standard systematic TRUS biopsies. If the visible lesion was in the field of a standard 
or systematic template this could still be classified as a targeted biopsy but not an 
‘additional targeted biopsy’. Therefore, it assumed that all patients with a visible 
lesion in theory will have had a cognitive fusion targeted biopsy. 
 
When analysing the 46 patients with a visible lesion on pre-biopsy MRI, 38 (82.6%) 
had a positive biopsy that correlated with the lesion seen on MRI. The remaining 8 
patients with visible lesions on MRI had biopsy results that did not correlate with the 
scan (Table 5.9). 
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Of the 23 patients that had an additional targeted biopsy, 15 were positive and 8 
were negative. The cases that did not correlate with MRI included 4 negative biopsies 
and 4 with low volume Gleason 6 (Table 5.9). 
 
PATIENTS WITH VISIBLE 
MRI LESIONS 
(N=46) 
CORRELATION WITH 
BIOPSY 
NO CORRELATION WITH 
BIOPSY 
NO. OF CASES 38 8 
MEDIAN MAX CORE 
LENGTH 
7mm 
Range 2-20mm 
3mm (only 4 patients) 
Range 1-6mm 
OUTCOME OF BIOPSY   
NEGATIVE  0 4 
GLEASON 6 24 4 (3 had 1 positive core, 1 
had 3 positive cores) 
GLEASON 3+4 14 0 
Table 5.9. Table to highlight the outcome of TRUS biopsy in men whose biopsy 
outcome did and did not correlate with the lesion seen on pre-biopsy MRI. In men 
who underwent protocol restaging as part of a stable AM cohort. 
 
Of the 140 patients with MRI scans (and biopsy) at restaging 48 (34.3%) had visible 
lesions and 92 (65.7%) did not. In these men, there were nearly identical percentages 
of Gleason 6 disease identified on subsequent biopsy for both groups. However, for 
those patients with a detectable lesion nearly a third (31.2%) had Gleason 3+4 
disease compared to just 7.6% in the group that had normal MRIs (Table 5.10). The 
presence of a higher Gleason grade on biopsy was significantly associated with a 
visible lesion on scan when compared to a normal MRI, P-value of <0.001 (Table 
5.10). 
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 VISIBLE LESION ON 
MRI 
NORMAL MRI P-VALUE 
NUMBER OF CASES 
(N=140) 
48 92  
MEDIAN MAX CORE 
LENGTH 
6mm 
Range 1-20mm 
2mm 
Range 1-11mm 
<0.001 
Kruskal-Wallace 
 
OUTCOME OF 
BIOPSY 
  0.00014 (chi 
square) 
NEGATIVE  4 (8.3%) 31 (33.7%)  
GLEASON 6 29 (60.4%) 54 (58.7%)  
GLEASON 3+4 15 (31.2%) 7 (7.6%)  
NO BIOPSY 1 (2.1%) 0  
Table 5.10. Outcome of TRUS biopsy following a normal or abnormal MRI scan. Effect 
of having a lesion on the scan was significantly associated with higher grade disease 
on biopsy, P-value 0.00014. Maximum positive core length was significant predictor 
of lesion on MRI. In men who underwent protocol restaging as part of a stable AM 
cohort. 
 
Further sub-analysis of the 7 patients that had Gleason 3+4 disease at restaging and 
a normal MRI shows that 2 patients had a significant PSA rise and should probably 
have been offered triggered restaging. Aside from this, one could also argue that 
given the PSA rise they would have been recommended to have a re-biopsy 
regardless of the MRI result. For the remaining 5 patients, all the other clinical 
parameters were stable and therefore if one had relied on MRI alone to decide on 
ongoing surveillance the grade progression would be missed (Table 5.11). Based on 
the PROMIS definition 1 (Gl ≥4+3 or maximum core length >6mm) two of these 
patients would be classified as having significant cancer not identified on MRI. 
Therefore, 2/92 (2.2%) men with a normal MRI had significant cancer based upon 
these criteria. 
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 PSA AT 
RESTAGE 
(NG/ML) 
PSA 
CHANGE 
FROM 
DIAGNOSIS 
CLINICAL 
STAGE AT 
RESTAGE 
MRI 
STAGE 
AT 
RESTAGE 
MAX 
CORE 
LENGTH 
(MM) 
POSITIVE 
CORES  
(NO. 
INCREASED) 
TIME TO 
RESTAGE 
(YRS) 
PT 1 8.9 2.7 T1c T1c 5 1 4.1 
PT 2 5.9 -1.5 T1c T1c 1 1 1.4 
PT 3 4.4 -0.3 T1c T1c 7 4 (1) 1.2 
PT 4 6.5 2.6 T1c T1c 2 3 (2) 4.5 
PT 5 6.5 0.4 T1c T1c 3 4 (3) 1.1 
PT 6 14.3 6.7 T1c T1c 1 3 (2) 1.1 
PT 7 14.5 7.4 T1c T1c 8 3 (1) 2.0 
Table 5.11. Table identifying the clinical and pathological parameters of the 7 
patients that had Gleason 3+4 disease at restaging with a normal MRI scan. In men 
who underwent protocol restaging as part of a stable AM cohort 
 
Clinical stage at restage 
16.7% (24/144) of patients had clinical stage progression at the time of restage. 50% 
of these had grade progression on biopsy and 50% also had progression on MRI. 75% 
of these had an increase in the number of positive cores at restaging. 
 
Volume of disease at restage 
One patient did not have a re-biopsy. Of those that did have re-biopsy 32.9% 
(47/143) had an increase in at least one positive core. Those cases with an increased 
number of positive cores, 40.4% had just one more positive core, 25.5% had two and 
23.4% had an increase of three. The highest number of increased positive cores was 
5. 
 
Change in D’Amico risk classification 
25% of restaging TRUS biopsies were negative therefore this group could not be 
classified as per D’Amico. For purposes of comparison this group were deemed low 
risk. 
At diagnosis 88.2% of cases were low risk versus 74% at restaging (including group 
with negative biopsy). 11.8% were intermediate risk at diagnosis versus 23.6% at 
restaging. 1.4% of cases were classified high risk after restaging  
. 
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Outcome following restaging 
76.4% of patients that were restaged continued with active surveillance. 22.2% went 
on to receive treatment with 12.5% having a prostatectomy and 9.7% having 
external beam radiotherapy. 1.4% were changed to a watchful waiting regime. 
 
When comparing treated and non-treated groups the time to restage and age at 
diagnosis were very similar. There was a slightly higher PSA change in the group that 
received treatment. As one would expect there were a higher number of patients 
with Gleason 3+4 at restage that went on to have treatment. Patients that were 
treated also had higher levels of volume, grade, stage and MRI progression and all 
were statistically significant reasons for treatment with P-values all <0.001. 
However, 25% of those that had treatment were still classified as low-risk, 72% were 
intermediate risk compared to 11% in the non-treated group (Table 5.12). 
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 TREATED (N=32) NON-TREATED 
(N=112) 
CHI-SQUARE 
TEST 
TIME TO RESTAGE 
(YRS) 
Mean 3.3  
Median 2.6 
Mean 3.8 
Median 2.6 
- 
MEDIAN AGE AT 
DIAGNOSIS  
64.6 64.9 - 
MEDIAN PSA AT 
RESTAGE 
7.5 6.4 - 
MEDIAN PSA CHANGE 2 0.2 - 
GL SCORE RESTAGE 
3+3 
3+4 
NEGATIVE 
NO BIOPSY 
 
12 
20 
0 
0 
 
73 
2 
36 
1 
P-value <0.001 
MEDIAN NO. POS 
CORES 
4 (Range 1 to 10) 2 (Range 0 to 7) - 
% MAX CORE LENGTH 38.8 15 - 
VOLUME 
PROGRESSION 
78% (25/32) 19.8% (22/111) 
1 case did not have 
biopsy 
P-value <0.001 
GRADE PROGRESSION 59.4% (19/32) 1.8% (2/111) 
1 case did not have 
biopsy 
P-value <0.001 
STAGE PROGRESSION 56.3% (18/32) 5.4% (6/112) P-value <0.001 
MRI PROGRESSION 34.4% (11/32) 8.3% (9/109)  
3 cases did not have 
MRI 
P-value <0.001 
D’AMICO RISK GROUP 
LOW 
INTERMEDIATE 
HIGH 
 
25% (8/32) 
72% (23/32) 
3% (1/32) 
 
88% (99/112) 
11% (12/112) 
1% (1/112) 
P-value <0.001 
Table 5.12. Table to compare results of re-staging investigations between those men 
that went on to receive treatment after re-staging versus those that continued with 
surveillance. In men that who underwent protocol restaging as part of a stable AM 
cohort. 
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5.4.3. Aim 3 - Compare the outcomes of restaging in the stable active-monitoring 
cohort with clinical change or triggered re-staging and protocol restaging as 
part of active surveillance (at 12 months) 
 
5.4.3.1 Restaging Group 2 - outcomes of a clinical change/triggered restaging 
cohort 
 
Number of cases 
132 patients were identified with a date of diagnosis between 8th August 2000 and 
8th March 2013. All patients were enrolled on an active monitoring program and had 
restaging following clinical change/trigger. 
 
5.4.3.1.1 Characteristics at diagnosis 
Median age was 66 years. (range 45 to 83 years). Median PSA was 7.2ng/ml (range 
0.5 to 21.2ng/ml). 89.4% were Gleason 3+3=6 at diagnosis and 10.6% were Gleason 
7. All but one of the Gleason 7 cases were 3+4. Clinical and radiological stage, 
number of positive cores and MCCL can be seen in Table 5.21. 
 
68.9% were low risk at diagnosis. 30.3% were intermediate risk and 0.8% were high 
risk. 
 
5.4.3.1.2. Outcomes of Restaging 
Time to restage 
Mean time to restage was 3.9 years and median was 3.4 years. Range was 0.5 to 12.5 
years. 
 
Reason for re-stage 
91.7% (121/132) had re-staging due to a rise in PSA level, 4.5%(6/132) had clinical 
change and 3.8% (5/132) did so at patients request. 
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Re-MRI 
90.9% (120/132) of patients who were restaged because of a clinical trigger had a 
repeat MRI. All the patients that did not have restaging MRI did however have a re-
biopsy (Figure 5.22). 
 
 Of the patients that did have a repeat MRI, 90% had one scan and 10% had 2 (i.e. 
were restaged on more than occasion). 30.8% of those that had both an MRI and 
biopsy as part of restaging had the MRI prior to the biopsy. 
 
Re-biopsy 
65.2% (86/132) of patients who were restaged because of a clinical trigger had a 
repeat TRUS biopsy (Table 5.13). Of the patients that had a re-biopsy 89.3% had only 
1 re-biopsy, 9.5% had 2 biopsies and 1.2% had 3 biopsies. 
 
 RE-MRI 
NO 
 
YES 
 
TOTAL 
RE-BIOPSY    
NO 0 46 46 
YES 12 74 86 
TOTAL 12 120 132 
Table 5.13. Table to show number of men who received a TRUS biopsy and a MRI 
scan as part of clinically triggered re-staging. 
 
When reviewing those patients who had a change in treatment following restaging 
44.7% had a biopsy prior to this 
 
Change in PSA 
Mean change in PSA at the time of restaging was a rise of 4.9 ng/ml and median 
change was 4.3 ng/ml. Range in change was a decrease of 8.4 to a rise of 31.5ng/ml 
(Figure 5.22) 
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MRI at restage 
90.9% (120/132) of patients had an MRI as part of restaging. Of those that had an 
MRI 90% had one MRI and 10% had 2 MRI scans, i.e. had restaging on more than one 
occasion. 
 
When comparing MRI at diagnosis with the restaging scan 57.6% had evidence of 
progression, 25% did not and 9.1% could not be assessed for progression as did not 
have an MRI and 8.3% could not be assessed. 
 
Grade progression 
Of the 65.2% (86/132) patients that a re-biopsy 33.7% (29/86) demonstrated grade 
progression and 65.1% (56/86) did not.  27 patients progressed Gleason 3+3=6 to 
Gleason 3+4, 2 from Gleason 3+3 to 4+3, and 1 progressed from Gleason 3+4 to 4+3. 
15.3% had a negative biopsy (1 patient histology not available) (Table 5.14). 
 
GLEASON GRADE 
 
AT DIAGNOSIS 
 
AT RESTAGE 
NEGATIVE 
 
 
3+3 
 
 
3+4 
 
 
4+3 
3+3 13 40 27 2 
3+4 0 0 3 1 
Figure 5.14. Table showing change in Gleason score at diagnosis compared to restage 
in men who had triggered restaging (n=86). 
 
Clinical stage progression 
18.9% of cases had documented clinical stage progression. 37.1% did not progress 
and 43.9% could not be assessed due to lack of documentation. 
 
Volume of disease at restage 
46 patients did not have a biopsy, 1 result was unavailable. Of the cases that had a 
re-biopsy 56.5% (48/85) had an increase in at least one positive core. Those with an 
increase number of positive cores at restaging, 20.1% had an increase of one positive 
core, 25% had an increase in 2 positive cores and 31.3% and increase in 3 positive 
cores. 
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Change in D’Amico risk classification 
26.6% of patients could not accurately be assigned D’Amico classification following 
restaging due to lack of clinical stage data or lack of histological diagnosis. Despite 
this there did appear to a significant shift to patients with more advanced risk groups 
(Figure 5.16). 
 
 
Figure 5.16. D’Amico risk stratification at diagnosis and following triggered re-
staging. 
 
Outcome following restaging 
21.2% of patients continued active surveillance following restaging. 69% of patients 
went on to receive treatment with the remaining 9.8% patients moving to a watchful 
waiting program. 17.4% of patients went on to have radical prostatectomy and 
47.7% had radical radiotherapy. 2.3% and 1.5% had hormones and brachytherapy 
respectively. 
 
When comparing those patients that had treatment with those that did not after 
triggered re-staging there are many obvious differences. Those that continued with 
active surveillance had a longer time to restage, a slightly lower PSA, significantly 
0
10
20
30
40
50
60
70
80
90
100
Low Intermediate High Not recorded
N
u
m
b
er
 o
f 
ca
se
s
Risk group
D'Amico risk group
Diagnosis Restaging
 198 
lower rates of grade and radiological progression and a much lower percentage of 
D’Amico intermediate risk disease (Table 5.15). 
 
 TREATED (N=91) CONTINUE AS (N=28) 
TIME TO RESTAGE (YRS) Mean 3.5 
Median 3.2 
Mean 4.3 
Median 4.0 
MEDIAN AGE AT 
DIAGNOSIS  
66 66 
MEDIAN PSA AT RESTAGE 12 10.1 
MEDIAN PSA CHANGE 4.7 3.5 
GLEASON SCORE RESTAGE 
3+3 
3+4 
4+3 
NEGATIVE 
NO BIOPSY 
 
26 
23 
3 
3 
36 
 
11 
1 
- 
9 
7 
GRADE PROGRESSION 43.6% (24/55) 
36 cases did not have 
biopsy 
4.8% (1/21) 
7 cases did not have biopsy 
STAGE PROGRESSION 42 cases not recorded so 
not compared 
11 cases not recorded so 
not compared 
MRI PROGRESSION 36.4% (28/77) 
14 cases not comparable 
4.8% (1/21) 
7 cases not comparable 
D’AMICO RISK GROUP 
LOW 
INTERMEDIATE 
HIGH 
NOT CLASSIFIED 
 
5.5% (5/91) 
59.3% (54/91) 
11% (10/91)  
24.2% (22/91) 
 
28.6% (8/28) 
32.1% (9/28) 
3.6% (1/28) 
35.7% (10/28) 
Figure 5.15. Table to demonstrate differences in patients undergoing treatment 
compared those that continue with active surveillance after a triggered re-stage. 
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5.4.3.2 Restaging group 3 - Outcomes of the first protocol restaging in an AS cohort 
 
Number of cases 
114 cases were identified with a date of diagnosis between 14th March 2014 and 4th 
December 2015. All patients were enrolled on an active surveillance program and 
had undergone restaging. 
 
5.4.3.2.1 Characteristics at diagnosis 
Median age at diagnosis was 65.0 years of age (range 51-80 years). Median PSA was 
5.9ng/ml (range 0.2 to 37.6 ng/ml). 96.5% (110/114) were Gleason 6 at diagnosis and 
the remaining 4 patients all had Gleason 3+4=7 disease. Clinical and radiological 
stage, number of positive cores and MCCL can be seen in Table 5.21. 
 
24.6% of MRIs were performed pre-biopsy. 74.6% were post-biopsy and only one 
patient did not have a staging MRI 
 
86.8% cases were classified as low-risk. 10.5% were intermediate risk and 2.6% were 
high risk. 
 
5.4.3.2.2 Outcomes of restaging 
Time to restage 
Mean time to restage was 1.3 years and median time was 1.2 years. Range was 0.9 
years to 2.3 years. 
 
MRI timing at restage 
All restaging MRI scans were bi-parametric. Of the 114 patients identified 1.8% did 
not have a repeat MRI and 21.1% did not have a repeat biopsy. 76.3% had a pre-
biopsy MRI and 0.9% (1/114) had an MRI post re-biopsy. 
Change in PSA 
Mean and median PSA at restage was 5.9. The mean change in PSA at restage was -
0.7 and median was 0. Range in change of PSA was a decrease of 35 to a rise of 8. 
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Gleason grade at restage 
24 (21.1%) patients did not have a repeat biopsy. Of those that had a biopsy 16.7% 
(15/90) demonstrated grade progression. One patient was upgraded from Gleason 
6 to Gleason 4+4, 13 patients progressed from Gleason 6 to Gleason 3+4 and one 
had Gleason 3+3 but new tertiary pattern 4. 22.2% had a negative restaging biopsy 
(Table 5.16) 
 
 
Gleason grade 
 
At diagnosis 
 
At restage 
Negative 
 
 
3+3 
 
 
3+4 
 
 
4+4 
 
 
No biopsy 
3+3 20 53 13 0 24 
3+4 0 1 2 1 0 
Table 5.16. Table to show outcomes of TRUS biopsy and at first protocol re-stage in 
an AS cohort. 
 
 
MRI at restage 
Only one patient did not have a restaging MRI. Of the remaining 113 patients only 1 
(0.9%) demonstrated progression on MRI. 22.1% (25/113) of those that had a 
restaging MRI had a lesion (i.e. T2a or above). Of the 25 patients with a lesion, 5 
patients did not go on to have a restaging biopsy.  
 
When comparing the MRI with the biopsy results of the 20 patients that had had 
both investigations it was found that 65% (13/20) of the MRIs correlated with biopsy 
results. 14 patients had additional targeted lesions above the standard template if 
this was thought not to include the lesion seen on MRI. 10/14 of these additional 
targets were positive for tumour. There was a higher percentage of higher grade 
disease in those cases where MRI and biopsy correlated. The 8 patients that had 
Gleason 3+4 disease and correlation of MRI and biopsy all had grade progression at 
restaging (Table 5.17). 
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PATIENTS WITH VISIBLE 
MRI LESIONS  
N=20 
CORRELATION WITH 
BIOPSY 
NO CORRELATION WITH 
BIOPSY 
NO. OF CASES 13 7 
MEDIAN MAX CORE 
LENGTH 
7mm 
Range 3-18 
3mm 
Range 2-11 
OUTCOME OF BIOPSY   
NEGATIVE  0 3 
GLEASON 6 5 3 
GLEASON 3+4 8 1 
Table 5.17. Table to highlight the outcome of TRUS biopsy in men whose biopsy 
outcome did and did not correlate with the lesion seen on pre-biopsy MRI. 
 
 
 VISIBLE LESION ON 
MRI 
NORMAL MRI P-VALUE 
NUMBER OF CASES 25 88  
MEDIAN MAX CORE 
LENGTH 
5mm 
Range 2-18 
4mm 
Range 1-12 
0.300 
Kruskal-Wallis 
OUTCOME OF 
BIOPSY  
  0.005 (Chi-square) 
NEGATIVE  3 (15%) 17 (27.5%)  
GLEASON 6 8 (40%) 45 (65.2%)  
GLEASON 3+4 9 (45%) 6 (8.7%)  
GLEASON 4+4 - 1 (1.5%)  
    
NO BIOPSY 5 19   
Table 5.18. Outcome of TRUS biopsy following a normal or abnormal MRI scan. Effect 
of having an abnormal scan did significantly alter the outcome of biopsy, P-value 
0.005. Length of max positive core length was not significant.  
 
Comparison of those men with a normal MRI and those with a visible lesion shows 
those with a visible lesion to have a higher percentage of patients with higher grade 
disease, with 45% having Gleason 3+4 disease compared with 8.7% with a normal 
MRI. This was statistically significant with a p-value 0.005. The length of maximum 
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positive core length was not a significant predictor of abnormality on MRI (Table 
5.18). 
 
As in the protocol restaging of an AM cohort I have further sub-analysed the patients 
with higher grade disease but a normal MRI (i.e. Gleason 3+4 and 4+4 in this cohort). 
 
 GL 
SCORE 
DIAG 
GL SCORE 
RESTAGE 
PSA AT 
RESTAGE 
(NG/ML) 
PSA 
CHANGE 
CLINICAL 
STAGE 
MRI 
STAGE 
POSITIVE 
CORES (NO. 
INCREASED)  
MAX 
TUM. 
LEGNTH 
TIME TO 
RESTAGE 
(YRS) 
PT 
1 
3+3 4+4 7.1 -0.8 T2a T1c 2 (1)  5mm 1.22 
PT 
2 
3+3 3+4 7.0 0.6 T1c T1c 3 9mm 1.34 
PT 
3 
3+3 3+4 6.8 -0.1 T1c T1c 1 5mm 1.11 
PT 
4 
3+3 3+4 5.4 0.3 T1c T1c 2 (1) 3mm 1.03 
PT 
5 
3+3 3+4 6.7 -0.8 T1c T1c 3 (2) 4mm 1.22 
PT 
6 
3+3 3+4 8.8 2.3 T2a T1c 4 (1) 12mm 1.1.42 
PT 
7 
3+3 3+4 10.1 3.9 T1c T1c 2 (1) 4mm 2.0 
Table 5.19. Table identifying the clinical and pathological parameters of the 7 
patients that had Gleason 3+4 disease at restaging with a normal MRI scan. 
 
All the patients with a normal MRI but higher grade disease on biopsy did 
demonstrate grade progression at restaging. When assessing other clinical 
parameters one patient demonstrated clinical stage progression (Patient 1) and one 
patient had a significant PSA rise of 3.9 (Patient 7) (Table 5.19). Again, based on 
PROMIS definition 1, 3 out of 88 (3.4%) patients would be defined as having 
significant cancer and a normal MRI. 
 
Clinical stage progression 
Only 2.6% had clinical stage progression documented and 94.7% of patients did not. 
2.6% did not have stage documented so could not be assessed. Of the patients that 
had stage progression only one also demonstrated grade progression. None had 
progression on MRI 
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Volume of disease at restage 
30% (27/90) of the patients who had a re-biopsy had an increase in at least one 
positive core; 59.3% had an increase of just one positive core, 22.2% had an increase 
of 2 cores and 7.4% an increase of 4 cores. 
 
Change in D’Amico risk classification 
There was a decrease in low-risk patients from 86.6% to 78.9% following restaging 
and an increase in the number of intermediate risk patients from 10.5% to 18.4%. 
 
Regarding the high-risk patients at diagnosis, two were clinical T2c but both T1c on 
MRI and low volume Gleason 6, the third had a PSA in the 30’s which dropped to 11 
on restage and was likely related to a UTI at presentation. At restage, one case 
remained high risk as was still thought to be cT2c and the other two cases both 
dropped risk groups (Figure 5.17). 
 
 
Figure 5.17. Graph to show the D’Amico risk classification before and after protocol 
re-staging. 
 
Outcome following restaging 
84.2% of patients continued active surveillance following re-staging. 13.1% received 
treatment with equal numbers having surgery and external beam radiotherapy and 
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one patient (0.9%) having brachytherapy. 1.8% changed to a watchful waiting 
approach and one patient was still yet to decide on treatment course at the time of 
review. 
 
When comparing outcomes of men following their first protocol re-staging higher 
Gleason grade at restage, evidence of grade progression and higher D’Amico risk 
groups were all associated with significantly higher treatment rates. Neither MRI 
progression or clinical stage at restage were significant in those patients receiving 
treatment (Table 5.20). 
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 TREATED (N=15) CONTINUE AS 
(N=97) 
P-VALUE (CHI-
SQUARE) 
TIME TO RESTAGE 
(YRS) 
Mean 1.3 
Median 1.2 
Mean 1.3 
Median 1.3 
 
MEDIAN AGE AT 
DIAGNOSIS  
67 65  
MEDIAN PSA AT 
RESTAGE 
6.7 5.4  
MEDIAN PSA CHANGE 0.5 -0.1  
GLEASON SCORE 
RESTAGE 
3+3 
3+4 
4+4 
NEGATIVE 
NO BIOPSY 
 
 
3 
9 
1 
0 
2 
 
 
51 
6 
- 
20 
20 
<0.001 
GRADE PROGRESSION 69.2% (9/13) 
2 cases did not have 
biopsy 
7.8% (6/77) 
20 cases did not 
have biopsy 
<0.001 
STAGE PROGRESSION 7.1% (1/14) 
1 cases did not have 
recorded 
2.1% (2/95) 
2 cases did not have 
recorded 
0.738 
MRI PROGRESSION 0/15 1% (1/96) 
1 case did not have 
MRI 
0.986 
D’AMICO RISK GROUP 
LOW 
INTERMEDIATE 
HIGH 
 
20% (3/15) 
66.7% (10/15) 
13.3% (2/15) 
 
88.7% (86/97) 
10.3% (10/97) 
1% (1/97) 
<0.001 
Table 5.20 Table to compare results of re-staging investigations between those men 
that went on to receive treatment after first protocol re-staging versus those that 
continued with surveillance. 
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5.4.3.3 Overall comparison between groups 1, 2 and 3  
The three restaging groups represent distinctly different populations. Restaging 
group 1, are men who have been under AM without prior protocol or triggered. 
Restaging group 2, represent men who have had a clinically triggered restaging 
investigation, and restaging group 3 represent men who are on surveillance having 
their first protocol led restage. 
 
When comparing characteristics at diagnosis between the three groups that were 
restaged the ages were very similar and PSA levels were slightly higher in the 
triggered restage group. There were lower rates of clinical and radiological T1 
disease in the triggered restage group although a significant number were not 
recorded for clinical stage in this. The numbers of positive cores and max cancer core 
length were not significantly different between the groups. There was also a higher 
proportion of D’Amico intermediate risk in the triggered restage group compared to 
the other two groups which were very similar (Table 5.21). 
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Table 5.21. Table showing patient demographics and disease status at diagnosis of 
three different AM/AS re-staging groups. 
S GROUP 1. 
PROTOCOL RESTAGE 
STABLE AM COHORT 
GROUP 2. 
TRIGGERED  
RESTAGE 
GROUP 3. 
PROTOCOL  
RESTAGE AS  
NUMBER OF CASES 144 132 114 
AGE AT DIAG. (YRS) 
MEAN 
MEDIAN 
RANGE 
 
64.0 
64.8 
42.1 to 78.2 
 
65.6 
66 
45 to 83 
 
65.0 
65.0 
51 to 80 
PSA AT DIAGNOSIS 
(NG/ML) 
MEAN 
MEDIAN 
RANGE 
 
6.2 
5.7 
0.5 to 18.2 
 
7.8 
7.2 
0.5 to 21.2 
 
6.6 
5.9 
0.2 to 37.6 
GLEASON SCORE (N) 
3+3 
3+4 
4+3 
 
143 
1 
- 
 
118 
13 
1 
 
110 
4 
- 
CLINICAL STAGE (%) 
T1 
T2A 
T2B 
T2C 
T3A 
N/R 
 
81.8 
16.1 
2.1 
- 
- 
- 
 
50 
20.5 
9.8 
0.8 
- 
18.9 
 
80.8 
15.8 
- 
2.6 
- 
0.9 
MRI STAGE (%) 
T1 
T2A 
T2B 
T2C 
T3A 
NOT DONE 
 
59 
22.2 
12.5 
4.2 
0.7 
1.4 
 
49.2 
28.0 
18.2 
- 
- 
4.6 
 
77.2 
14.9 
0.9 
5.3 
0.9 
0.9 
MRI TIMING (%) 
PRE-BIOPSY 
POST-BIOPSY 
NO MRI 
NOT KNOWN 
 
2.8 
93.8 
1.4 
2.1 
 
- 
95.4 
4.6 
- 
 
24.6 
74.6 
0.9 
- 
NUMBER OF POSITIVE 
CORES (%) 
1 
2 
3 
>4 
NOT KNOWN 
 
 
50 
27.1 
10.4 
11.3 
- 
 
 
40.2 
20.5 
18.9 
18.9 
1.5 
 
 
38.6 
21.9 
23.7 
12.4 
3.5 
MAX. CANCER CORE 
LENGTH (MM) 
MEAN 
MEDIAN 
RANGE 
 
 
2.9 
2 
1 to 15 
 
 
3.5 
3 
1 to 14 
 
 
3.4 
3 
1 to 15 
D’AMICO RISK GROUP (%) 
LOW 
INTERMEDIATE 
HIGH 
 
88.2 
11.8 
- 
 
68.9 
30.3 
0.8 
 
86.8 
10.5 
2.6 
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When comparing the results of restaging in the three different groups as expected 
the median time to restage was longer in the triggered restaging group (group 2). 
The timing of MRI in those patients that had both an MRI and a biopsy was also more 
likely to be before the biopsy in those patients undergoing protocol restaging. The 
median PSA change was very similar in the protocol-led groups (group 1 and 3) with 
very little change from diagnosis, as one would expect the PSA rise in the triggered 
group (group 2) was significant.  
 
In those patients that had a restaging biopsy the rates of upgrading were again 
similar between the protocol groups (group 1 and 3) but was more than double in 
the triggered restaging cohort (group 2) with just over a third of patients upgraded.  
 
The rates of progression on MRI scan was also significantly different between the 
groups with <1% of patients having progression in the protocol restaging AS group 
(group 3), rates were higher in the stable AM protocol restaging group (group 1) but 
still only 13.6%, while over two-thirds of men demonstrated progression in the 
triggered restaging cohort (group 2). No meaningful comparisons could be made 
between the groups with clinical stage progression due to high rates of missing data 
in the triggered restage cohort. When comparing volume progression this was again 
very similar in the two protocol restaging groups and nearly twice as high in the 
triggered restage group (Table 5.22). 
 
The outcome on course of treatment after restaging was significantly different 
between the 3 groups. Only 1 in 5 men continued surveillance after triggered 
restaging (group 2) and of those that went on receive treatment only a quarter chose 
radical prostatectomy and over two-thirds having radical radiotherapy. For patients 
having protocol restaging treatment rates were slightly higher in the AM group than 
the AS (23% vs 13%), however, treatment chosen was roughly equal between 
radiotherapy and surgery (Table 5.22). 
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 GROUP 1. 
PROTOCOL RESTAGE 
STABLE AM COHORT 
GROUP 2. 
TRIGGERED  
RESTAGE 
GROUP 3. 
PROTOCOL  
RESTAGE AS  
P-VALUE 
CHI SQ. 
TIME TO RESTAGE 
(YEARS) 
MEAN 
MEDIAN 
RANGE 
 
 
3.7 
2.6 
1.0 to 12.6 
 
 
3.9 
3.4 
0.5 to 12.5 
 
 
1.3 
1.2 
0.9 to 2.3 
- 
MRI TIMING (%) 
PRE-BIOPSY 
POST BIOPSY 
 
95.7 
4.3 
 
30.8 
69.2 
 
98.9 
1.1 
- 
PSA CHANGE (NG/ML) 
MEAN 
MEDIAN 
RANGE 
 
0.7 
0.6 
-11.4 to 12.5 
 
4.9 
4.3 
-8.4 to 31.5 
 
-0.7 
0 
-35 to 8 
- 
GRADE PROG (%) 
YES 
NEGATIVE BIOPSY 
 
14.9 
25.6 
 
34.1 
15.3 
 
16.7 
22.2 
0.0014 
MRI PROG. (%) 
YES 
NO 
 
13.6 
86.4 
 
69.7 
30.3 
 
0.9 
99.1 
<0.001 
CLINICAL STAGE 
PROGRESSION (%) 
YES 
NO 
N/R 
 
 
16.7 
83.3 
- 
 
 
N/A 
N/A 
 
 
2.6 
94.7 
2.6 
n/a 
VOL. PROG. (%) 
YES 
NO 
IF YES, NO. INCREASE, 
1 
2 
3 
>4 
 
32.9 (47/143) 
67.1 (96/143) 
 
40.4% 
25.5% 
23.4% 
10.7% 
 
56.5 (48/85) 
43.5 (37/85) 
 
20.1% 
25% 
31.3% 
23.6% 
 
30 (27/90) 
70 (63/90) 
 
59.3% 
22.2% 
- 
18.5% 
0.0003 
D’AMICO AT RESTAGE 
(%) 
LOW 
INTERMEDIATE 
HIGH 
N/A 
 
 
74 
23.6 
1.4 
- 
 
 
10.6 
53.0 
9.8 
26.6 
 
 
78.9 
18.4 
2.6 
- 
- 
OUTCOME OF RESTAGE 
(%) 
CONTINUE AS 
WW 
TREATMENT 
NOT KNOWN 
 
 
76.4 
1.4 
23.2 
- 
 
 
21.2 
9.8 
69 
- 
 
 
84.2 
1.8 
13.1 
0.9 
<0.001 
TREATMENT RECEIVED 
(%) 
SURGERY 
EBRT 
BRACHYTHERAPY 
HORMONES 
 
 
53.9 
46.1 
- 
- 
 
 
25.3 
69.2 
2.2 
3.3 
 
 
46.7 
46.7 
6.7 
- 
0.054 
 
Table 5.22. Table showing the outcomes of restaging when comparing three 
different restaging cohorts. 
 
 
 210 
5.5 Discussion 
 
This chapter reports the outcomes for men with localised prostate cancer on a 
deferred treatment strategy be that active surveillance or its predecessor active 
monitoring. It reports on the outcomes of introducing re-staging protocols in to an 
established clinically stable population on active monitoring and the effect that this 
can have on treatment rates. It also reports on the outcomes of restaging in 3 
different surveillance populations; clinically triggered restaging, protocol restaging 
in an established stable active monitoring group and the first standard protocol 
restaging in an active surveillance group. Finally, it reports on the potential use of bi-
parametric MRI in active surveillance and the possibility of avoiding prostate 
restaging biopsy in men with a normal scan. 
 
5.5.1 Aim 1 – Outcomes of a deferred treatment strategy 
The results from this cohort of patients represent a group that were surveyed using 
both active monitoring and active surveillance protocols. Initial inclusion criteria in 
the early stages of recruitment were based on criteria similar to the ProtecT study 
(Hamdy et al., 2016), and then subsequently based on new NICE guidance. However, 
it must be remembered that there was not a strict entry criteria like other published 
single institution surveillance protocols. Over the period of the study the surveillance 
strategies changed with the introduction of protocol restaging, the timing of MRI and 
the upgrading of MRI technology. Therefore, when reviewing the outcomes of 
deferred treatment in this cohort it must be remembered that it represents a 
heterogeneous group and one that accurately reflects practice at the time. In view 
of all these factors one would expect outcomes potentially to be worse than those 
with strict entry criteria. 
 
Entry criteria 
In this study, the median age at diagnosis of 66 years was similar to large published 
cohorts of a similar and larger size (Hamdy et al., 2016, Dall'Era et al., 2012, Bokhorst 
et al., 2016). The majority were D’Amico low risk (72.4%) and Gleason 6 (87%) at 
diagnosis. All, except the Royal Marsden group, of the surveillance cohorts reviewed 
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by Dall’Era et al recruited only Gleason 6 disease and criteria were such that only low 
volume D’Amico low risk would have been eligible for enrolment (Dall'Era et al., 
2012). ProtecT was less strict and had a lower percentage of Gleason 6 disease at 
77%, however, PRIAS reported 99%(Hamdy et al., 2016, Bokhorst et al., 2016). The 
Klotz et al cohort had a similar number of Gleason 6 and 7 cases to this cohort (Klotz 
et al., 2010). It must also be remembered nearly 97% of this study cohort had an MRI 
scan at diagnosis, few other studies are able to match this. The reported series from 
Dall’Era’s review have similar median follow up times to our cohort but as one would 
expect the prospective studies such as ProtecT and PRIAS report figures from a 
longer period. Overall, this study represents a large series of a contemporary UK 
practice with good medium to long term follow-up with a more heterogeneous 
patient population than many published series of AS cohorts. 
 
Time to treatment 
Of the 7 different active surveillance series, in Europe and North America, reviewed 
by Dall’Era et al median follow-up times ranged from 1.8 to 3.9 years. The percentage 
of patients treated varied from 11 to 33 % with median time to treatment varying 
between 1.3 to 3.5 years (related to median follow-up time). The percentage of 
patients treated at 2 years was around 20% although this statistic was missing from 
a number of studies (Tosoian et al., 2011, Klotz et al., 2010, Cooperberg et al., 2011, 
van den Bergh et al., 2009, van As et al., 2008, Adamy et al., 2011, Soloway et al., 
2010) The more recent ProtecT trial published around 20% radical treatment rates 
at 2 years follow up and 54.8% had had treatment at 10 years’ follow-up (Dall'Era et 
al., 2012). PRIAS reports 48% still on AS at 5 years and 27% at 10 years with 34% and 
41% discontinued for clinical reasons (clinical progression) (Bokhorst et al., 2016). In 
another large series of AS patients with good median follow-up Klotz et al reported 
that 72% remained on AS after 5 years and 62% after 10 years (Klotz et al., 2010). 
 
This study reports a median follow-up time of 3.7 years with an overall radical 
treatment rate of 34.8% and 42.7% of patients continuing AS at the time of review. 
The rate of treatment for patients that reached 5 years and 10 years was 28.3% and 
39.4% respectively. These figures compare very favourably with the ProtecT and 
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PRIAS studies. It is difficult to determine the exact reason for lower treatment rates 
seen in our cohort. With only 10% of our study population reaching 10 years’ follow-
up and only a third reaching 5 years it may be that when the cohort matures higher 
treatment rates are seen. Higher treatment rates for the Protect study may equally 
be a result of higher numbers of men with higher Gleason disease at presentation. 
Also, the PRIAS study included multiple protocol restaging biopsies which detected 
disease progression in around 1 in 8 men. This will have affected treatment rates.  
Lower treatment rates in this study cohort is unlikely to have been a result having 
protocol restaging as only a third of patients received it. These patients would have 
been part of the more recent patients and would not have reached 5 and 10 year 
follow up. The widespread use of MRI at diagnosis may have reduced the number of 
patients potentially under staged at hence reduced the number of un-detected 
significant cancers that could progress. It is well known that MRI can detect more 
aggressive tumours and is useful at the entry point of AS (Radtke et al., 2015, Ahmed 
et al., 2017). It must also be remembered that many of these patients would not 
have had mpMRI, let alone bpMRI and therefore if the lower rates of treatment are 
a result of high use of MRI then the effects that modern mpMRI may have on 
ensuring optimum patient selection will hopefully be much more encouraging.  
 
In men that went on to receive treatment it was only Gleason grade at diagnosis that 
was a significant predictor of time to treatment and this must be remembered when 
counselling patients regarding the likely outcome for surveillance. The large 
multicentre PRIAS study also demonstrated that Gleason grade, and clinical T3 
disease, were the only significant predictors for adverse pathology for men exiting 
AS and proceeding to prostatectomy (Bokhorst et al., 2016). This is important 
information to know particularly when counselling younger men on surveillance 
programmes. 
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5.5.2 Aim 2 – Assess the outcomes of introducing protocol re-staging in a cohort of 
clinically stable active monitoring patients 
Grade progression 
Most surveillance strategies now have repeat or confirmatory biopsies with the aim 
to avoid under-staging the disease and to detect any potential tumour growth or 
grade progression/de-differentiation (Dall'Era et al., 2012).  However, the timing of 
such biopsies is still a subject of debate and the earlier that it is done the lower the 
likelihood of detecting tumour progression but the higher chance of avoiding under-
staging. Several studies, with the timing of first protocol re-biopsy between 3 months 
and 2 years, reported rates of grade progression between 8.9 and 28% and negative 
biopsies rates of between 21-37% of cases (Berglund et al., 2008, Bul et al., 2012, 
Venkitaraman et al., 2007). 
 
The PRIAS study, a larger and more up to date study, followed over 5000 men on an 
active surveillance regime over a period of 10 years. A re-biopsy was performed and 
1, 4, 7 and 10 years after diagnosis and grade progression rates were noted to be 
between 13-16% at each subsequent re-biopsy (Bokhorst et al., 2016).  
 
The 14.9% grade progression rate noted in this study correlates well with other 
reported rates, however, it must be remembered that the population in our study is 
different to the reported studies and had been under surveillance for a median time 
of just under 3 years already. 
 
MRI progression 
The PRIAS study did not initially use MRI re-staging as standard and recommended 
its use when there were 2 or more positive cores present. This recommendation 
however was amended and its use was suggested as the best method for predicting 
grade progression (Bokhorst et al., 2016). The use of MRI in AS has previously been 
shown to have a negative predictor value of near 100% for detecting Gleason grade 
progression (Barrett and Haider, 2017, Schoots et al., 2015). Therefore, if a lesion is 
detected it should be targeted at subsequent biopsy. It is suggested that MRI and 
targeting may be able to replace systematic biopsies but more information is 
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required on the number of men who have a negative MRI and the outcomes of 
subsequent systematic biopsies (Bokhorst et al., 2016). 
 
In this study, we demonstrated that those patients with a lesion visible on pre-biopsy 
MRI and went on to have targeted biopsies had a high correlation with higher grade 
tumours (Gleason 3+4). Those biopsies that were positive and did not correlate with 
the lesion on MRI were all Gleason 6 and appropriate to continue with surveillance. 
For those patients with a normal MRI, 7.6% were found to harbour biopsies 
indicating grade progression, albeit 28.6% (2/7) of these patients did demonstrate a 
significant PSA rise and would have been offered biopsies because of that alone. On 
this basis, one could argue that if MRI alone were used as a re-staging tool, a normal 
MRI would miss around 5% of grade progression, and if a lesion were present only 
targeted biopsies are required and the morbidity of systematic biopsies could be 
avoided. 
 
Clinical progression 
One could argue the benefit of repeat DRE in the context of AS if patients are also 
receiving MRI scans. With previously reported progression rates of around 10% 
(Bokhorst et al., 2016) this study was slightly higher at around 17%. With around 50% 
of patients with clinical progression demonstrating grade and MRI progression this 
further highlights the relevance of DRE and whether patients should be spared this 
on a less frequent basis. 
 
Overall usefulness of the study 
The main difference of this study compared to previous studies is that the population 
being re-staged was different to a standard surveillance group. They had not 
previously been re-staged and not had been through a second checkpoint to ensure 
suitability for a surveillance population.  Despite this we have demonstrated a similar 
rate of grade progression at re-biopsy. The study has also highlighted the value of bi-
metric MRI in restaging and a potential move away from the standard use of 
systematic biopsies and the potential for only targeted biopsies. 
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Despite only 14.9% patients demonstrating Gleason grade progression, just over 1 in 
5 went on to receive radical treatment after restaging. The reason for this must be 
assumed to be multifactorial; Patient choice and progression in other parameters 
other than Gleason grade influencing decision, given that Gleason grade progression 
is the only statistically significant predictor of adverse features at RP. Patients should 
be aware of the difficult decisions that may arise after restaging and have this 
discussed at the outset of starting surveillance. 
 
5.5.3 Aim 3 and 4– outcomes of restaging different populations and the use of MRI 
in the AS pathway 
 
As one might expect the rates of grade, radiological and volume progression are very 
similar between the group of patients that had their first protocol restaging following 
diagnosis (group 3) and those patients that were stable on an active monitoring 
program (group 1). However, it is interesting to note that nearly a quarter of men in 
the stable AM group went on to receive radical treatment after restaging compared 
to around 1 in 8 men in the AS cohort despite only being on surveillance for around 
one and a half years longer (median). This decision again must be attributed to other 
factors and it is well known that the longer patients are on surveillance there is a 
natural tendency for patients to opt for treatment due to anxiety (Latini et al., 2007).  
 
The rates of progression in all parameters noted in the clinically triggered restaging 
cohort (group 2) clearly justify the need for triggered restaging. There was a higher 
proportion of men with intermediate risk disease at diagnosis in the triggered re-
stage group which would suggest that these men potentially require more intense 
follow-up than low-risk men. There was a significantly higher proportion of patients 
with progression noted on MRI compared with the other groups and around double 
the percentage of patients with grade progression. Unfortunately, only a third of 
patients in the triggered cohort had MRI pre-biopsy therefore no meaningful 
assessment can be made comparing the MRI with biopsy results as in the other 2 
cohorts. If patients underwent triggered restaging only 1 in 5 continued surveillance 
following with a much higher proportion of men who had treatment receiving 
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radiotherapy compared with surgery, whereas it is similar for the men having 
treatment in the other cohorts. Considering the age at diagnosis between the 3 
cohorts was very similar the reason for the difference is not clear and requires 
further investigation.  
 
When reviewing the use of bpMRI in the protocol restaging of AS only 10.2% of 
patients with a normal MRI (no lesion seen) had Gleason >6 on re-biopsy and of these 
only 3 had significant cancer based on PROMIS definition 1. If one combines this 
cohort of normal bpMRIs with the normal bpMRIs in the stable AM cohort only 3% 
(5/170) would harbour significant cancer. Of this 3%, 40% (2/5 men) had changes in 
other clinical parameters that may have led to re-staging biopsies despite a normal 
MRI. Therefore, one could argue that in this cohort of patients, those with a normal 
MRI scan and no other change in clinical parameters have a 1.8% (3/170) chance of 
significant cancer if biopsied. Therefore, one could considering omitting a biopsy. 
Further reassurance can be seen in those patients where the biopsy result does not 
correlate with the lesion on MRI, only one patient had Gleason 3+4 disease, the 
remainder were all Gleason 6 or negative. It must also be remembered that within 
this study the MRIs used in these cohorts were bi-metric and not mpMRI. The other 
striking figure in the protocol restaging group (group 3) is that 99% of MRIs were 
unchanged at 1 year suggesting that it is too soon to re-stage with MRI. In a similar 
study by Gallagher et al using mpMRI they concluded that men who had a normal 
MRI at restaging had a 1.6% chance of detecting Gleason 3+4 cancer on subsequent 
systematic biopsy (Gallagher et al., 2019). 
 
One recent study, by Thurtle et al (2018), has suggested that including annual mpMRI 
scans has led to a significant reduction in the number of men progressing to radical 
treatment, with only 7.6% having treatment after 3 years’ surveillance. In 104 men 
on surveillance, 20 were detected to have grade progression, with half detected on 
MRI, but only half of these corresponding to the targeted biopsy. This emphasised 
the need for both targeted and systematic biopsies and raised the question as to 
whether the biopsy had indeed missed the MRI lesion (Thurtle et al., 2018). This 
study data, as well as that from a recent meta-analysis supports the conclusion that 
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changes in MRI should not alone be used to recommend a change in treatment 
strategy (van den Bergh et al., 2014). 
 
Given that nearly a third of patients with grade progression in the Thurtle et al (2018) 
study had a normal MRI they suggested the continued use of systematic biopsy and 
this was also suggested by another study using template biopsy as a baseline, 
suggesting that MRI has a relatively low sensitivity in this setting (Ma et al., 2017, 
Thurtle et al., 2018). However, this study would suggest that if the MRI scan is 
normal, i.e. no lesions present, then a biopsy can be safely avoided, as the risk of 
having significant cancer is very low, <2%, particularly if there were no other clinical 
parameters that had changed. This would be supported by Gallagher et al (2019) 
who showed that PSA velocity was significantly associated with disease progression 
in men with a normal MRI (Gallagher et al., 2019). 
 
5.5.4 Conclusion 
Active surveillance is an important treatment option for men with low-risk organ 
confined prostate cancer with the aim of avoiding over-treatment of potentially 
insignificant disease. 
 
Restaging represents an essential part of AS and this study has shown that its results 
can have a significant impact on the treatment pathway that a patient takes. 
 
MRI will improve the restaging process and this study has shown that bpMRI offers 
a safe alternative to mpMRI. There is little potential value in performing a re-staging 
MRI at 12 months after diagnosis as it is unlikely to have changed and affect 
treatment. If, when a restaging bpMRI is performed and it is normal, in the presence 
of stable clinical parameters then repeat biopsy may be avoided, in discussion with 
the patient. Indeed, the use of MRI in the restaging pathway has been identified by 
NICE as an area for further research (NICE., 2019). 
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Chapter 6. Discussion 
 
It is well known that the use of MDT meetings improves cancer outcomes and as 
such is mandatory within UK practice for all new cases of cancer. This study has 
highlighted that prospectively collected data from patients discussed at a specialist 
MDT can be of high quality and as a result be used to address a wide range of 
clinical questions, further adding to the value of MDT discussion. MDT meetings are 
undoubtedly labour intensive but we have shown that with the correct personnel 
and data capture process data quality can be high. 
 
This study has been able to demonstrate changes in disease presentation and 
treatment over a long period in a cohort whose staging investigations has remained 
essentially the same throughout. It has shown that, in line with UK practice, the 
rates of radical treatment for low risk disease appear to be falling and the rate of 
men receiving radical treatment for high risk disease increasing. Encouragingly, the 
proportion of men with low risk disease choosing surveillance is also high. 
 
There is debate as to whether the presence of symptoms at presentation is 
associated with more aggressive disease. This study did not show that, the only 
significant association of symptoms was with age, with older men presenting with 
more symptoms. This is most likely associated with age related LUTS rather than 
any association with aggressive cancer.  This study did show that men with 
symptoms were less likely to have radical treatment than those without symptoms. 
It would be worth exploring this further given results from an Australian study 
which suggested that men presenting with symptoms have a poorer disease 
specific survival at 10 years (Beckmann et al., 2017). 
 
Encouragingly this study has shown that men with a family history are presenting 
with higher rates of low risk disease than men without. They are also more likely to 
have radical treatment. This would seem logical given the potential anxiety 
associated with a positive family history. It is also reassuring to note that no strong 
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evidence exists to suggest that men with a positive family history treated early do 
worse than men without it. This information is vital when counselling men with a 
positive family history prior to deciding on diagnostic investigation. 
 
As discussed, men have been staged in a very uniform manner through the period 
of the EPC database with over 90% receiving a staging MRI and over 93% of 
intermediate and high risk men receiving isotope bone scans. This widespread and 
uniform staging process has enabled the thesis aims to answered with accuracy. 
 
The use of isotope bone scan remains the most common imaging modality for the 
investigation of bone metastases. Prior to this study the available guidelines on the 
use of bone scan were inconsistent in men with intermediate risk disease with the 
EAU offering the most concise recommendation (Mottet et al., 2017a). This study 
has provided strong evidence that BS can be safely omitted in men with 
intermediate risk disease with ISUP grade group 2. However, for intermediate risk 
disease with ISUP grade group 3 and high risk disease BS should be performed. This 
is in line with current EAU guidelines. 
 
The use of MRI in the diagnostic pathway of prostate cancer is a fast-changing field 
with two recent landmark papers, PROMIS and PRECISION, changing the way MRI is 
now used pre-TRUS biopsy (Ahmed et al., 2017, Kasivisvanathan et al., 2018). 
Recently published updated NICE guidance now recommends pre-TRUS biopsy 
mpMRI with a possibility of avoiding TRUS biopsy in certain low risk cases (NICE., 
2019). However, it is less clear the impact that updated MRI technology has had on 
the correct staging of prostate cancer. This study has shown that the ability of MRI 
has not changed significantly over time in accurately predicting disease stage and 
indeed radiological T-stage was not shown to be a significant predictor of disease 
recurrence regardless of the MRI technology used. This study has emphasised the 
importance of established predictors of biochemical recurrence, specifically T-
stage, ISUP grade group and margin status. 
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This study also highlighted the use of PROMIS definitions of significant cancer and 
how these must be used with caution in the context of predicting disease outcome. 
Rates of BCR were very similar for significant cancer when using either PROMIS 
definition 1 or 2, mirroring results for D’Amico classified intermediate risk disease. 
Patients with non-significant cancer as defined by definition 1 had nearly double 
the rate of BCR compared with the D’Amico low risk and the rate of BCR was not 
significantly different to those that had significant cancer. This information must be 
considered when counselling patients regarding treatment or indeed whether to 
have a biopsy or not. It also highlights that D’Amico classification remains more 
sensitive at predicting BCR than PROMIS definitions of significant cancer.  
 
The outcomes in this study for men on an active monitoring or surveillance regime 
for localised prostate cancer demonstrate encouraging results when compared to 
other large established series. It is also reassuring to note that the rate of grade 
progression when introducing protocol restaging in to a cohort of stable active 
monitoring patients was equivalent to that of the first protocol restage in an active 
surveillance cohort. However, despite this the treatment rate following restaging 
was significantly higher in the stable AM cohort suggesting that men who have 
been surveyed longer may be more inclined to consider treatment despite any 
evidence of disease progression. This must be considered when counselling men 
about protocol restaging whilst on AS.  
 
The use of MRI in surveillance strategies remains a topic of debate. Updated NICE 
guidance suggests repeat MRI at 12-18 months following entry in to AS (NICE., 
2019). This study would suggest that protocol restaging with an MRI at 1 year 
offers no benefit and should perhaps be deferred to at least 2 years. This study also 
reports a very low risk, <3%, of significant cancer if the MRI scan is reported as 
normal and there is no other evidence of disease progression, such as a rising PSA, 
and hence a re-staging biopsy can be avoided. It must be remembered that this 
study reports on the use of bpMRI rather than mpMRI with equivalent results. This 
therefore, represents a potentially safer, cheaper and quicker alternative that is 
not inferior. Further work is required to define the optimum active surveillance 
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protocol and has been started within the department because of this study. We are 
extending the current study to the present day to review the outcomes of all 
bpMRI performed at the time of first restaging. This updated cohort will have a 
significantly higher proportion of patients with a pre-biopsy bpMRI at diagnosis 
than in the current study and hence eliminate any uncertainty that post-biopsy 
artefact may cause. It is hoped that this future study will further clarify the use of 
bpMRI in the AS pathway. 
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